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ABSTRACT 
 
This thesis investigates the neuroimaging and neuropsychological characteristics of 
Posterior Cortical Atrophy (PCA) which is most often caused by Alzheimer’s disease 
(AD) pathology. Posterior cortical atrophy describes a predominantly posterior pattern of 
atrophy and cognitive deficits. PCA has been poorly characterized and is likely to have 
been under-recognized. Using magnetic resonance imaging (MRI), patterns of cortical 
thickness were assessed in patients with pathologically-confirmed AD and different 
clinical presentations during life (including amnestic, visual and behavioural 
phenotypes). In addition to atrophy in the medial temporal lobe, tissue loss in posterior 
regions is indicative of AD pathology. Since medial temporal lobe atrophy is not specific 
to AD, posterior atrophy may aid distinction between AD and other dementias. Using 
easily-applied visual rating scales for medial temporal and posterior atrophy in patients 
with pathologically-confirmed AD and frontotemporal lobar degeneration (FTLD), it was 
shown that posterior atrophy ratings improve classification accuracy of AD from FTLD 
and controls. 
 
Cross-sectional and longitudinal image analysis techniques were used to characterize 
atrophy patterns in PCA compared with controls and typical amnestic AD. Whilst the 
cross-sectional analysis revealed differential patterns of tissue loss in these two groups, 
with PCA showing greatest atrophy in posterior parietal regions, and typical AD 
predominantly in medial temporal lobe regions, longitudinal results showed that at five 
years disease duration, both PCA and typical AD had global grey matter loss and 
cortical thinning compared with controls.  
 
The nature of visual deficits in PCA was assessed by administering detailed 
neuropsychological tests. The behavioural data showed that visual deficits were not 
uniformly affected in PCA, with considerable heterogeneity of visual impairments shown. 
Cortical thickness measures were used to assess atrophy patterns in PCA patients with 
predominant space versus object perception impairments, revealing overlap in cortical 
thinning patterns between these two PCA subgroups.   
 
In summary this thesis investigates the common and differential atrophy patterns of 
atypical AD presentations as well as the degree of heterogeneity of deficits which exist 
within the PCA presentation.   
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AIMS OF THIS THESIS 
 
The Problem 
Alzheimer’s disease (AD) is one of the leading public health issues of our time. With 
ageing populations, the number of patients with degenerative dementias such as AD will 
rise dramatically, estimated to affect 81.1 million people worldwide by 2040. AD is 
characterized by specific pathological changes which are often accompanied by atrophy 
that can be measured non-invasively using a variety of structural imaging techniques. 
Structural imaging methods have become widely used tools which assist diagnosis. 
Whilst most AD patients present with memory complaints and atrophy mainly in the 
medial temporal lobes, a number of studies have demonstrated significant heterogeneity 
in the clinical presentations of AD. In addition to the typical amnestic presentation in AD, 
atypical non-amnestic phenotypes including early aphasic or behavioural variants have 
been highlighted. Other patients may present with visuospatial, visuoperceptual, praxis, 
calculation, and spelling difficulties which implicate early parietal and occipital lobe 
involvement. The posterior pattern of atrophy with which these presentations are 
associated has led to the term posterior cortical atrophy (PCA). Atypical variants of AD 
have until recently been under-recognized and have been poorly studied. Studying 
atypical variants of AD is crucial in order to identify the biological factors and processes 
that drive the heterogeneity of phenotypes in AD, and may lead to a better 
understanding of AD as whole. 
 
Aims 
1) To assess patterns of cortical thickness in patients with pathologically-confirmed AD 
who had typical and atypical clinical presentations during life, and in patients with 
Frontotemporal Lobar Degeneration (FTLD).  
2) To develop a visual rating scale for posterior atrophy and assess its reliability and 
clinical utility in pathologically-confirmed AD and FTLD patients. 
3) To assess cross-sectional and longitudinal patterns of cortical thickness and grey 
matter loss in well-characterized individuals with PCA, and compare these with typical, 
amnestic AD and healthy controls. 
4) To investigate the nature of visual deficits in PCA. Specifically, the aim was to 
characterize basic visual processing deficits in PCA, and to assess associations of 
higher-order visual processing deficits with basic visual processing impairments. 
5) To assess patterns of cortical thickness in PCA patients with predominant object and 
space perception deficits. 
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1. INTRODUCTION 
 
1.1 Chapter introduction 
Dementia is one of the leading public health issues of our time: it has a great effect on 
the quality of life for the patient and the caregivers and it places heavy demands on 
health care systems. The most common cause of dementia in people over the age of 65 
years is Alzheimer’s disease (AD) (Hebert et al., 2003). The greatest risk factor for 
dementia is advancing age, with the prevalence of developing AD increasing 
exponentially over the age of 65 years, affecting up to 20% of those over the age of 80 
years (Jorm and Jolley, 1998). With ageing populations, the number of patients with 
degenerative dementias such as AD will rise dramatically, estimated to affect 81 million 
people worldwide by 2040 (Ferri et al., 2005). 
 
Few causes of dementia are currently treatable. Whilst early diagnosis is important now 
for patients and families, in the future an early and accurate diagnosis may become 
crucial since a) new disease-modifying drugs are currently being developed, some of 
which are in phase III clinical trials, and b) potential therapeutic agents may have their 
greatest efficacy when administered in the early stages of the disease before extensive 
cognitive deficits develop. Furthermore, potential therapeutic drugs are likely to be 
pathology-specific, making accurate diagnoses essential to prevent those without the 
targeted pathology being given potentially harmful and unnecessary medications. 
 
Structural neuroimaging techniques have become widely used tools which assist 
diagnosis through the exclusion of other treatable causes, the discrimination of 
neurodegeneration from normal ageing, and differentiating between degenerative 
diseases (e.g. Likeman et al., 2005). As such, structural imaging is included in 
diagnostic guidelines for both Europe (Hort et al., 2010; Waldemar et al., 2007) and the 
US (Knopman et al., 2001). Imaging has also been shown to predict conversion to 
dementia in individuals who are worried about their memory and cognition (for a review 
see Fennema-Notestine et al., 2009). Finally, serial neuroimaging can be used to track 
disease progression and may provide a good outcome measure for the efficacy of 
therapeutic drugs. 
 
In recent years, a number of studies have demonstrated significant heterogeneity in the 
clinical presentations of AD. In addition to the typical amnestic presentation in AD, 
atypical non-amnestic phenotypes including early aphasic and visual problems have 
been highlighted. Increasing the clinical and scientific community’s knowledge of these 
atypical variants is important in order to identify the biological factors which promote or 
protect against pathological changes in different brain regions. Furthermore, 
understanding atypical forms of AD and the factors driving the heterogeneity in AD may 
- 15 - 
lead to a better understanding of AD as a whole, and will improve the support, care and 
education that can be given to the patients, carers and healthcare professionals. This 
chapter describes the clinical, pathological, epidemiological, genetic and 
neuropsychological characteristics of the main dementias assessed in this thesis. 
 
1.2 Dementia 
Dementia can be defined as an acquired deficit involving multiple domains of cognitive 
function, including memory in the presence of normal consciousness, and sufficient to 
impact normal activities of daily living (Rossor, 1993). Whilst the most common 
pathological disease causing dementia is AD, other non-AD pathological processes 
have been identified, including frontotemporal lobar degeneration (FTLD), vascular 
dementia (VaD), dementia with Lewy Bodies (DLB), corticobasal degeneration (CBD), 
and Creutzfeld Jakob disease (CJD). Clinical distinction between these different 
diseases can often be problematic and some pathologies can be found together. This 
thesis focuses on AD and its atypical presentations as well as some diseases which are 
difficult to differentiate from AD. 
 
1.2.1 Alzheimer’s disease 
1.2.1.1 Pathology 
AD is characterized by two neuropathological hallmarks: extracellular deposits of 
amyloid (Aβ plaques) and intracellular neurofibrillary tangles (Braak and Braak, 1991). 
Progression of pathology has been described with neurofibrillary tangles first seen in the 
trans-entorhinal cortex and then in the hippocampus (Arnold et al., 1991; Braak and 
Braak, 1995). In contrast, amyloid deposition is first seen in the basal portions of the 
isocortex of temporal, parietal and occipital lobes, whereas the hippocampus remains 
relatively devoid of amyloid (Braak and Braak, 1991). In addition to these pathological 
protein deposits, AD pathology can exist alongside other pathologies including DLB and 
vascular disease (Jellinger and Attems, 2005; Jellinger and Attems, 2008). AD is 
characterized by a marked loss of neurons and synapses in many areas of the central 
nervous system, particularly in areas such as the basal forebrain and hippocampus. This 
neuronal loss is accompanied by gross atrophy: an example of atrophy in the medial 
temporal lobe typically found in AD is shown in Figure 1.1 (left).  
 
1.2.1.2 Epidemiology and genetic risk factors 
Whilst the vast majority of the AD population are elderly, there is a proportion of people 
who get AD earlier in life. Studies therefore often distinguish between early- and late-
onset AD typically defined arbitrarily as age at onset before and after 65 years, 
respectively. Most research studies in AD focus on younger old persons (age <80 
years). The association between AD pathology and dementia is stronger in younger old 
persons than in older old persons (Savva et al., 2009) suggesting that additional factors 
- 16 - 
may determine the clinical expression of dementia in the oldest old. These findings also 
suggest that it is important to take age into account when assessing the effects of 
interventional treatments against dementia.  
 
A small proportion of the early-onset patients (0.5% according to 
www.molgen.ua.ac.be/ADMutations) carry an autosomal dominant mutation causing a 
predictable age of onset which is closely related to the ages of onset of other family 
members. These individuals are referred to as familial AD patients. Familial AD has 
been associated with mutations in the amyloid precursor protein (APP), presenilin 1 
(PSEN1) and presenilin 2 (PSEN2) genes (Campion et al., 1999). 
 
However, in the majority of AD patients the disease is sporadic. One of the most 
important genetic risk factors for developing sporadic AD is the presence of an 
apolipoprotein E (ApoE) ε4 allele (Okuizumi et al., 1994). The presence of a single ε4 
allele increases the lifetime risk of AD by 2-4-fold relative to the more common ε3 allele 
(Meyer et al., 1998). Over recent years, evidence has suggested that the presence or 
absence of an ε4 allele may also influence the pattern of atrophy and the associated 
clinical phenotype in AD, with regions in the medial temporal lobe being more affected in 
ε4-carriers than non-carriers (Gutierrez-Galve et al., 2009; Hashimoto et al., 2001). This 
is in accordance with studies showing that the presence of ε4 is particularly associated 
with greater memory impairment (Marra et al., 2004; Snowden et al., 2007b). ApoE ε4 
has also been shown to be associated with an earlier onset of disease and possibly a 
more aggressive disease course (Cosentino et al., 2008; Okuizumi et al., 1994; 
Saunders et al., 1993). 
 
1.2.1.3 Clinical diagnostic criteria for sporadic AD 
AD is most commonly characterized by an insidious onset of memory impairment which 
progresses to involve multiple cognitive domains (McKhann et al., 1984). This amnestic 
presentation is in accordance with histopathological evidence for early medial temporal 
lobe involvement described above. The NINCDS-ADRDA criteria (see Appendix 1) offer 
three categories of diagnostic certainty for AD: i) definite AD, which can only be 
established by post-mortem or biopsy examination; ii) probable AD, which is made upon 
fulfilment of a certain set of criteria established by clinical and neuropsychological 
examination, and iii) possible AD when there is an atypical onset, presentation or 
progression, without a known aetiology, and absence of co-morbid diseases capable of 
producing dementia (McKhann et al., 1984). Since the publication of the NINCDS-
ADRDA criteria in 1984, a better understanding of the underlying disease processes in 
AD has led to efforts to develop more sophisticated criteria which take other biomarkers 
into account. Recently proposed research criteria move diagnosis of AD earlier in the 
disease course by removing the need for subjects to have impairments of multiple 
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cognitive domains and utilizing one or more biomarkers (Dubois et al., 2007). According 
to these criteria a diagnosis of AD can be made when a patient presents with memory 
impairment and has supportive evidence of one of the following: medial temporal lobe 
atrophy from structural imaging, reduced glucose metabolism in bilateral temporal 
parietal regions on positron emission tomography (PET), or markers of pathology 
including evidence of amyloid deposition using either PET imaging (Klunk et al., 2004) or 
reduced amyloid and increased tau levels obtained from a cerebrospinal fluid (CSF) 
sample (Dubois et al., 2007).  
 
Whilst the majority of AD patients typically present with an amnestic presentation, 
‘atypical’ forms of AD in which memory is not the primary deficit (Galton et al., 2000) 
have until recently been under-recognized and have been poorly studied. Some of these 
patients may present with marked behavioural features and are often referred to as 
‘frontal-variant AD’ (Johnson et al., 1999; Taylor et al., 2008), whilst others have a 
predominantly language presentation which often has features of logopenic progressive 
aphasia (LPA) (Gorno-Tempini et al., 2008). Yet others may present with visuospatial, 
visuoperceptual, praxis, calculation, and spelling difficulties which implicate early parietal 
and occipital lobe involvement (Benson et al., 1988; Cogan, 1985; Ross et al., 1996). 
The posterior pattern of atrophy with which these presentations are associated has led 
to the term posterior cortical atrophy (PCA). An example of the posterior atrophy pattern 
in a patient with PCA is illustrated in Figure 1.1. Growing efforts to characterize the 
clinical manifestation of AD has led to the realization that focal, non-amnestic 
phenotypes of AD represent a much higher proportion of cases than previously 
recognized, and these atypical presentations will likely be included in new consensus 
criteria for AD that are currently being formulated 
(http://www.alz.org/research/diagnostic_criteria/overview.asp, see also Dubois et al., 
2010). 
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Figure 1.1: Patterns of atrophy in typical amnestic AD and PCA. Shown are structural MRI scans, coronal and sagittal views, of a typical, amnestic AD 
patient (top) showing prominent medial temporal lobe atrophy in the absence of prominent posterior atrophy, and a PCA patient (bottom) showing atrophy in 
posterior regions in the absence of marked medial temporal lobe atrophy. HPC - hippocampus, PAR - parietal lobe, PCS - posterior cingulate sulcus, PRE - 
precuneus, POS - parieto-occipital sulcus,  L - left hemisphere, R - right hemisphere, A - anterior, P - posterior. 
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1.2.2 Posterior Cortical Atrophy (PCA) 
1.2.2.1 Nosology 
Individuals with PCA typically show a progressive and relatively selective decline in 
visual processing skills and other posterior functions. The term PCA was first introduced 
by Benson (1988) who reported five patients with predominant deficits in higher-order 
visual processing and neuronal loss in parieto-occipital areas (on computed tomography 
and magnetic resonance images, see section 2.2) (Benson et al., 1988). Other early 
studies have focussed mainly on the clinical and neuroimaging characteristics of PCA 
(Cogan, 1985; De Renzi, 1986). Subsequent histopathological studies identified AD as 
the most common underlying pathology which includes the presence of amyloid plaques 
and neurofibrillary tangles. PCA is therefore often considered a variant of AD and is also 
referred to as ‘biparietal’ or ‘visual’ variant AD (e.g. Bokde et al., 2001; Galton et al., 
2000; Levine et al., 1993; Ross et al., 1996; Schott et al., 2006). However, PCA has 
been associated with other, non-AD pathologies, which has led to suggestions for PCA 
to be considered a distinct nosological entity with its own diagnostic criteria (Mendez et 
al., 2002; Tang-Wai and Mapstone, 2006). Other studies suggest that PCA should be 
considered as a point on a continuum of phenotypic variation in AD (Stopford et al., 
2007).  
 
Questions remain over whether PCA should be considered a unitary clinico-anatomical 
syndrome or rather a collection of related but distinct syndromic subtypes. Extrapolating 
from basic neuroscientific evidence of distinct cortical streams which process different 
types of visual information (Goodale and Milner, 1992; Ungerleider and Mishkin, 1982), it 
has been suggested that separate parietal (dorsal) and occipito-temporal (ventral) forms 
of PCA exist (Ross et al., 1996). A third, primary visual (striate cortex; caudal) form of 
PCA has also been proposed (Galton et al., 2000). However, these claims are largely 
based on findings from single case reports. The most detailed neuropsychological study 
of PCA to date found evidence of object perception deficits, faces and colours in a 
proportion of the patients tested, but overall the pattern of impairments was suggestive 
of greater impairment of the dorsal than ventral visual processing streams as no pure 
ventral stream syndrome was detected (McMonagle et al., 2006). 
 
1.2.2.2 Epidemiology 
The exact prevalence and incidence of PCA are currently unknown and any figure is 
likely to be an underestimate because of poor general knowledge of the syndrome’s 
existence. However, in a study by Snowden et al. it was shown that 5% of 523 patients 
with AD presenting to a single specialist cognitive disorders centre had a visual 
presentation (also labelled posterior cortical atrophy) (Snowden et al., 2007b). Age at 
onset tends to be earlier in PCA (van der Flier et al., 2010), with studies reporting 
disease onsets in patients’ mid 50s and early 60s (e.g. McMonagle et al., 2006; Mendez 
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et al., 2002) although a wide distribution has been described (40-86 years; Tang-Wai et 
al., 2004). In terms of gender distribution, some studies have reported no difference in 
the prevalence between the genders (e.g. McMonagle et al., 2006; Mendez et al., 2002; 
Renner et al., 2004), whereas others have reported an over-representation of women 
(e.g. Snowden et al., 2007b; Tang-Wai et al., 2004). 
 
1.2.2.3 Genetics 
Remarkably, to date, there have been no studies reporting an autosomal dominant 
inheritance pattern in PCA. Although 11 patients in a study by Tang-Wai et al. had a 
family history of dementia, none of those family members had a posterior cortical 
syndrome (Tang-Wai et al., 2004). Furthermore, there is no significant difference in the 
number of patients with a positive family history of dementia in PCA compared with 
typical AD (Mendez et al., 2002; Tang-Wai et al., 2004). Nonetheless there does seem 
to be an important modulating effect of genetic factors. Studies assessing ApoE in PCA 
have reported significant differences between the ApoE status of patients with posterior 
cortical presentations of AD and amnestic AD (see Table 1.1, Schott et al., 2006; 
Snowden et al., 2007b). Schott et al. described 20% of biparietal AD patients (PCA) 
were ApoE ε4-positive (which corresponds to an ε4-allele frequency of 10%), which was 
significantly lower compared with a typical AD group of who 86% were ε4-positive (ε4-
allele frequency 52%). However, subject numbers were relatively small in this study (10 
PCA). A larger study by Snowden et al. examined the relationship between cognitive 
profile and ApoE status in 302 patients with typical or atypical AD (Snowden et al., 
2007b), and revealed that 30% of patients with a visual presentation were ε4-positive. 
This was significantly lower than the proportion of ε4 allele carriers in AD patients with 
an amnestic presentation (defined as severe memory impairments in absence of other 
cognitive dysfunctions, 82%) and patients with a memory/semantic presentation (defined 
as symptoms of memory loss and semantic memory impairment, 80%). Conversely, 
presence of the ε4 allele in the visual AD group did not differ to a population of 756 
healthy individuals from the same region (27%, Pendleton et al., 2002). Since this study 
did not report the number of PCA and typical AD patients for whom ApoE data were 
available, ApoE ε4 allele frequencies cannot be determined at this stage. 
 
Other studies, however, have reported no significant difference in ApoE between PCA 
and typical AD (Table 1.1, Mendez et al., 2002; Tang-Wai et al., 2004). Mendez et al. 
reported ε4 allele frequency of 25% in 8 PCA patients, with none of the patients having 
two ε4 alleles (50% were ε4-positive). These were compared with an AD cohort 
described in Saunders et al. who reported ApoE ε4 allele frequency of 40% in 176 
autopsy-proven sporadic AD patients (Saunders et al., 1993). Tang-Wai et al. reported 
ε4 allele frequency of 26% in a group of 27 PCA patients (48% were ε4-positive). Only 
one patient was ε4-homozygous. These were compared with the ApoE ε4 prevalence of 
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AD patients described in Farrer et al., who reported an ε4 allele frequency of 37% 
(Caucasian AD patients, Farrer et al., 1997). Farrer et al. also report ε4 allele frequency 
of 14% for Caucasian control subjects. Discrepancies in the findings obtained in these 
studies may reflect differences in factors such as inclusion criteria used to define PCA 
and typical AD, and age at onset. Studies using larger sample sizes are required to 
obtain more conclusive results.  
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Table 1.1: Overview prevalence of ApoE ε4 in PCA, AD and controls. Shown are data from 4 studies that have reported ApoE ε4 frequency in PCA, and 
compared these with typical (or sporadic) AD and controls. 
 
* reported significant difference in ApoE ε4 between PCA and AD 
†
 Farrer et al. 1997 
‡
 Saunders et al. 1993 
¶
 Pendleton et al. 2002 
§
 for whole PCA group, age at onset for subset of patients with ApoE unknown 
¥
 amnestic AD; proportion ε4-positive in memory/semantic AD group = 80% 
 
 
 
 
 
 PCA AD Controls 
Study Total N Age at 
onset 
N with 
ApoE 
ε4 
frequency 
ε4 
positive 
N Age at 
onset § 
N with 
ApoE 
ε4 
frequency 
ε4 
positive 
N ε4 
frequency 
ε4 
positive 
Tang-Wai et al. 2004 40 60.5 (8.9) § 27 26% 48% 5107 † - 5107 37% 59% 6262 † 14% 26% 
Mendez et al. 2002 15 58.2(5.1) § 8 25% 50% 176 ‡ - 176 40% - - - - 
Snowden et al. 2007 * 24 58.0 (4.0) § - - 30% 321 58.0 (4.0) - - 82% ¥ 767 ¶ 14% 27% 
Schott et al. 2006 * 10 56.1 (4.1) 10 10% 20% 29 65.6 (6.9) 29 52% 86% - - - 
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1.2.2.4 Pathology 
Pathological studies have shown that AD is the most common underlying cause of PCA 
(Alladi et al., 2007; Galton et al., 2000; Hof et al., 1989; Hof et al., 1990; Renner et al., 
2004; Tang-Wai et al., 2004). However, a small number of cases are attributable to other 
aetiologies such as CBD (Renner et al., 2004; Tang-Wai et al., 2003a), DLB (Renner et 
al., 2004; Tang-Wai et al., 2003b), prion disease (including CJD and familial fatal 
insomnia; Renner et al., 2004; Victoroff et al., 1994), and subcortical gliosis (Victoroff et 
al., 1994). These studies provide first insights into the prevalence of the different 
pathologies in PCA. For example, Renner et al. reported pathological data of 27 PCA 
patients of whom 13 (48%) had AD, 2 (7%) had CBD, 1 (4%) had DLB, 1 (4%) had CJD 
and 2 (7%) had prion disease (Renner et al., 2004). Tang-Wai et al. reported 7/9 (78%) 
PCA patients had AD pathology, whereas the remaining 2 (22%) had CBD (Tang-Wai et 
al., 2004).  
 
Although the patterns of the distribution of pathology have been shown to be different in 
PCA compared with typical AD, the exact pattern of the pathological changes revealed 
by these studies is inconsistent and based on very small numbers of cases. Some 
studies have demonstrated differences in both plaques and neurofibrillary tangles 
between PCA and typical AD (Hof et al., 1997; Levine et al., 1993; Ross et al., 1996), 
whereas others have found no differences in the plaque distribution (Renner et al., 2004; 
Tang-Wai et al., 2004). For example, Levine et al. reported the pathological findings of 1 
PCA patient who showed greatest density of senile plaques and neurofibrillary tangles in 
occipitoparietal regions, and lowest density in frontal lobe regions (Levine et al., 1993). 
Hof et al. reported similar findings with plaques and tangles found predominantly in 
primary visual and visual association areas around the occipito-parieto-temporal 
junction, whereas frontal regions such as the prefrontal cortex showed very low densities 
of pathological changes (Hof et al., 1993; Hof et al., 1997). In contrast, Tang-Wai et al. 
compared pathological changes in 9 PCA patients with 30 typical AD patients. The PCA 
group showed significantly higher density of neurofibrillary tangles in visual and visual 
association cortices and fewer tangles and senile plaques in the hippocampus and 
subiculum. However, density of senile plaques in other cortical areas was comparable in 
both groups (Tang-Wai et al., 2004). Reasons for the discrepant findings in these 
autopsy studies are unclear, however, differences in inclusion criteria and 
demographical characteristics (such as age and disease severity) as well as differences 
in the methods used to quantify the pathological changes (such as different staining 
techniques, and discrimination between diffuse and neuritic plaques) may have 
contributed. Studies assessing CSF biomarkers (Aβ1-42, T-tau and P-tau181) have 
reported similar concentrations in PCA compared with AD (Baumann et al., 2010; de 
Souza et al., 2011), supporting previous reports that PCA is often associated with 
underlying AD pathology.  
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1.2.2.5 Proposed diagnostic features 
Two sets of diagnostic criteria have been proposed and are frequently used in research 
studies (Mendez et al., 2002; Tang-Wai et al., 2004, Appendix 2). Core features for a 
diagnosis of PCA include: (i) insidious onset and gradual progression; (ii) presentation of 
visual deficits in the absence of ocular disease; (iii) relatively preserved episodic 
memory, verbal fluency and personal insight; (iv) presence of symptoms including visual 
agnosia, simultanagnosia, optic ataxia, ocular apraxia, dyspraxia and environmental 
disorientation; and (v) absence of stroke or tumour. Supportive features include alexia, 
ideomotor apraxia, agraphia, acalculia, onset before the age of 65 years and 
neuroimaging evidence of posterior cortical atrophy or hypoperfusion.  
 
1.2.2.6 Neuropsychological features 
PCA is characterized by a number of different neuropsychological deficits, the most 
frequently cited ones are visuospatial and visuoperceptual deficits, including alexia and 
neglect, as well as features of Balint’s syndrome (simultanagnosia, oculomotor apraxia, 
optic ataxia, environmental agnosia) and Gerstmann’s syndrome (acalculia, agraphia, 
finger agnosia, left/right disorientation) (Andrade et al., 2010; Charles and Hillis, 2005; 
McMonagle et al., 2006; Mendez et al., 2002; Renner et al., 2004; Tang-Wai et al., 2004; 
Whitwell et al., 2007a). It should be noted that, whilst terms such as Balint’s and 
Gerstmann’s syndrome are still frequently used in the literature, these syndromes are 
often inconsistently defined and tested, and patients often show additional symptoms, 
limiting their diagnostic utility in PCA. 
 
The most detailed neuropsychological study of 19 PCA patients to date by McMonagle 
et al. suggests that of the symptoms mentioned above, agraphia, alexia, 
simultanagnosia and optic ataxia are the most consistently identified features 
(McMonagle et al., 2006). Additional features reported in this study included agnosia for 
objects, faces and colours, though interestingly no pure ventral stream syndrome was 
detected, suggesting greater impairment of the dorsal stream in the PCA patients in this 
study. However, a clear distinction between patients with predominantly parietal deficits 
and impairments of basic visual processing skills has been shown (e.g. figure-ground 
discrimination, shape discrimination, visual crowding; Crutch and Warrington, 2007), 
with atrophy predominantly affecting the striate and extrastriate cortices (e.g. Galton et 
al., 2000). Overall, the visual deficits commonly reported in PCA have predictable 
consequences on performance on more general neuropsychological tests such as IQ 
(performance IQ is often up to 30-40 points lower than verbal IQ scores) and 
constructional tasks (e.g. Rey figure copy and clock drawing). Longitudinal studies have 
shown that anterograde memory and frontal lobe functions as well as linguistic skills, 
which are sometimes strikingly preserved in the earlier stages of the disease, gradually 
deteriorate in some patients as they progress to a more global dementia state (e.g. 
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Levine et al., 1993; McMonagle et al., 2006) making their cognitive phenotype ultimately 
virtually indistinguishable from that found in typical AD (DellaSala et al., 1996). 
 
1.2.3 Frontotemporal lobar degeneration (FTLD) 
A number of important other non-AD pathological processes cause dementia. FTLD, 
although less prevalent, is almost as common as AD below the age of 65 years (Harvey 
et al., 2003; Ratnavalli et al., 2002)  and can be difficult to distinguish from AD at any 
age especially in early disease stages. There is great heterogeneity in the clinical, 
genetic and pathological phenotypes in FTLD (for a review see Seelaar et al., 2010b). 
 
1.2.3.1 Pathology 
Pathologically, FTLD is rather heterogeneous. It can be divided into two major subtypes: 
FTLD with tau-positive inclusions (FTLD-tau), and FTLD with ubiquitin-positive and TDP-
43-positive, but tau-negative inclusions (FTLD-TDP) (Mackenzie et al., 2010). FTLD-tau 
includes patients with microtubule-associated protein tau (MAPT) mutations, Pick’s 
disease, progressive supranuclear palsy (PSP), CBD, argyrophilic grain disease and 
multiple system tauopathy with dementia (Mackenzie et al., 2010). MAPT mutations are 
associated with different types of tau inclusions (Pick bodies, neurofibrillar tangles and 
pretangles) in the frontal and temporal cortex, hippocampus and subcortical nuclei, and 
sometimes in midbrain, brainstem, cerebellum and spinal cord (van Swieten and 
Spillantini, 2007).  
 
FTLD-TDP is characterized by ubiquitin-positive inclusions that have the TDP-43 protein 
as major constituent (Neumann et al., 2006). FTLD-TDP is further divided into four 
different subtypes (Mackenzie et al., 2006) according to the morphology and distribution 
of the inclusions and correspond, to some extent, to the clinical phenotype (see 1.2.3.2): 
semantic dementia is strongly associated with abundant dystrophic neuritis; FTD-MND is 
characterized by numerous neuronal cytoplasmatic inclusions in both superficial and 
deep cortical laminae; progranulin (GRN) mutations are associated with cytoplasmatic 
inclusions, dystrophic neurites and neuronal intranuclear inclusions; and valosin 
containing protein (VCP) mutations are characterised by numerous intranuclear and 
infrequent number of neuronal cytoplasmatic inclusions and dystrophic neurites (Cairns 
et al., 2007). It remains unclear what differences in underlying pathophysiology 
determine the distinction between these TDP-43 subtypes.  
 
Recently, a small number of FTLD cases with ubiquitin-positive, TDP-43 negative 
pathology have been reported to show immunoreactivity with the FUS antibody 
(Neumann et al., 2009a; Seelaar et al., 2010a). The FUS protein contains 526 amino 
acids and is as a nuclear protein involved in DNA repair and the regulation of RNA 
splicing (Vance et al., 2009). FTLD-FUS cases are characterised by a young age at 
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onset, a behavioural FTD (bvFTD) phenotype (see 1.2.3.2), a negative family history 
and caudate atrophy on MRI (Josephs et al., 2010; Seelaar et al., 2010a). FUS-positive 
inclusions are also found in patients with neuronal filament inclusion disease (NIFID) 
(Neumann et al., 2009b). NIFID patients most commonly present with bvFTD symptoms, 
a negative family history and pyramidal and/or extrapyramidal movement symptoms 
(Neumann et al., 2009b). Finally, cases have been described with ubiquitin-positive, 
TDP-43 and FUS-negative inclusions, termed FTLD-UPS. Most of the FTLD-UPS cases 
carry a CHMP2B mutation (Holm et al., 2009) but there are a few without CHMP2B 
mutations (Urwin et al., 2010). 
  
1.2.3.2 Clinical presentations 
FTLD comprises three prototypical clinical syndromes: frontotemporal dementia (FTD) or 
behavioural variant FTD (bvFTD), progressive non-fluent aphasia (PNFA), and semantic 
dementia (SemD). PNFA and SemD are also collectively referred to as primary 
progressive aphasia (PPA). BvFTD affects predominantly the frontal and anterior 
temporal lobes (Figure 1.2A) and presents with prominent behavioural and personality 
changes, followed by disturbances of executive functions, language and memory (Neary 
and Snowden, 1996; Snowden et al., 2007a). PNFA is associated with atrophy 
predominantly of areas around the left perisylvian fissure (Figure 1.2B) and is 
characterized by difficulty in speech production with agrammatism and apraxia of 
speech in the presence of relative preservation of comprehension (Neary et al., 1998). 
SemD usually presents with fluent aphasia and severely impaired comprehension and 
naming (Hodges and Patterson, 2007; Snowden et al., 2007a). Neuroimaging reveals 
atrophy predominantly in the left anterior temporal lobe, particularly the temporal pole, 
entorhinal cortex and fusiform gyrus (Figure 1.2C; Chan et al., 2001b; Galton et al., 
2001; Rosen et al., 2002).  A further syndrome has been described in which patients 
show predominant atrophy in the right temporal lobe (Figure 1.2D), and mainly 
behavioural symptoms as well as memory loss, topographical disorientation and 
prosopagnosia (Chan et al., 2009; Evans et al., 1995; Thompson et al., 2003). 
 
1.3 Chapter conclusions 
Dementia is a major and growing socioeconomic and public health problem. The most 
common disease which causes dementia is AD. AD can be difficult to distinguish 
clinically from other pathologies such as FTLD, especially in the early stages. Therefore 
methods which aid distinction of AD from non-AD pathologies are important. AD typically 
presents with episodic memory impairment leading to decline in multiple domains. An 
atypical variant is PCA which involves initial visual and parietal impairments which 
eventually lead to generalized cognitive decline.  
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Figure 1.2: Patterns of atrophy in bvFTD, SemD, PNFA and right temporal lobe FTD. Presented are structural MRI scans of patients with A) bvFTD 
showing predominant frontal atrophy, B) SemD showing prominent left temporal lobe atrophy, C) PNFA showing atrophy in the left perisylvian fissure, and D) 
in right temporal FTD showing predominant atrophy in the right temporal lobe. 
A B C D
L RL L RRR L
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2. IMAGING IN DEMENTIA 
 
2.1 Chapter introduction 
Whilst a definitive diagnosis of AD can only be made with histopathological data, 
pathological changes are often accompanied by atrophy which can be measured non-
invasively using a variety of structural imaging techniques. What this reveals about AD 
and PCA in particular will be the focus of this thesis. Therefore this chapter will mainly 
describe structural imaging methods, but for completeness a brief description of other 
imaging techniques, such as functional imaging, which reveal additional biological 
changes or deficits in the AD brain will be included. After describing the main tools 
available to measure structural and functional characteristics of the brain, this chapter 
will demonstrate how these have been used to characterize normal ageing, AD, PCA 
and FTLD. 
 
2.2 Structural imaging techniques 
Structural imaging, such as computed tomography (CT) or magnetic resonance imaging 
(MRI), allows non-invasive visualization of brain anatomy. In dementia, pathological 
changes result in neuronal loss which may be visualized as macroscopic atrophy using 
such imaging techniques. Although CT is relatively cheap and widely available, low 
image contrast makes it a less useful technique to assess atrophy, in particular for 
research purposes. However, CT can be used for patients for whom MRI is 
contraindicated, such as those with pacemakers. MRI is a technique which produces 
high-resolution and contrast images and which has become increasingly available in 
clinical practice. By using different pulse sequences and by changing the imaging 
parameters, different image contrasts can be achieved, such as T1, T2 and proton 
density, which relate to specific tissue characteristics. Figure 2.1 provides an overview of 
commonly used MRI sequences. In the studies described in this thesis only T1-weighted 
images were used. MRI‑based patterns of atrophy are useful diagnostic markers and 
serial MRI can be used to assess disease progression. Atrophy patterns have been 
shown to correlate well with cognitive deficits (e.g. Fox et al., 1999; Mungas et al., 2005; 
Ridha et al., 2008), and correspond to areas with greatest tangle deposition at post-
mortem (Vemuri et al., 2008; Whitwell et al., 2008b). 
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Figure 2.1: Overview of CT, T1, FLAIR, T2 and PD images. Shown are examples for each type of scanning sequence and a brief description of their main 
application. 
T1 FLAIR T2 PDCT
Computed tomography
CT scanning produces 
images on which CSF 
appears dark, and brain 
tissue brighter. It is often 
used to assess atrophy, 
and to detect infarction, 
tumours, calcifications, 
haemorrhages and bone 
trauma.
T1-weighted scans
T1-weighted images have 
similar applications and a 
similar appearance as CT 
images, but has a better 
grey/white matter contrast 
(with grey matter 
appearing darker than 
white matter).
Fluid Attenuated Inversion 
Recovery (FLAIR)
FLAIR is an inversion 
recovery technique that nulls 
fluids. For example, it can be 
used to suppress CSF in 
order to bring out 
periventricular hyperintense
lesions, such as multiple 
sclerosis plaques.
T2-weighted scans
In T2-weighted images 
fat, water and fluid 
appear bright. These are 
useful to pick up 
oedema as collections of 
abnormal fluid are bright 
against the darker 
normal tissue.
Proton density (PD)
PD scans measure the 
proton concentration in a 
structure. They are used 
to assess periventricular
and subcortical lesions 
such as inflammatory 
damage, microinfarcts, 
and arteriosclerotic
white matter lesions.
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2.2.1 Cross-sectional image analysis 
2.2.1.1 Visual assessment 
In a clinical setting CT and MR images are most commonly assessed by visual 
inspection by a radiologist. Atrophy is typically evaluated using MR-based T1-weighted 
images. Tissue damage such as vascular lesions or microbleeds is better investigated 
using T2-weighted images and FLAIR (fluid attenuated inversion recovery, Figure 2.1). 
Although visual assessment has been shown to be useful in differential diagnosis, co-
existing pathologies (e.g. AD and vascular dementia) or overlap in the atrophy patterns 
of different diseases (e.g. AD, DLB and normal ageing), especially in the early stages of 
the disease, makes accurate radiological diagnosis using brain atrophy patterns 
problematic. To allow a more systematic method of assessment, visual rating scales 
have been developed such as the Scheltens scale which measures the degree of 
atrophy in the medial temporal lobe: an area affected early by AD pathology and atrophy 
(Scheltens et al., 1992, chapter 3, section 3.5.3.1.1). This scale has good intra- and 
inter-rater reliabilities, and has been shown to discriminate well between AD and healthy 
controls, and predict the conversion from mild cognitive impairment (MCI) to AD (Korf et 
al., 2004; Scheltens et al., 1992; Scheltens et al., 1995). A study by Wattjes et al. further 
showed that MTA can also be applied to CT as well as T1-weighted MRI (Wattjes et al., 
2009). Other scales have been developed to assess global atrophy (Scheltens et al., 
1997), and white matter changes (Wahlund et al., 2001). These scales are easy to 
apply, require minimal training and have been validated extensively. They therefore 
represent a convenient way of assessing atrophy patterns and other pathologies and 
may aid differential diagnosis in a clinical setting. 
 
2.2.1.2 Manual delineation of brain structures 
Currently the gold standard for measuring and quantifying atrophy in regions of interest 
(ROI) is by manual delineation. A number of protocols have been developed to delineate 
and determine the volumes of different regions, particularly for regions in the medial 
temporal lobe owing to its early and disproportionate involvement in AD (see Figure 2.2 
for an example of manual delineations of temporal lobe regions). A number of protocols 
have been developed to delineate the hippocampus (Jack, Jr., 1994; Killiany et al., 
1993; Pantel et al., 2000; Pruessner et al., 2000; Watson et al., 1992); a more extensive 
list of available protocols can be found on http://www.hippocampal-
protocol.net/site/sops_protocols.html. Protocols have also been developed to segment 
the amygdala (Basso et al., 2006; Morey et al., 2009; Whitwell et al., 2005b), entorhinal 
cortex (Du et al., 2003; Insausti et al., 1998). Manual delineation protocols have also 
been developed for the cingulate gyrus and its subsections (Jones et al., 2006), and 
total intracranial volume (TIV) (Whitwell et al., 2001). A number of studies using manual 
volumetric data have shown greater atrophy in AD compared with healthy controls in 
regions of the medial temporal lobe, in particular in the hippocampus, entorhinal cortex, 
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amygdala, and parahippocampus (e.g. Basso et al., 2006; Chan et al., 2001b; Jack, Jr. 
et al., 1992; Juottonen et al., 1998; Teipel et al., 2006). Manual volumes of medial 
temporal lobe structures have further been shown to predict conversion from MCI to AD 
(e.g. Fox and Schott, 2004; Jack et al., 1999; Rusinek et al., 2004). However, manual 
delineation is time-consuming, labour-intensive, and subject to operator error. It is 
therefore less suitable as a routine diagnostic tool in a clinical setting. 
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Figure 2.2: Schematic illustration of individual regions of the left temporal lobe of a control subject. A) Regions produced by manual delineation 
(adapted from Chan et al., 2001b), B) Regions obtained from an automated technique (FreeSurfer) (Lehmann et al., 2010). EC - entorhinal cortex, PHG - 
parahippocampal gyrus, MITG - medial-inferior temporal gyrus, MTG - medial temporal gyrus, ITG - inferior temporal gyrus, STG - superior temporal gyrus. 
 
A – manual delineation B – automated delineation
Amygdala
Hippocampus
EC
PHG
Fusiform gyrus
MITG
MTG
ITG
STG
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2.2.1.3 Automated techniques 
With improving MRI quality, semi-automated and automated segmentation tools 
including the use of ‘brain atlases’ (template images with specific regions outlined) have 
been developed and are increasingly used to conduct not only ROI analyses, but also 
whole brain analyses which are not biased to a set of regions chosen a priori. Unlike 
relatively laborious manual delineation approaches, these techniques also have the 
advantage of being more reliable and potentially reducing operator time. There are 
online resources such as www.idoimaging.com which provide comprehensive and 
continuously updated overviews of current tools.  
 
2.2.1.3.1 Between-subject registration 
Many automated techniques require between-subject registration in order to achieve 
correspondence. A number of registration algorithms have been developed varying in 
their complexity and accuracy. Linear registration describes techniques where the same 
set of parameters is applied to all image voxels, for example to transform them onto a 
standard template. A rigid body registration applies translations and rotations in each of 
the x, y and z directions. This type of linear registration is referred to as having six 
degrees of freedom (dof). It is also possible to add scaling factors, increasing the 
degrees of freedom to nine. Finally, a 12 dof, or affine registration, includes shears in 
addition to the previous transformations. In contrast, non-linear registration describes a 
process in which the registration parameters are allowed to vary throughout the image 
(see Figure 2.3). This allows a more accurate matching of gyral anatomy by providing 
more freedom to warp one image onto another. There are a variety of different non-
linear matching procedures. For example, there are high-dimensional mapping 
techniques which aim to achieve an exact match between two images, eliminating 
morphological differences between scans. In theory any shape can be warped into 
another, but it is important that solutions are biologically plausible, so that the topology 
of brain tissue is maintained. This type of non-linear matching algorithm is generally 
based on a physical model, which includes some type of constraint to limit ‘unlikely’ 
deformations. One example is the fluid registration (see chapter 7, section 7.2.5) where 
deformations are confined by the properties of a viscous compressible fluid.  
 
The choice of registration algorithm depends on the question being addressed. All 
registration techniques result in images being in correspondence to a greater or lesser 
extent, i.e. one point on one image corresponds to a particular point on the other image. 
Theoretically these two points represent the same type of tissue in each scan although 
the correspondence is limited by the chosen algorithm. Note that the term ‘spatial 
normalisation’ refers to the mapping of a single subject's brain image into a standard 
space. This is commonly performed for both manual and automated procedures to 
ensure that all subjects and images are processed in the same stereotactic space and 
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that subsequent procedures are not affected by differences in head orientation and 
positioning. 
 
2.2.1.3.2 Brain atlases / templates 
Brain templates combined with atlases have two main uses: they can be used in order to 
obtain spatial correspondence between subjects within the atlas space or they can be 
used to delineate regions within native space of the region using a process of image 
registration and region propagation (see section 2.2.1.3.1). Originally atlases were 
derived from single subjects, such as the Montreal Neurological Institute (MNI)-single 
subject T1-volume used in AAL (Automatic Anatomical Labeling, Tzourio-Mazoyer et al., 
2002), or even single hemispheres such as the Talairach atlas brain (Talairach and 
Tournoux, 1988). However more recent atlases represent an average of multiple 
subjects or a library of subjects, with the advantage that they incorporate greater 
between subject variability. For example the brain atlas developed by Hammers et al. 
comprises 20 subjects and provides labels for a number of regions including temporal 
lobe structures, which can be used to propagate regions onto new subjects (Hammers et 
al., 2003). It should be noted, however, that the majority of brain atlases have the 
disadvantage that they represent labels which can be used to label regions on an MRI 
scan. Most of them do not represent tools which can perform automatic segmentations. 
Other software packages such as FSL (FMRIB Software Library) (Smith et al., 2004) are 
fully automated but only provide segmentations of a limited number of structures. 
 
2.2.1.3.3 Voxel-based morphometry 
Voxel-based morphometry (VBM) is a neuroimaging analysis technique that allows 
investigation of focal differences in brain anatomy between subject groups using 
statistical parametric mapping (SPM) (Ashburner and Friston, 2000, 
http://www.fil.ion.ucl.ac.uk/spm). It typically uses T1-weigthed volumetric MRI scans and 
performs statistical tests to compare scans from different groups on a voxel by voxel 
basis throughout the whole image. It represents an ‘unbiased’ method which is not 
dependent on a priori assumptions about which regions may be affected in a disease. 
VBM involves a number of processing steps including: i) spatial normalisation; ii) 
segmentation of the images into different tissue compartments (i.e. grey matter, white 
matter, CSF) with analysis typically being performed separately on each tissue class; iii) 
modulation which adjusts the image for the warping necessary during the spatial 
normalisation step in order for the resulting image to again represent volume; and iv) 
smoothing at each voxel in order for the value at a given voxel to become a weighted 
average of the surrounding voxels. The methods have been described in much detail by 
Ashburner and Friston (Ashburner and Friston, 2000). The spatial normalisation step 
ensures that all the subjects’ data are transformed into the same stereotactic space. It is 
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generally achieved by registering each image onto the International Consortium for Brain 
Mapping (ICBM) Montreal Neurological Institute (MNI) template image (Mazziotta et al., 
1995). Recently, DARTEL (SPM8; Wellcome Trust Centre for Neuroimaging, London, 
United Kingdom), a fast diffeomorphic registration algorithm, has been developed for 
use with VBM (Ashburner, 2007). This involves creating a mean image of all images 
taken, which serves as a subject-specific template. Subsequently, whole-brain images of 
individual subjects are normalized to the template, modulated, and smoothed. DARTEL 
has been shown to improve registration and provide precise and accurate localization of 
structural damage and functional overlays (Takahashi et al., 2010). Parametric statistical 
analysis is then performed on the smoothed images at every voxel with the tests 
normally used being t-tests. This generates maps showing all voxels that show 
differences in tissue intensities (commonly interpreted as differences in volumes) 
between groups at a certain, user-selected, p value. Because the statistical tests involve 
the comparison of a very large number of voxels, it is important to correct for multiple 
comparisons to reduce the occurrence of false positives. 
 
Whilst VBM has been widely used in neuroimaging research due to the fact that it is 
relatively quick and easy to apply, there are also certain limitations that need to be 
considered when using VBM and interpreting the results. First, VBM is greatly affected 
by variability which can reduce sensitivity for detecting group differences. Variability 
between individuals can be caused by heterogeneity within the sample as well as errors 
introduced by the preprocessing steps. For example, the power to detect a difference in 
a particular region is particularly dependent on the accuracy of the normalisation 
(Bookstein, 2001). VBM does not differentiate between changes in tissue content and 
local misregistration of images. This may be a particular problem for small structures 
such as the amygdala or hippocampus that not only have a complex shape but may also 
be highly variable between subjects (Good et al., 2002). Normalisation, however, has 
improved with the introduction of DARTEL. Variability and normalisation errors can also 
produce false negatives, which represents a further limitation of VBM. Whilst the 
presence of false positives (i.e. the rejection of a true null hypothesis) can, to some 
extent, be controlled for by using multiple comparison corrections, the occurrence of 
false negatives (i.e. the failure to reject a false null hypothesis) cannot be controlled for 
in VBM, and needs to be considered when interpreting the results. This means that if no 
difference was found between two groups in a certain brain region, this does not mean 
that there is no difference, but rather that no difference was detected using the current 
method. 
 
Furthermore, the segmentation step provides an additional source of error. The 
misclassification of tissue is especially likely in atrophic brains, because there is a 
greater potential for partial volume effects between grey matter and CSF, and because 
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tissue pathology may be associated with reduced grey/white matter contrast (Good et 
al., 2002). Errors in segmentation can also occur due to the displacement of tissue. This 
is a particular problem in subcortical grey matter structures surrounding the ventricles, 
which can shift due to enlargement of the ventricular system. However, it should be 
noted that segmentations have greatly improved with the introduction of the unified 
segmentation model in SPM5, which combines image registration, tissue classification, 
and bias correction within the same generative model (Ashburner and Friston, 2005). 
Finally, the smoothing step involves a trade-off: whereas high levels of smoothing 
increase the ability of VBM to detect grey matter differences by reducing the variance, 
excess smoothing diminishes its ability to accurately localize change. 
 
There are often significant variations across studies in the VBM preprocessing steps, the 
size of the smoothing kernel, and in the level of significance applied, making it difficult to 
compare results directly across studies. It is essential, therefore, that parameter choice 
is documented, as outlined in the paper by Ridgway et al. (Ridgway et al., 2008). 
 
2.2.1.3.4 Surface-based techniques 
An alternative method to investigate anatomical differences between groups is by using 
surface-based methods. These techniques are used to construct and analyse surfaces 
that represent structural boundaries within the brain. As such, they differ from voxel-
based techniques which analyse image properties at a voxel by voxel level. Whilst some 
of the processing steps are similar to those in VBM, there are also fundamental 
differences. Typically surface-based methods involve: i) brain segmentation which 
produces boundaries between grey and white matter; and white matter and CSF; ii) 
generation of corresponding surfaces by using a meshing algorithm; and iii) mapping of 
the surfaces to a unit sphere to achieve between-subject correspondence. Once the 
brain surfaces are in the same space and the gyri and sulci are well matched, a number 
of different variables can be assessed, which include measuring the distance between 
different surfaces, known as cortical thickness, sulcal depth, and also some local or 
global measures of area and curvature (e.g. gyrification). Cortical thickness measures 
have been extensively used in dementia research and a number of algorithms have 
been developed for this type of analysis (Dale et al., 1999; Lerch et al., 2005; 
MacDonald et al., 2000; Thompson et al., 2001). One of these tools which is widely used 
and is freely available from the web is FreeSurfer (Dale et al., 1999; Fischl et al., 1999, 
http://surfer.nmr.mgh.harvard.edu/fswiki).  
 
FreeSurfer allows a large number of different analyses, including the measuring of 
different morphometric properties of the brain such as cortical thickness, regional 
volumes (see Figure 2.2 for an example of temporal lobe regions obtained by 
FreeSurfer) and surface areas. The cortical surface stream of FreeSurfer involves the 
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following steps: registration to the Talairach atlas space, intensity normalisation, skull 
stripping, segmentation of white matter, and tessellation of the grey/white matter 
boundary, inflation of the folded surface tessellation patterns and automatic topology 
correction. This surface is then used as the starting point for a deformable surface 
algorithm to find the grey/white and grey/CSF surfaces. This method uses both intensity 
and continuity information from the surfaces in the deformation procedures to produce 
representations of cortical thickness, calculated as the closest distance from the 
grey/white boundary to the grey/CSF boundary at each vertex on the tessellated 
surface.  
 
A cortical surface-based atlas has been defined based on average folding patterns 
mapped to a sphere. Surfaces from individuals can be aligned with this atlas with a high-
dimensional nonlinear registration algorithm. The registration is based on aligning the 
cortical folding patterns and so directly aligns the anatomy instead of image intensities. 
The spherical atlas naturally forms a coordinate system in which point-to-point 
correspondence between subjects can be achieved. This coordinate system can then be 
used to create group maps.  
 
FreeSurfer further allows the extraction of subcortical volumes obtained from the 
volume-based stream (which is different to the surface-based stream described above). 
The stream consists of several stages (Fischl et al., 2002): the first stage is an affine 
registration with Talairach space specifically designed to be insensitive to pathology and 
to maximize the accuracy of the final segmentation (this is different to that used in the 
surface-based stream). This is followed by an initial volumetric labelling and intensity 
correction. A high dimensional nonlinear volumetric alignment to the Talairach atlas is 
then performed. After the preprocessing, labels are transferred onto the volume. Both 
the cortical and the subcortical labelling use the same basic algorithm. The final 
segmentation is based on both a subject-independent probabilistic atlas and subject-
specific measured values. The atlas is built from a training set, i.e., a set of subjects 
whose brains (surfaces or volumes) have been labelled by hand. These labels are then 
mapped into a common space (Talairach space for volumes and spherical space for 
surfaces) to achieve point-to-point correspondence for all subjects. 
 
Whilst techniques such as FreeSurfer have the advantage of being fully automated, they 
are also highly dependent on good image quality (i.e. good grey/white matter contrast). 
Poor image quality may cause the algorithm to either fail or to produce unsatisfactory 
results which may motivate further manual intervention, reducing the advantage of this 
method being an automated procedure. Furthermore, techniques such as FreeSurfer are 
also prone to fail in the presence of severe atrophy. This has been demonstrated in 
SemD patients who often show great atrophy in the left temporal lobe (Lehmann et al., 
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2010). Finally, unless segmentation protocols are similar across methods and studies, 
regions obtained by manual and automated methods can vary greatly, which makes 
comparisons between studies using manual and automated regions more difficult (see 
section 2.2.1.4). 
 
2.2.1.3.5 Machine-learning algorithms 
Classification algorithms are increasingly used to test whether specific imaging features 
can differentiate between different types of dementia. In neuroimaging research, 
machine-learning algorithms such as support vector machines (SVM, Vapnik, 1995; 
Vapnik, 1998) have been used to conduct such classification analyses. The standard 
SVM is a non-probabilistic binary linear classifier. It typically involves training a set of 
example inputs (e.g. scans of different subjects), with each input being defined as 
belonging to one of two categories (e.g. different groups). For each subsequent input the 
SVM predicts whether the subject is more likely to fall into one group or the other.  
 
In studies which assess whether subjects belong to one disease group or another, the 
SVM essentially represents these subjects as points (based on imaging features) in an 
n-dimensional space. The SVM then identifies the optimal separating hyperplane in this 
space such that subjects from each group lie as far as possible from the hyperplane on 
opposite sides. Once the hyperplane has been defined, scores can be generated by 
projecting the point (i.e. the subject) onto the normal of the hyperplane. The direction of 
the normal can be visualized as an image, showing the relative weights and signs of 
vertices’ contributions to the classifier scores.  
 
For small group analyses, where an example set to train the SVM is not available, the 
classifier can be trained using a leave-one-out loop (Wilson et al., 2009). By leaving 
each scan in turn entirely out of the training procedure, an unbiased estimation of 
generalisation accuracy is ensured. 
 
SVMs are increasingly used in imaging studies to test the ability of a certain imaging 
measure to distinguish between subject groups. Since new scans can be tested against 
trained data sets and can in turn be categorized as members of a particular clinical 
group (e.g. AD), it has been suggested that SVMs have the potential to become valuable 
diagnostic tools in the future (Kloppel et al., 2008). SVMs have the advantage that they 
generalize well to new data sets, and generalize across image sets from different 
centres (Kloppel et al., 2008). This is very important as it could facilitate the generation 
and use of SVMs for rarer forms of dementia (such as PCA and LPA) using scans from 
multiple imaging sites. 
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Whilst some patients may be differentiated relatively easily from controls using less 
intensive methods (e.g. using paper and pencil tests), these might be less specific in 
milder patients that only have very subtle cognitive impairments. Furthermore, SVMs 
may be used to differentiate disorders that show overlapping clinical symptoms and 
atrophy patterns, but differ in their neuropathological characteristics, such as AD and 
FTLD (see chapter 4). Unlike methods that include expert-dependent hippocampal 
tracing (2.2.1.2), SVMs are fully automated and can use all the information in a brain 
scan. The fact that SVMs are automated eliminates observer/experimenter bias, 
generates reproducible results with the same image set and makes the method much 
less labour-intensive. These are important characteristics for a method proposed for 
clinical use. 
 
Although the processing and preparation of a training dataset can be relatively time 
consuming, this may not necessarily be a limiting factor. First, this represents computer 
processing time without user interaction. Secondly, once a training dataset is prepared, 
spatial normalisation and classification of any new scan can be performed within 
minutes. Finally, the time required is likely to shorten further with increasing computing 
speeds. 
 
2.2.1.4 Differences between manual and automated methods 
Automated segmentation methods are increasingly used owing to the need for 
segmentation of large datasets which include thousands of scans. Studies which 
compare different segmentation algorithms are of increasing importance since 
inaccuracy of segmentation methodologies can lead to reduced power of a study to 
detect anatomical changes. For example, a recent study by Clark et al. showed that the 
choice of segmentation algorithm had the largest impact on variability, whereas the 
choice of pulse sequence had the second largest impact. It further showed that the 
classification of grey matter is the most variable, and that the optimal segmentation 
protocol may differ across tissue types (Clark et al., 2006). In particular segmentation 
methods which exhibit disease-related or atrophy-related biases can lead to 
overestimates or underestimates in subject group differences. However, studies which 
compare automated techniques with “gold standard” manual techniques or other 
automated techniques are often hampered by the lack of standardisation of 
segmentation protocols across laboratories on which methods are based. This is 
naturally unproblematic for laboratories where the techniques being compared have 
been developed, but for techniques to demonstrate wider utility, use at different centres 
is required. Therefore, in addition to traditional voxel overlap analyses which may be 
confounded by differences in protocols, studies which investigate whether patterns of 
atrophy in specific diseases are replicated across techniques are useful. 
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A small number of studies have focused on the comparison of different segmentation 
methods. In the FreeSurfer validation paper by Fischl et al., segmentation accuracy of 
FreeSurfer compared with manual delineations was assessed in seven healthy 
volunteers for two temporal lobe structures (hippocampus and amygdala), and other 
brain structures including the caudate, putamen, thalamus and ventricles, showing that 
FreeSurfer is comparable in accuracy to manual methods (Fischl et al., 2002). A study 
by Morey et al. compared FreeSurfer and FSL segmentations of the hippocampus and 
amygdala with manually delineated regions using 3T MRI scans of 20 healthy subjects 
(Morey et al., 2009). This study found relatively good correlations and agreements of 
volumes produced by FreeSurfer and manual methods, and overall greater voxel 
overlap and smaller volume differences of FreeSurfer regions compared with manual 
delineations than regions produced by FSL compared with manual methods. The 
percent volume overlap (Dice coefficient) between FreeSurfer and manual 
segmentations of the hippocampus was above 81%.  
 
In a study by Lehmann et al., eight temporal lobe structures in each hemisphere and 
ventricles were delineated using FreeSurfer and compared with manual segmentations 
in 10 control, 10 AD, and 10 SemD subjects (Lehmann et al., 2010). The study revealed 
differences in segmentation protocols between FreeSurfer and manual methods, 
including the exclusion of the temporal stem white matter in the manual segmentation 
which affected volumes of most temporal lobe regions (Figure 2.2). Another difference 
was the exclusion of the hippocampal tail in the manual hippocampal segmentations, 
and the inclusion of the cerebellum in the manual whole brain segmentations. Finally, 
differences in ventricular segmentations were observed, with manually segmented 
ventricles including the posterior horns of the ventricles which are not consistently 
included in the FreeSurfer ventricle segmentation. These differences in protocol led to 
differences in absolute volumes and overlap ratios between the methods, making the 
evaluation of segmentation accuracy of these methods problematic. However, despite 
differences in protocol and volumes, both methods showed similar atrophy patterns in 
the patient groups compared with controls, and similar right-left differences, suggesting 
that both methods distinguish between the three groups with similar accuracies. Other 
studies have focused on assessing the patterns of regional volume differences in 
different diseases. Hippocampal volumes produced by FreeSurfer were compared with 
manual measurements in patients with chronic major depressive disorder and healthy 
controls (Tae et al., 2008). FreeSurfer showed good agreement with manual method 
regarding hippocampal volumes; however, in the right hippocampus in particular 
volumes produced by FreeSurfer were greatly larger than those obtained from manual 
method. 
 
- 41 - 
Other studies have compared different automated techniques with each other. 
Klauschen et al. compared FSL, SPM5 and FreeSurfer using a set of simulated MRI 
data of 10 healthy brains obtained from BrainWeb (resembling ∼1.5 T), and a set of real 
1.5 T MRI data of 9 healthy volunteers (Klauschen et al., 2009). They showed that 
volumetric accuracy for grey and white matter was similar in SPM5 and FSL, and better 
than in FreeSurfer. FSL showed the highest stability for white, and FreeSurfer for grey 
matter for the simulated data set. Another study compared VBM with region-of-interest 
(ROI) measurements of temporal lobe structures in 10 AD patients and 10 SemD 
patients (Good et al., 2002). It was shown that VBM detects a general trend of atrophy 
similar to that of expertly labelled ROI measurements in both disease groups; however, 
they also found discrepancies in the ranking of severity and in the significance of volume 
reductions that were more marked in AD.  
 
 
2.2.2 Longitudinal image analysis 
Longitudinal image analysis can be used to assess the progression of tissue loss over 
time. It involves the comparison of two scans taken at different time points from the 
same subject. Each subject therefore acts as his/her own control, which can reduce 
between-subject variability in morphology. A number of different methods are available 
to quantify the change between different time points and most techniques rely on some 
form of within subject registration. 
 
2.2.2.1 Within-subject image registration 
One of the key steps for the majority of more recent longitudinal processing methods is 
the aligning of scans from different time points so that they are in the same spatial 
framework. However, in dementia, atrophy complicates matters since tissue is lost and 
replaced by fluid which makes very accurate tissue correspondence problematic for 
linear registration since this type of registration is only able to match the linear 
differences between the images (rotations, translations, scaling and shears), and the 
way in which the brain atrophies over time is not linear. The remaining lack of 
correspondence following linear registration (see difference image in Figure 2.3) is a 
mixture of atrophy and non-linear imaging artefacts. Following linear registration, 
changes in brain volume can be easier to visualise. This easy visualisation can be 
clinically useful since establishing whether a disease is progressing in a patient may be 
crucial in making an accurate diagnosis. The benefits of linearly co-registering two scans 
has been demonstrated in a study by Barnes et al. which showed that co-registration of 
two serial scans may improve visual diagnosis in dementia (Barnes et al., 2010). 
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2.2.2.2 Measuring change in volume and cortical thickness 
A number of techniques have been developed to study longitudinal changes in specific 
structures and across the whole brain. Widely used methods to quantify changes over 
time in whole brain volume are the boundary-shift integral (BSI) (Freeborough and Fox, 
1997) and SIENA (Structural Image Evaluation using Normalisation of Atrophy, Smith et 
al., 2001; Smith et al., 2002). Both techniques rely on pairs of images spatially matched 
using linear registration. The BSI determines the total volume through which the 
boundaries of the brain (or any given cerebral structure) have moved (Figure 2.3). It 
therefore measures volume change directly from voxel intensities. The original BSI 
algorithm has recently been improved by applying tissue-specific intensity normalisation 
and automated BSI parameters selection to improve consistency over time and between 
scanners (KN-BSI, Leung et al., 2010). The BSI method has been applied to measure 
whole brain atrophy in a range of neurological disorders including AD (Schott et al., 
2005), FTLD (Knopman et al., 2009), multiple sclerosis (Anderson et al., 2007), 
Huntington’s disease (Henley et al., 2006), and PSP (Paviour et al., 2006) and it is also 
used as an outcome measure in clinical trials of AD (Fox et al., 2005; Salloway et al., 
2009). SIENA involves a slightly different quantification approach but gives highly 
correlated results compared with BSI (Smith et al., 2002). Such changes in volume are 
often represented as annualised percent changes compared with baseline volume which 
allows for the fact that people have differing initial brain volumes.  
 
Another method which is used to assess volumetric changes in grey matter, white 
matter, and CSF over time across the whole brain is non-linear registration based 
techniques which quantify change on a voxel-wise basis determined by the deformation 
field required to match the images. One such technique is the fluid registration method 
(Freeborough and Fox, 1998). This technique takes the linearly registered paired images 
and registers these using a non-linear (fluid) algorithm which is based on a physical 
model of a compressible viscous fluid resulting in accurate tissue correspondence. The 
deformations required to achieve this non-linear registration can be stored and these 
represent how much and where the images needed to be warped in order to obtain 
accurate correspondence. This deformation field can be visualized as voxel-
compression maps which show regions that contract and expand over time (Figure 2.3).  
Fluid registration can be used to illustrate structural changes in individual subjects (an 
example is shown in Appendix 3), and it can be used in combination with VBM to assess 
volume changes in specific tissue types that are statistically significant, and compare 
these between subject groups. 
 
Finally, changes in cortical thickness can be measured and quantified using FreeSurfer 
(section 2.2.1.3.4) which has a longitudinal processing stream incorporated 
(http://surfer.nmr.mgh.harvard.edu/fswiki/LongitudinalProcessing). The longitudinal 
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stream involves the creation of a template brain using both time points, which represents 
a rough estimation of the segmentation and surface reconstruction. This template brain 
is then used to initiate the real segmentation and surface reconstruction of both time 
points. This procedure ensures that there is no bias towards any one time point.  
 
2.2.3  Diffusion tensor imaging (DTI) 
DTI is a relatively novel technique that allows the measurement of the diffusion of water 
in brain tissue, which gives information about the structural integrity of white matter. 
From DTI, white matter tracts throughout the brain can be identified (tractography) and 
such methods are useful in assessing connections and how these may be disrupted in 
different types of disease. 
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Figure 2.3: Structural T1 and difference images as well as examples of outcome measures for linear and non-linear registration. Shown are a 
baseline and a follow-up scan of a patient with PCA (left), difference images resulting from linear and linear plus non-linear registration of the repeat scan to 
the baseline (middle), and examples of outcome measures, namely BSI and voxel-compression map derived from linear and non-linear registration 
respectively (right). 
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2.3 Functional image analysis 
Functional imaging techniques are useful in measuring physiological activities within the 
brain, including changes in metabolism, blood flow or the chemical composition of certain 
substances in the brain. Techniques most commonly used in dementia research include 
single photon emission computerised tomography (SPECT), positron emission tomography 
(PET), and functional MRI (fMRI). Since the focus of this thesis is on structural imaging, these 
functional methods will only be described briefly. 
 
2.3.1 Techniques measuring metabolic changes 
Because metabolic changes have been suggested to coincide or even precede structural 
changes, measuring these changes does not only provide valuable insights into the 
underlying pathophysiological processes but may also aid early diagnosis. SPECT is a non-
invasive technique which uses gamma rays to produce 3D images of the brain. It requires the 
injection of gamma-emitting radioisotopes into the bloodstream of the subject. Brain 
metabolism can also be studied using PET, which is a non-invasive tomographic method for 
imaging the regional distribution of radioactive tracers. The most commonly used tracer is 
labelled glucose, [18F]fluorodeoxyglucose (FDG), which provides qualitative and quantitative 
estimates of the cerebral metabolic rate of glucose, an index of synaptic functioning and 
density (Pellerin and Magistretti, 1994; Rocher et al., 2003). PET provides very similar 
information as SPECT, and typically produces higher-resolution images. 
 
2.3.2 Functional MRI (fMRI) 
Functional MRI (fMRI) measures the haemodynamic response (i.e. change in blood flow) in 
the brain, from which inferences about the neural activity in the brain can be drawn. 
Historically, it has mainly been used to measure activation during performance of cognitive 
tasks, however, more recently it is increasingly used to assess brain activity during resting 
state and therefore provides useful information about the functional connectivity of networks 
in the brain (Greicius et al., 2003). 
 
2.4 Imaging pathology 
Imaging of pathological markers in the brain provides the opportunity to visualize and quantify 
the evolution of pathology in vivo. The first amyloid imaging agent developed to be used in 
humans was 18fluoro-labelled1,1-dicyano-2-[6-(dimethylamino)-2-naphthalenyl]propene 
(FDDNP), which is a fluorinated derivative of a non-specific cell membrane dye (Agdeppa et 
al., 2001). FDDNP binds in vitro to amyloid conformations of Aβ, as well as to tau and prion 
protein (Agdeppa et al., 2001; Bresjanac et al., 2003). Elevated FDDNP-uptake in one patient 
who came to autopsy matched regions with significant plaque and tangle pathology (Small et 
al., 2006). The most widely used amyloid marker, and one which appears to have superior 
amyloid detection, is 11C-labelled [N-methyl]-2-(4’-methylaminophenyl)-6-
hydroxybenzothiazole, or short Pittsburgh Compound-B (PIB) (Klunk et al., 2004). PIB binds 
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specifically to extracellular and intravascular fibrillar Aβ deposits. Post-mortem studies have 
shown that elevated regional PIB signal during life strongly correlates with in vitro measures 
of Aβ pathology (both plaques and vascular amyloid) found at autopsy (Bacskai et al., 2007; 
Ikonomovic et al., 2008). A number of other amyloid imaging tracers have been subsequently 
developed, which include F18 ligands (for review see Rabinovici and Jagust, 2009). 
 
2.5 Clinical application of imaging techniques 
 
2.5.1 Normal ageing 
The brain changes structurally throughout life: normal ageing, in the absence of a 
neurodegenerative process, is associated with structural changes in the brain (Fox and 
Schott, 2004). Since patterns of atrophy in AD and other dementias are typically compared 
with those in a healthy control group, it is important to understand the structural changes 
associated with normal ageing. A number of different image analysis techniques, including 
visual assessment, volumetric and surface-based methods, have been used to study atrophy 
patterns in healthy older controls.  
 
Early cross-sectional CT and MRI studies showed a reduction in whole brain volume and an 
increase in ventricular volume with advancing age (Coffey et al., 1992; Pfefferbaum et al., 
1994). Studies using manual and automated imaging techniques measuring changes in 
volume and cortical thickness on MRI have consistently demonstrated enlargement of the 
ventricles as well as atrophy in temporal, parietal and frontal regions (e.g. Allen et al., 2005; 
Good et al., 2001; Raz et al., 2004; Resnick et al., 2000; Salat et al., 2004). Longitudinal 
studies have further suggested that atrophy rates accelerate with advancing age (Fjell et al., 
2009; Scahill et al., 2003), with some regions (in particular in dorsal frontal and parietal 
association areas) showing a particularly strong non-linear association with age (Sowell et al., 
2003). Annualised whole brain atrophy rates have been reported to increase gradually from 
0.2% per year at age of 30-50 to 0.5% at age 75-80 years (Jack, Jr. et al., 2004; Resnick et 
al., 2003; Scahill et al., 2003; Schott et al., 2003; Silbert et al., 2003; Wang et al., 2002). 
Similarly, hippocampal atrophy rates increase from around 0.1-0.2% a year in apparently 
healthy control subjects aged 30-50, to around 0.8% in subjects in their mid-70s, rising further 
to 1.5-2% a year at an age of 80-90 in subjects who do not have a diagnosis of dementia (Fox 
and Schott, 2004; Jack, Jr. et al., 2000; Schott et al., 2003). Whilst the association of 
pathological changes with age attenuates in the very old, cerebral atrophy was shown to 
maintain a relationship with age in younger old persons with dementia (75 years of age) and 
older old persons with dementia (95 years of age, Savva et al., 2009). 
 
Interestingly, studies measuring amyloid deposition in healthy controls using PIB-PET have 
reported around 20% of older control subjects being PIB-positive (Aizenstein et al., 2008; 
Rowe et al., 2007, mean age 74 and 73 years respectively), which means that there is a 
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certain proportion of cognitively normal older subjects showing levels of amyloid deposition 
similar to that found in AD. The question of whether these subjects represent very early 
stages of AD is unclear. 
 
2.5.2 Alzheimer’s disease 
Neuroimaging techniques have been used extensively to study AD. One of the main 
objectives of these studies is the identification of atrophy patterns which are typical for AD, 
and which may therefore aid the differentiation of AD from other dementias and normal 
ageing. Atrophy in the medial temporal lobe has been shown to occur early in the disease 
which is in accordance with pathological and cognitive features of AD (early studies include 
Ball et al., 1985; Fox et al., 1996b; Jack, Jr. et al., 1997; Lehericy et al., 1994). Atrophy in the 
medial temporal lobe, in particular in the hippocampus, has been shown to be a good marker 
to distinguish AD from normal ageing. For example, visual assessment using Scheltens scale 
has been shown to discriminate well between AD and healthy controls (Scheltens et al., 
1992). It also correlates well with manual delineations of medial temporal lobe structures 
(Bresciani et al., 2005; Scheltens et al., 1992; Wahlund et al., 2000) and has been shown to 
predict conversion from MCI to AD (Korf et al., 2004).  
 
The predictive power of atrophy in structures of the medial temporal lobe, in particular in the 
hippocampus, has been supported by manual volumetric studies (Jack et al., 1999; Rusinek 
et al., 2004). However, since the region showing earliest tau accumulation is the entorhinal 
cortex (Arnold et al., 1991; Braak and Braak, 1991), it has been suggested that atrophy of this 
region may be a better marker of conversion to AD. Hippocampal and entorhinal volume loss 
have been shown to have similar accuracies for discriminating AD from controls and both 
measures together were shown to improve discrimination accuracy, suggesting that AD is 
characterized by atrophy in both these regions (Juottonen et al., 1999). However, the 
diagnostic benefits of atrophy in the entorhinal cortex are attenuated by the higher variability 
of the manual volumetric measures of this region due to differences in the manual delineation 
protocols used in imaging studies (Du et al., 2001; Xu et al., 2000). Manually obtained regions 
of the entorhinal cortex have also been shown to differ to those obtained by automated 
methods such as FreeSurfer (Lehmann et al., 2010, Figure 2.2). Overall, a number of other 
manual volumetric investigations have revealed a consistent pattern of regions showing 
greater atrophy in AD compared with healthy controls; these include the hippocampus, 
entorhinal cortex, amygdala, and parahippocampus (e.g. Basso et al., 2006; Chan et al., 
2001c; Jack, Jr. et al., 1992; Juottonen et al., 1998; Teipel et al., 2006), as well as cingulate 
gyrus (Barnes et al., 2007a; Jones et al., 2006; Killiany et al., 2000). Whole brain losses are 
an early feature too (Fox et al., 1996a; Ridha et al., 2006). With disease progression, atrophy 
typically spreads from focal temporal lobe regions to cortical areas (Fox et al., 1996b; Scahill 
et al., 2002). 
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Studies using VBM support these findings, showing significant grey matter loss mainly in the 
medial temporal lobe, but also in the posterior cingulate gyrus, precuneus, insula, temporal-
parietal association cortex and prefrontal gyrus in AD (Baron et al., 2001; Boxer et al., 2003; 
Good et al., 2002; Karas et al., 2004). A number of studies assessing patterns of cortical 
thickness have also demonstrated cortical thinning predominantly in temporal and parietal 
regions in AD when compared with healthy controls (Du et al., 2007; Lerch et al., 2005; 
Richards et al., 2009). Cortical thinning in these areas has also been shown to separate AD 
groups from controls (Lerch et al., 2008). 
 
Longitudinal volumetric studies have given further insights into the progression of atrophy 
patterns in AD. Studies have demonstrated whole brain atrophy rates of around 2% per year 
in AD which is several times higher than that found in healthy controls (0.2-0.5% per year 
depending on age, Bradley et al., 2002; Evans et al., 2010; Fox and Freeborough, 1997; 
Jack, Jr. et al., 2005; O'Brien et al., 2001; Wang et al., 2002). Measures of whole brain 
atrophy rate have been used as an outcome measure in clinical trials of therapies targeted at 
AD pathology (Fox et al., 2005; Salloway et al., 2009). Whole brain atrophy has been shown 
to be non-linear, with atrophy rates gradually increasing as the disease progresses (Chan et 
al., 2003). Ventricular expansion has also been shown to be a non-specific marker of 
progression, with studies demonstrating annual expansion rates between 4-8% (of baseline 
ventricular volume) in AD (Jack, Jr. et al., 2004; Schott et al., 2005; Whitwell et al., 2007b). 
Atrophy rates for the hippocampus have been found between 4-7% per year (Barnes et al., 
2009 (meta-analysis); Cardenas et al., 2003; Du et al., 2004; Hashimoto et al., 2005; Jack, Jr. 
et al., 1998; Jack, Jr. et al., 2000), whereas atrophy rates for the entorhinal cortex tend to be 
a little higher, around 7-9% per year (Cardenas et al., 2003; Du et al., 2004; Schott et al., 
2003).  
 
An increasing number of studies in AD report atrophy in posterior regions such as precuneus 
and posterior cingulate gyrus (Barnes et al., 2007a; Frisoni et al., 2007; Galton et al., 2000). 
Atrophy in posterior regions may be particularly prominent in early-onset AD (Frisoni et al., 
2007; Ishii et al., 2005a; Shiino et al., 2008). Amyloid deposition is seen in posterior regions 
very early in AD (e.g. Devanand et al., 2010; Kemppainen et al., 2007; Klunk et al., 2004). 
The FDNNP-PET-tracer, which binds to both tangles and plaques, shows increased uptake in 
AD compared with controls in the entorhinal, inferior temporal and frontal cortices, but also in 
parietal and secondary visual cortex regions (Shin et al., 2010).  
 
Recent studies using fMRI have provided new insights into the functional connectivity of 
different brain regions. There is increasing evidence that the regions typically affected in AD 
overlap with a network of regions active during resting state which is referred to as the 
‘default-mode network’ (Greicius et al., 2003). The default-mode network represents a 
network of regions which show co-ordinated low frequency fluctuations and elevated activity 
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during resting state (Buckner et al., 2008; Raichle et al., 2001). The key regions associated 
with the default-mode network are the medial temporal lobe, lateral parietal regions, 
precuneus, extending into posterior cingulate and retrosplenial cortices as well as medial and 
lateral frontal regions. The same regions that are activated at rest appear to be suppressed 
during various cognitive tasks, including the encoding of new memories (Pihlajamaki et al., 
2008). There is also evidence that failure to suppress activity in some of the core default-
mode regions is associated with unsuccessful encoding and poor performance in subsequent 
memory tests in cognitively normal young and old subjects (Grady et al., 2006; Miller et al., 
2008; Otten and Rugg, 2001). Future studies should provide valuable insights into how 
functional networks are affected in different phenotypical presentations of AD. 
 
2.5.3 PCA 
As the term PCA suggests, the syndrome is associated with tissue loss primarily of the 
occipital, parietal and temporo-occipital cortices. Whilst the neuroimaging signature of PCA 
may often be evident from clinical inspection of structural MR images (e.g. DellaSala et al., 
1996; Galton et al., 2000; Mendez et al., 2002, Figure 1.1), image analysis tools can be useful 
in localizing and quantifying the patterns of atrophy in these patients. To date only one study 
has used VBM to assess patterns of grey matter atrophy in PCA, and compared these with 
healthy controls and typical AD (Whitwell et al., 2007a). This study revealed distinct patterns 
of grey matter loss in both the PCA and typical AD group compared with controls, however, 
the direct comparison between PCA and typical AD did not show any statistically significant 
differences after multiple comparison correction. Differential patterns of cortical thickness 
between PCA and typical AD, as well as longitudinal changes in grey matter volume and 
cortical thickness in PCA have previously not been investigated. 
 
There have been a greater number of group-based functional imaging studies than structural 
imaging in PCA. Data from functional imaging studies using SPECT and FDG-PET are often 
consistent with structural changes in occipitoparietal areas (e.g. Aharon-Peretz et al., 1999; 
Cohen et al., 2010; Goethals and Santens, 2001; Nestor et al., 2003; Pietrini et al., 1996). 
Using SPECT, Ross et al. showed hypoperfusion in 4 PCA patients mainly in the bilateral 
parietal lobe (Ross et al., 1996). Using FDG-PET, Freedman et al. showed strikingly 
asymmetric hypometabolism with areas in the left hemisphere showing greater reductions 
than in the right (Freedman et al., 1991). The area showing greatest reduction in glucose 
metabolism (50%) was shown to be the left occipital lobe. Wakai et al. showed reduced 
metabolism mainly in dorsal regions, also asymmetric (Wakai et al., 1994). In addition to 
posterior regions, FDG-PET has revealed specific areas of hypometabolism in the frontal eye 
fields bilaterally which may occur secondary to loss of input from occipitoparietal regions and 
underpin ocular apraxia in PCA (Nestor et al., 2003).  
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To date only a very limited number of studies have assessed patterns of amyloid deposition 
using PIB-PET in PCA. Two single case studies have reported increased Aβ accumulation 
predominantly in the occipital and parietal lobes (Kambe et al., 2010; Tenovuo et al., 2008). 
Ng et al. further showed greater Aβ deposition in the occipital lobe in a single PCA patient 
compared with 10 typical AD subjects (Ng et al., 2007). Only one study has compared PIB 
uptake in a group of PCA patients (N=12) with a group of typical AD (N=14) (Rosenbloom et 
al., 2010). Interestingly, there was no evidence of a significant difference in amyloid 
deposition between PCA and typical AD, with both groups showing diffuse PIB uptake 
throughout frontal, temporoparietal and occipital cortex. However, this study may not have 
been powered to detect significant differences in the direct comparison.  
 
New image analysis tools such as DTI have been applied to investigate atrophy in the white 
matter tracts in PCA. Yoshida et al. applied DTI to 1 PCA patient and compared it with 5 
typical AD patients (Yoshida et al., 2004). The fractional anisotropy (FA) index was lower in 
the splenium (posterior end) of the corpus callosum than the genu (anterior end) in the PCA 
patient, whereas the typical AD group showed the reversed pattern. The PCA patient further 
showed reduced anisotropy and fiber volume in the splenium compared with typical AD. 
These findings may suggest that the splenium of the corpus callosum degenerates 
secondarily as a result of the neuronal degeneration of the temporal, parietal and occipital 
cortices. A more recent longitudinal DTI study by Duning et al. assessed the progression of 
white matter changes in 1 PCA patient over a period of 15 months, and compared the FA and 
volumetric changes with 1 typical AD patient and 65 healthy controls (Duning et al., 2009). 
The PCA patient showed reductions in FA mainly in the occipital lobe in the early stages of 
the disease which, with disease progression, tended to align with the FA ratios of the typical 
AD patient, involving increasingly regions in the parietal lobe. These results may suggest that 
PCA begins as a distinct clinical syndrome with its later course turning into a final pathway 
shared with typical AD. 
 
2.5.4 FTLD 
Clinically, the distinction between patients with AD and FTLD pathology is often challenging 
since there is considerable overlap in both the clinical symptoms and the cognitive domains 
impaired (Hodges et al., 2004; McKhann et al., 1984; Neary et al., 1998; Siri et al., 2001). 
Cross-sectional structural MRI studies have revealed characteristic patterns of atrophy in 
different FTLD phenotypes, mainly affecting temporal and frontal lobe regions (e.g. Grossman 
et al., 2004; Rosen et al., 2002; Whitwell et al., 2005a). Delineation of temporal lobe 
structures has been shown to provide an effective tool to discriminate between AD and FTLD 
phenotypes (Chan et al., 2001b; Galton et al., 2001; Laakso et al., 2000, Figure 2.2). 
Longitudinal studies in SemD have suggested that patients who present with predominantly 
left-sided temporal lobe atrophy develop clinical and structural features of right temporal lobe 
damage as the disease evolves (Chan et al., 2001c; Diehl-Schmid et al., 2006; Seeley et al., 
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2005). In patients with disease duration of around 4 years, the right temporal lobe has further 
been shown to atrophy more rapidly than left temporal lobe regions (Rohrer et al., 2008). 
Whole brain volume loss as measured using the BSI has been shown to be between 1-3% 
per year, whereas ventricular expansion was shown to be between 6-12% per year (Gordon 
et al., 2010; Knopman et al., 2009; Whitwell et al., 2008a). Both whole brain and ventricular 
BSI measures produced feasible sample size estimates for detecting meaningful treatment 
effects, suggesting that these semi-automated methods might be useful biomarkers to assess 
progression in FTLD (Gordon et al., 2010). 
 
Automated methods such as VBM measuring grey matter and cortical thickness have also 
been shown to aid the distinction between AD and FTLD (e.g. Du et al., 2007; Gee et al., 
2003; Grossman et al., 2004; Kitagaki et al., 1998). However, because medial temporal lobe 
atrophy is also a hallmark of AD, a division based on MRI is problematic, leading to 
misdiagnoses. For example, a post-mortem study revealed that 32% of patients diagnosed 
with a language subtype of FTLD (i.e. PNFA, SemD) had AD pathology (Knibb et al., 2006). 
Information about metabolic and pathological changes in these groups as measured using 
FDG-PET and PIB-PET, respectively, may aid clinical distinction from AD (Drzezga et al., 
2008; Foster et al., 2007; Rabinovici et al., 2007). 
 
2.6 Chapter conclusions 
Structural image analysis is a valuable tool to exclude treatable causes of cognitive deficits 
and to aid diagnosis. Quantification of structural changes using serial imaging is a powerful 
and objective measure of disease progression and as such can be useful in both diagnosis 
and in clinical trials. Other forms of imaging give complementary information regarding 
function and pathology in the brain. These methods have been used to describe changes in 
the brain owing to normal ageing as well as the natural history of AD, PCA and other 
neurodegenerative diseases such as FTLD. 
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3. METHODS OVERVIEW 
 
3.1 Chapter introduction 
This chapter provides a general overview of the subjects and the methods used in the 
experiments presented in this thesis. Deviations from the procedures described here as well 
as relevant additional details are provided in the corresponding chapters.  
 
3.2 Subjects 
 
3.2.1 Healthy controls 
Neurologically healthy subjects without family history of dementia were recruited as controls. 
These were mostly spouses of affected or at-risk study participants; a small number of normal 
volunteers were also included. Typically individuals had a detailed history taken and 
underwent neurological and brief neuropsychological examination which includes the Mini-
Mental State Examination (MMSE) (Folstein et al., 1975). If there was no evidence to suggest 
cognitive problems and no contraindications to MRI, subjects underwent MR scanning. The 
spouses of study subjects were usually assessed and scanned on the same day as their 
partners. 
 
3.2.2 Patients 
All clinically affected subjects had attended the Specialist Cognitive Disorders Clinic at the 
National Hospital for Neurology and Neurosurgery, Queen Square, London, UK. This is a 
secondary/tertiary referral centre and consequently these individuals tend to represent 
younger patients and those in whom there is more diagnostic uncertainty. The subjects 
recruited from the clinic included patients with sporadic AD (including typical, amnestic 
cases), PCA patients, and FTLD subjects. All patients underwent full clinical and 
neuropsychological assessment as well as imaging. 
 
3.2.3 Pathologically-proven cases 
Some patients agreed to a post-mortem to obtain confirmation of the underlying pathology 
and disease, and to contribute to research. These cases are very valuable since pathological 
confirmation is still regarded as the only way to obtain a definite diagnosis of disease. 
Additionally, some patients had a brain biopsy taken to determine the cause of disease; this 
usually involves the right (or non-dominant) frontal lobe. Brain biopsy cases are more likely to 
be younger individuals with dementia where a treatable cause (e.g. vasculitis) is considered.  
 
Whilst including post-mortem confirmed cases in research studies has the great advantage of 
having a definite confirmation of the underlying pathology in each subject, it may also 
introduce a bias in that patients may be more atypical and have an earlier onset of disease 
than patients that did not go to post-mortem and that are typically seen in memory clinics and 
- 53 - 
referral centres. Therefore, for all studies that included pathologically-confirmed subjects in 
this thesis, patient notes were reviewed to assess the ante-mortem clinical diagnosis of each 
subject, ensuring that patients who were included as ‘typical amnestic AD’ patients did indeed 
have a typical amnestic presentation during life.  
 
All subjects have given written informed consent and the Local Ethics Research Committee 
had given approval of all studies detailed in this thesis. 
 
3.3 Clinical assessment 
All subjects attending the Specialist Cognitive Disorders Clinic undergo comprehensive 
diagnostic evaluation. A full history is taken from the patient and (usually separately) from a 
close informant. A full clinical assessment is performed, which typically includes: 
1) Detailed neuropsychology in order to establish the nature and severity of any cognitive 
deficits. 
2) Standard screening blood tests to exclude other treatable causes of cognitive problems 
such as impaired renal or liver function, B12 and thyroid function.  
3) EEG to exclude seizures, or identify patterns indicative of a particular type of dementia. 
4) Neuroimaging, typically MRI, in order to exclude other treatable causes such as tumours 
and subdural haematomas and assess patterns of atrophy and vascular disease. 
 
In addition to the routinely administered assessments above, patients may also undergo: 
1) Genetic testing: In affected individuals with an age at onset or family history suggestive of 
an autosomal dominant inheritance, screening for known genetic mutations (AD or FTLD as 
appropriate) may be undertaken. In at risk cases where individuals have a known mutation in 
their family, genetic testing may be offered to determine whether the subject is carrying the 
mutation. This is supported by a genetic counselling service. 
2) Lumbar puncture and CSF analysis: This investigation may be used to detect evidence of 
inflammation and to measure neuron-specific proteins (tau and Aβ1-42). 
 
3.4 Patient inclusion criteria 
All PCA and typical, amnestic AD patients included in research studies described in this 
thesis had to fulfil a number of stringent inclusion criteria based on performance on specific 
neuropsychological tests. These are designed to minimize the overlap between these two 
groups whilst excluding suspected non-AD pathologies where possible. 
 
3.4.1 PCA 
Individuals were only included in the PCA group if clinical assessment and investigation did 
not suggest a non-AD dementia (e.g. DLB, CBD) and if they also fulfilled the following 
behavioural criteria: i) relatively preserved episodic memory (>5th percentile on a Recognition 
Memory Test; Warrington, 1984; Warrington, 1996) and ii) neuropsychological deficits (<5th 
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percentile) in at least two of the following four tests of posterior functions: 1) object perception  
(VOSP (Visual Object and Space Perception Battery) Object Decision test; Warrington and 
James, 1991, Appendix 4); 2) space perception (VOSP Number Location test, Appendix 4); 3) 
calculation (Graded Difficulty Arithmetic test; Jackson and Warrington, 1986) and 4) spelling 
(Graded Difficulty Spelling test; Baxter and Warrington, 1994). In addition to these 
neuropsychological criteria, all PCA patients fulfilled the clinical criteria proposed by Mendez 
et al. and Tang-Wai et al., summarized in chapter 1 (section 1.2.2.5), and Appendix 2 
(Mendez et al., 2002; Tang-Wai et al., 2004). It should be noted that, whilst all PCA patients 
had to fulfil the above criteria at some stage in their clinical history, at the time of experimental 
investigations some PCA patients may have progressed to a more global pattern of 
impairment including memory impairment.  
 
3.4.2 Typical, amnestic AD 
Typical AD patients had to fulfil NINCDS-ADRDA criteria for probable AD with recently 
proposed revisions (Dubois et al., 2007; McKhann et al., 1984), and had to have a history 
suggestive of an amnestic presentation. Those individuals with typical AD who were included 
for comparisons with PCA also had to demonstrate significant episodic memory impairment 
(<5th percentile on verbal and visual Recognition Memory Tests; Warrington, 1984; 
Warrington, 1996). 
  
3.5 Imaging 
 
3.5.1 MRI acquisition 
The majority of scans were acquired on a 1.5T Signa MRI scanner (General Electric, 
Milwaukee, Wisconsin, USA) using a spoiled gradient echo (SPGR) technique. Scans 
typically included a sagittal T1-weighted scout sequence, an axial dual-echo sequence (T2-
weighted and proton-density weighted) and a T1-weighted volumetric image (124 contiguous 
1.5mm slices). A small number of scans were acquired on a Siemens Trio TIM 3T scanner 
using a magnetization-prepared rapid acquisition with gradient echo (MPRAGE) sequence. 
Imaging parameters varied according to study, details of which are given in Appendix 5. 
 
3.5.2 Image processing software 
Digitised images were transferred to a Linux workstation. A number of different software 
packages and programs were used for image and statistical analyses. 
  
3.5.2.1 MIDAS 
The MIDAS (Medical Information Display and Analysis System) software (Freeborough et al., 
1996; Freeborough et al., 1997) allows simultaneous multiplanar display of 3D imaging data. 
Brain structures, including whole brain (Freeborough et al., 1997) and ventricles, can be 
delineated using both semi-automated and manual procedures. The whole brain 
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segmentation tool is semi-automated and uses interactive thresholding, together with a series 
of erosions and dilations, to separate brain from non-brain-tissue such as scalp and dura. The 
simultaneous display of orthogonal views allows the operator to outline structures on one view 
(e.g. coronal view) whilst the segmentation is updated in real time in other views (e.g. sagittal 
and axial). Different types of registration (linear and non-linear), as described in chapter 2 
(sections 2.2.1.3.1 and 2.2.2.1), can be implemented within MIDAS over regions of interest 
such as whole brain. Quantification of volumes and change in volumes of specific structures 
can be performed using MIDAS. 
 
3.5.2.2 MATLAB  
Matlab (matrix laboratory) is a high-level language and interactive computing environment 
developed by MathWorks (Sherborn, Massachusetts). It allows matrix manipulations, plotting 
of functions and data, implementation of algorithms, creation of user interfaces, and 
interfacing with programs written in other languages. Software packages used in this thesis 
which were implemented in Matlab include SPM (section 3.5.3.2.1) and SurfStat (section 
3.5.4.2.2). 
 
 
3.5.3 Image analysis techniques 
3.5.3.1 Visual rating scales 
Visual rating scales are a convenient way of assessing atrophy patterns and may aid 
differential diagnosis in a clinical setting. Two different scales were used in this thesis: 
Scheltens scale to assess medial temporal lobe atrophy (MTA) (Scheltens et al., 1992) and a 
novel scale assessing posterior atrophy (PA) which was developed by Esther Koedam (VU 
Medical Centre, Amsterdam) and me. 
 
3.5.3.1.1 Medial temporal lobe atrophy (MTA) scale 
Visual ratings of MTA using Scheltens scale (Scheltens et al., 1992) are typically performed 
on T1-weighted images viewed in the coronal plane. The MTA scale rates atrophy on a 5-
point scale (Figure 3.1): 0 = absent, 1 = minimal, 2 = mild, 3 = moderate and 4 = severe, 
based on the width of the choroid fissure, the height of the hippocampus, and the width of the 
temporal horn. Separate scores for the left and right hemispheres are acquired. 
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Figure 3.1: Scheltens scale of medial temporal lobe atrophy. This 5-point scale rates the degree of atrophy in the medial temporal lobes based on the 
height of the hippocampal formation and the width of the choroid fissure and the temporal horn (circled region): A) grade 0=no atrophy; B) grade 1=minimal 
atrophy; C) grade 2=mild atrophy; D) grade 3=moderate atrophy; E) grade 4=severe atrophy.  
A B
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3.5.3.1.2 Posterior atrophy (PA) scale 
The PA scale was developed in conjunction with Esther Koedam (Amsterdam) and is 
described in detail in chapter 5, section 5.2. In brief, PA was scored on T1-weighted images 
viewed in the sagittal, axial and coronal planes. Separate scores for the left and right 
hemispheres were obtained. The 4-point scale (0 = no atrophy, 1 = mild widening of the sulci 
without evident volume loss of the gyri, 2 = substantial widening of the sulci and volume loss 
of the gyri, grade 3 = severe end-stage atrophy) includes the posterior cingulate sulcus, 
precuneus, parietal-occipital sulcus and parietal lobe. An overall score was given based on 
the presence of atrophy in all these regions. When there was a difference between scores in 
the different planes (e.g. score 1 for the sagittal view and score 2 for the axial view), the 
highest score was given.  
 
3.5.3.2 Image processing for voxel or vertex-wise whole brain analyses 
 
3.5.3.2.1 VBM 
VBM analyses were performed using either SPM version 5 or 8 (specified in corresponding 
chapters). Images were first converted to NIFTI (http://nifti.nimh.nih.gov) format and rigidly 
reoriented to standard space (ICBM template). The reoriented scans were then segmented 
into grey and white matter using a unified model (Ashburner and Friston, 2005). Default 
values were used for bias regularization (0.0001) and full-width at half-maximum (FWHM) cut-
off (60 mm). The resulting grey and white matter segments of all subjects were then imported 
for use with DARTEL (Ashburner, 2007) which iteratively registered the segments to an 
evolving estimate of their group-wise average. The segments were then normalized using the 
DARTEL transformations, modulated to account for local volume changes, and finally 
smoothed with a 6mm FWHM kernel. The smoothed modulated DARTEL-imported segments 
were then used for the analysis. Note that the procedure of using DARTEL-imported 
segments is described as an ‘alternative approach’ in the SPM8 manual 
(www.fil.ion.ucl.ac.uk/spm/doc/manual.pdf). It differs to the more standard approach of 
normalising all images to MNI space. In this thesis, coordinates extracted of specific clusters 
therefore represent DARTEL coordinates which were converted to MNI coordinates as 
specified in the corresponding chapters.  
 
3.5.3.2.2 FreeSurfer 
Cortical thickness analyses were performed using version 4.0.3, 4.1.0, 4.3.0 or 4.5.0 (the 
particular version is specified where used). An overview of bug fixes, new features and 
remaining issues for each version can be found on 
http://surfer.nmr.mgh.harvard.edu/fswiki/ReleaseNotes. One important fix concerns changes 
to the longitudinal stream in version 4.5.0. Improvements to the longitudinal stream include 
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the creation of a template brain using all time points which is used to initiate the actual 
surface reconstructions for each time, avoiding bias towards any one time point (chapter 2, 
section 2.2.2.2). 
 
Image processing in FreeSurfer involved the following steps: intensity normalisation, skull 
stripping, segmentation of white matter, and tessellation of the grey/white matter boundary, 
inflation of the folded surface tessellation patterns and automatic topology correction. This 
surface was then used as the starting point for a deformable surface algorithm to find the 
grey/white and grey/CSF surfaces. This method uses both intensity and continuity information 
from the surfaces in the deformation procedures to produce representations of cortical 
thickness, calculated as the closest distance from the grey/white boundary to the grey/CSF 
boundary at each vertex on the tessellated surface. Thickness measures were mapped to the 
inflated surface of each subject’s brain reconstruction, allowing visualization of data across 
the entire cortical surface. All images were aligned to a common surface template using a 
high-resolution surface-based averaging technique that aligned cortical folding patterns. 
Cortical thickness was smoothed with a 20mm FWHM surface-based Gaussian kernel to 
reduce local variations in the measurements for further analysis.  
 
In all FreeSurfer analyses described in this thesis, two modifications to the standard 
FreeSurfer processing stream were undertaken. First, a different skull stripping algorithm was 
applied which used a brain mask which was locally generated by a semi-automated 
segmentation procedure within MIDAS (section 3.5.2.1, Freeborough et al., 1997). Secondly, 
the white matter mask was modified by adding the ventricle segmentations from the 
FreeSurfer volume processing stream to improve the ventricle regions and limit the 
misclassification of CSF. 
 
All images were carefully visually inspected to ensure accurate identification of the grey/white 
matter boundary and the pial surface. Most scans underwent manual editing involving the 
addition of control points as well as changes to the white matter segmentations and the brain 
masks, as suggested on http://surfer.nmr.mgh.harvard.edu/fswiki/FsTutorial/Troubleshooting. 
Whilst manual editing may have introduced a bias into the results, all edits were performed 
before group differences were examined. However, the editing process resulted in improved 
grey matter segmentations as determined by visual inspection. To the best of my knowledge, 
there is, to date, no study that has systematically evaluated potential biases and effects of 
manual editing on the results obtained by FreeSurfer. It should further be noted that rerunning 
the longitudinal cortical analysis (chapter 7) using unedited scans produced very similar 
results to those presented in this thesis. Further details on how much editing was performed 
in each study are given in corresponding chapters. 
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3.5.4 Statistical models and software 
 
3.5.4.1 Stata 
Most statistical analyses in this thesis were conducted in STATA (Stata Corporation, College 
Station, TX, USA). STATA is a standard statistical package used for performing basic 
statistical analyses and producing graphs. Version 10 (Intercooled) was used for the majority 
of statistical analyses in this thesis. Demographical univariate group differences were 
analysed using t-tests and ANOVAs for continuous variables and χ2 tests for categorical data 
unless specified.  
 
3.5.4.2 Voxel and vertex-wise analyses  
 
3.5.4.2.1 VBM statistical analysis 
For the analysis, an explicit mask was applied to include only voxels for which the intensity 
was at least 0.1 in at least 80% of the images. This was preferred to the default ‘absolute 
thresholding’ mask option in SPM which would exclude any voxels for which one or more 
images had a value of less than 0.1 and therefore perhaps be unduly influenced by a single 
very atrophic or poorly registered scan (Ridgway et al., 2009). Results are displayed as 
overlays on a study-specific template which was created by normalizing all native space 
images using the DARTEL transformations and calculating the average of the warped brain 
images. A general linear model was typically used as described below. 
 
3.5.4.2.2 FreeSurfer statistical analysis 
Cortical thickness data from FreeSurfer were analysed and visualized using a Matlab toolbox 
called SurfStat (http://www.math.mcgill.ca/keith/surfstat). This is a freely available tool 
downloadable from the web which can be used for the statistical analysis of univariate and 
multivariate surface and volumetric data. Again, a general linear model was typically used as 
described below. 
 
3.5.4.2.3 General linear model (GLM) 
Imaging data were typically analysed using a general linear model (GLM). A GLM is a 
statistical linear model which can be expressed as follows: Y = b*x + ε, where Y is a matrix 
with series of multivariate measurements, x is a matrix that might be a design matrix, b is a 
matrix containing parameters that are usually to be estimated and ε is a matrix containing 
errors or noise. 
 
In the studies described in this thesis, GLMs were performed on a vertex-by-vertex or voxel-
by-voxel level. Atrophy A (i.e. volume or thickness) is typically modelled as a function of 
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group, controlling for specific co-variates, such as age, gender and TIV. For example, a GLM 
to compare two groups adjusting for age, gender and TIV looks as follows: A = β1 group1 + β2 
group2 + β3 age + β4 gender + β5 TIV + ε. The contrasts of interest were then calculated using 
t-tests (two-tailed for FreeSurfer, one-tailed for VBM) between the estimates of the group 
parameters, e.g. β1 and β2 to compare group1 with group2. The specific models used in each 
study are described in the corresponding chapters. 
 
3.5.4.2.4 Difference maps 
Differences between groups are visualized as difference maps. For FreeSurfer analyses, 
statistically-significant differences are presented as p-maps, whereas for VBM data 
statistically-significant differences are shown as t-maps. Corrections for multiple comparisons 
were made to control the false discovery rate (FDR) at a 0.05 level of significance (Genovese 
et al., 2002). In addition to statistical difference maps, data are also visualized as effect size 
maps, showing either percent differences or raw differences in mm for cortical thickness data, 
and correlation coefficients for VBM data. The type of map used in each study is described in 
the methods section in each chapter.  
 
3.5.4.2.5 Multiple comparison correction 
In the studies described in this thesis, FDR correction is the main method used to correct for 
multiple comparisons. Originally, familywise error (FWE) correction was widely used in 
neuroimaging studies and was the default technique within SPM. Whilst highly powered 
studies with multiple scans per subject such as fMRI are able to tolerate this harsh level of 
correction, structural studies using VBM often show no significance with FWE and numerous 
early studies resorted to reporting uncorrected data. FDR was introduced by Genovese et al. 
as an alternative family-wise error procedure (Genovese et al., 2002); FDR procedures are 
more sensitive because they do not control the false positive rate but the false discovery rate. 
The false discovery rate is the proportion of tests declared significant that have been falsely 
declared significant. Whilst FDR correction is widely used to correct for multiple comparisons 
in neuroimaging studies, recently limitations of this method have been highlighted (Chumbley 
et al., 2010; Chumbley and Friston, 2009). The problem of conventional FDR procedures is 
that they regard SPMs as a collection of discrete tests, i.e. inference using false discovery 
rate treats each voxel as a separate feature. However, when using SPM, inferences are made 
about a topological feature or clusters above a certain threshold, and not about each voxel in 
that cluster. This is why usually only clusters are reported, most commonly in terms of their 
maximum value and location. Conventional FDR procedures control the false discovery rate 
of voxels, whereas it is more appropriate to control the false discovery rate of features. An 
alternative correction method has been proposed that controls the false discovery rate of 
topological features as opposed to voxels. In other words, the FDR procedure can be applied 
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to the null distribution of features such as cluster-volume or peak height (Chumbley et al., 
2010).  
 
3.5.4.2.6 Support vector machine 
For classification analyses using volume or thickness data, a linear support vector machine 
(SVM, chapter 2, section 2.2.1.3.5) was used (Vapnik, 1995; Vapnik, 1998), implemented with 
LIBSVM version 2.89 (Chang and Lin, 2001) under MATLAB (version 7.2.0). In this thesis, 
outputs from specific analyses using T1-weighted MR images were used as input into the 
SVM. More specifically, for SVM analyses in which cortical thickness was used, all vertices 
were included except the medial wall as defined by FreeSurfer’s Desikan parcellation atlas 
(Desikan et al., 2006). For the classification analyses using longitudinal data (chapter 7), only 
the grey matter voxel-compression maps (see 7.2.6) were used for the VBM SVM analysis, 
whereas differences in cortical thickness between two time points (again excluding the medial 
wall) were used for the FreeSurfer SVM analysis. The C-SVM formulation was used, 
employing a two-level nested cross-validation to optimize the misclassification penalty 
parameter C using a leave-one-out procedure within the main leave-one-out loop (Wilson et 
al., 2009). This ensures an unbiased estimation of generalisation accuracy by leaving each 
scan in turn entirely out of the training procedure.  
- 62 - 
4. PATTERNS OF CORTICAL THICKNESS IN PATHOLOGICALLY-CONFIRMED TYPICAL 
AND ATYPICAL AD AND FTLD 
 
4.1 Chapter introduction 
Clinically, patients with AD and FTLD pathology may be difficult to differentiate because of 
overlapping symptoms (chapter 1, section 1.2) In particular ‘atypical’ forms of AD showing 
marked behavioural features (‘frontal-variant AD’) (Johnson et al., 1999; Taylor et al., 2008) or 
predominant language deficits (LPA) (Gorno-Tempini et al., 2008) can be difficult to 
distinguish from patients with FTLD pathology.  
 
A number of studies have used MRI to assess brain atrophy in these disorders (chapter 2, 
section 2.5). These patterns of atrophy may aid diagnosis; an in vivo atrophy ‘signature’ may 
predict the underlying pathology (Likeman et al., 2005). In many research studies, however, 
pathological confirmation is lacking and ‘clinically diagnosed’ patients are included. Clinical 
prediction of histopathology is inevitably imperfect; more importantly there is a risk of 
circularity. Clinically diagnosed subjects may reflect ‘typical’ presentations of these diseases 
as the purpose of clinical criteria is to describe the most typical presentations to reduce 
misdiagnosis.  
 
In this chapter, the term frontotemporal dementia (FTD) refers to the clinical (frontotemporal) 
syndrome including both behavioural and language variants, whereas FTLD refers to the 
confirmation of tau- or ubiquitin-positive pathology. Furthermore, the term ‘typical AD’ refers to 
patients with a typical amnestic presentation of AD and underlying AD pathology, whereas 
‘atypical’ AD in this study refers to patients with AD pathology but who had a clinical diagnosis 
of either FTD or PCA. Within this group, the term AD-FTD refers to those patients who 
presented with FTD symptoms (behavioural or language deficits) and yet had underlying AD 
pathology at autopsy. 
 
Atrophy patterns were investigated in patients with pathology confirmation including atypical 
and typical clinical presentations of AD and FTLD. Non-amnestic presentations of AD were 
incorporated including language and behavioural presentations which are more likely to 
overlap with FTLD in terms of atrophy. The aim of this study was to assess the commonality 
of cortical thickness patterns between patients with AD pathology who presented with either 
typical amnestic deficits or atypical non-amnestic deficits during life. Patients clinically 
diagnosed as FTD were further investigated to assess whether there were differences in 
cortical atrophy patterns between those who were subsequently found to have AD pathology 
and those with FTLD pathology. 
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4.2 Methods 
 
4.2.1 Subjects 
62 patients were initially selected from a database of pathologically-confirmed cases: 32 
individuals with a pathological diagnosis of AD and 30 subjects with pathologically-confirmed 
FTLD who had undergone volumetric MR imaging as part of their diagnostic work-up. Twenty-
five healthy controls that had undergone MRI assessment were also included. Some of these 
patients have been included in previous imaging studies (Barnes et al., 2007a; Kloppel et al., 
2008; Rohrer et al., 2009). Subjects with mixed AD and DLB pathology were excluded.  
 
The clinical notes were retrospectively reviewed by a clinician to determine the clinical ante-
mortem presentation of each patient. Based on this, pathologically-confirmed AD subjects 
were divided into typical and atypical AD. Typical AD patients were defined as those who 
presented with amnestic deficits during life and had been diagnosed ante-mortem with AD 
according to NINCDS-ADRDA criteria (McKhann et al., 1984). In contrast, atypical AD 
patients presented predominantly with language, behavioural or visuoperceptual and 
visuospatial deficits (Figure 4.1). After image processing, 11 subjects were excluded (see 
below). The study therefore included 28 AD patients, 23 with FTLD, and 25 controls: the 
demographics of the 76 subjects included are summarized in Table 4.1. Of the 11 typical AD 
subjects, 10 had post-mortem and 1 had brain biopsy confirmation. Of the 17 atypical AD 
subjects, 12 had post-mortem confirmation and 5 had biopsy confirmation. This group 
consisted of 9 patients who had a clinical diagnosis of PPA, 6 patients with PCA, and 2 
patients with bvFTD (Figure 4.1). Of the 23 pathologically-confirmed FTLD subjects, 20 had 
post-mortem confirmation and 3 had brain biopsy. The FTLD group comprised 10 tau-positive 
patients (5 bvFTD, 4 PNFA, 1 atypical SemD) and 13 tau-negative, ubiquitin-positive patients 
(10 SemD and 3 bvFTD). All FTLD subjects had been clinically-diagnosed with FTD (Neary et 
al., 1998). 
 
4.2.2 MRI acquisition 
Images were acquired as described in chapter 3 (section 3.5.1) and Appendix 5. 
 
4.2.3 Image processing 
Cortical thickness measurements were made using FreeSurfer version 4.0.3 (chapter 3, 
section 3.5.3.2.2). All images were visually inspected and on average edited and re-run three 
times. At this stage, as mentioned above, four individuals with AD and seven with FTLD were 
excluded due to poor image quality causing poor segmentations.  
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Figure 4.1: Overview groups and comparisons. Comparison 1 assessed differences in cortical thickness between patients with underlying AD pathology 
but different clinical presentations (‘typical’ amnestic vs. ‘atypical’ non-amnestic), whereas comparison 2 assessed differences in cortical thickness between 
patients with a clinic presentation of FTD and underlying AD pathology (AD-FTD) vs. FTD patients with FTLD pathology (FTD). 
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4.2.4 Statistical analysis 
Regional cortical thickness variations between the patient groups and the control group were 
assessed using a vertex-by-vertex GLM (chapter 3, section 3.5.4.2.3). Cortical thickness (C) 
was modelled as a function of group, controlling for age (mean-centred), gender and scanner 
by their inclusion as covariates. Separate models were used for the two comparisons of 
interest.  
 
Comparison 1 assessed cortical thickness in typical and atypical AD, and was modelled C = 
β1 (controls) + β2 (typical AD) + β3 (atypical AD) + β4 age + β5 gender + β6 scanner + ε, 
contrasting β1 vs. β2 (controls vs. typical AD), β1 vs. β3 (controls vs. atypical AD), and β2 vs. β3 
(typical AD vs. atypical AD; see Figure 4.1). Contrasts were calculated using two-tailed t-
tests.  
 
Comparison 2 assessed cortical thickness in AD-FTD (including the clinically diagnosed PPA 
and bvFTD patients with AD pathology) vs. FTLD, and was modelled C = β1 (controls) + β2 
(AD-FTD) + β3 (FTLD) + β4 age + β5 gender + β6 scanner + ε, contrasting β1 vs. β2 (controls vs. 
AD-FTD), β1 vs. β3 (controls vs. FTLD), and β2 vs. β3 (AD-FTD vs. FTLD, see Figure 4.1). 
Maps were produced showing percentage differences in average cortical thickness and 
statistically significant differences with FDR correction at p<0.05. Intersection maps highlight 
regions where the two patient groups commonly showed differences compared with controls. 
 
4.2.5 Support vector machine (SVM) 
Images were analysed using an SVM as described in chapter 3 (section 3.5.4.2.6). The same 
scans as in the vertex-wise statistical comparisons described above were used for this 
analysis. The comparison of interest was the classification of the FTLD and AD-FTD groups 
(which relates to comparison 2 described above, see Figure 4.1), i.e. assessing how well 
patients with a clinical diagnosis of FTD who were subsequently found to have either AD or 
FTLD pathology can be classified into their respective group.  
 
4.3 Results 
 
4.3.1 Subjects 
No significant differences across groups were found for gender, disease duration and time to 
death (Table 4.1). Age difference across all groups was not significant, however, the atypical 
AD group was significantly younger than controls and the typical AD group (p<0.05). MMSE 
scores were significantly different across groups (p<0.001), driven by statistically significant 
differences between patient groups and controls (p<0.001), as well as significantly higher 
MMSE scores in the FTLD group compared with typical and atypical AD (p<0.001 and p<0.01 
respectively).  
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Table 4.1: Subject demographics. 
  
N Gender § NS Age in years at 
scan ¶ NS 
MMSE at 
scan ¶ ¥ * 
Disease duration at 
scan ¶ NS 
Time to death 
from scan ¶ NS† 
Scanner                        
    
  % male mean (SD) mean (SD) mean (SD)  mean (SD)  a b c d 
Controls  25 68% 64.2 (9.4) 29.3 (0.9) - - 6 15 0 4 
      
      
Typical AD  11 73% 68.0 (10.5) 14.4 (7.0) 3.6 (2.3) 3.8 (2.7) 4 7 0 0 
  
          
Atypical AD  17 53% 59.2 (6.5) 17.7 (6.9) 3.7 (1.5) 4.7 (1.7) 0 14 3 0 
PPA  9 67% 58.6 (6.9) 16.6 (7.1) 3.8 (1.2) 3.5 (1.3) 0 7 2 0 
PCA  6 33% 60.2 (7.5) 22.2  (4.3) 3.4 (2.2) 6.0 (0.9) 0 5 1 0 
bvFTD  2 50% 59.0 (1.4) 9.5 (0.7) 4.4 (1.0) 6.6 0 2 0 0 
  
          
FTLD  23 57% 62.5 (10.1) 23.4 (5.6)  4.3 (2.1) 6.0 (3.4) 0 18 2 3 
SemD  11 55% 65.9 (6.0) 22.2 (5.6) 4.3 (2.4) 8.0 (3.0) 0 7 1 3 
bvFTD  8 50% 58.3 (14.2) 22.7 (5.1) 4.3 (2.3) 3.6 (2.3) 0 7 1 0 
PNFA   4 75% 62.8 (6.9) 27.7 (1.2) 4.4 (0.7) 4.0 (2.6) 0 4 0 0 
§
 Fisher's exact test; ¶ ANOVA; * p<0.001; † available in 10 typical AD, 13 atypical AD (7PPA, 5 PCA, 1bvFTD), and 21 FTLD (11SemD, 7bvFTD, 3PNFA);           
¥
 available in 12 controls, all typical and atypical AD, and 20 FTLD (10 SemD, 7 bvFTD, 3 PNFA); a, b, c, d - different 1.5T GE scanners (Appendix 5); NS = 
not significant 
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4.3.2 Comparison 1: typical vs. atypical AD 
Compared with controls, typical AD showed lower thickness across the cortex, with the most 
prominent reduction bilaterally in the medial and posterior temporal regions, posterior 
cingulate gyrus, and frontal lobe regions (Figure 4.2A). The atypical AD group showed 
reduced cortical thickness bilaterally in the medial temporal lobe, posterior cingulate gyrus, 
precuneus, posterior parietal lobe, and frontal pole compared with controls (Figure 4.2B). The 
intersection map shows areas of reduced cortical thickness common to both typical and 
atypical AD compared with controls (Figure 4.2C) bilaterally in the medial temporal lobe, 
posterior cingulate gyrus, precuneus, posterior parietal lobe, and frontal pole.  
 
The direct comparison of typical and atypical AD showed lower cortical thickness 
predominantly in the left posterior temporal lobe and left occipital lobe in the typical AD group 
compared with atypical AD (Figure 4.3A). However, this difference was reduced when 
including disease duration as covariate, and disappeared completely when correcting for 
MMSE. No regions were found to be significantly thinner in the atypical AD group compared 
with typical AD. However, the percent difference maps indicate trends towards lower cortical 
thickness bilaterally in the precuneus and superior parietal lobe in the atypical compared with 
typical AD group (Figure 4.3B). 
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Figure 4.2: Differences and similarities in reduced cortical thickness in typical and atypical AD compared with controls. The figure shows differences 
in cortical thickness between A) typical AD and controls, and B) atypical AD and controls. The colour scale represents FDR-corrected p values thresholded at 
a 0.05 significance level. Red and yellow represent lower cortical thickness in the patient group, whereas blue represents lower cortical thickness in the 
control group. C) Intersection map showing regional differences in cortical thickness between typical AD and controls, and atypical AD and controls. Blue 
represents areas which are reduced in the typical AD group only, green represents regions which are reduced in atypical AD only, and orange shows areas 
which are reduced in both typical and atypical AD compared with controls. 
Left Right
A
A A
P P
P P
A
A Left Right
A A
P P
P
AA
P
B Left Right
A P P A
AP PA
Atypical ADTypical AD BothNone
C
pFDR=1 pFDR<0.000005pFDR<0.000005
Typical ADControls
pFDR=1 pFDR<0.000005pFDR<0.000005
Atypical ADControls
- 69 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Differences in reduced cortical thickness between typical and atypical AD. Differences in cortical thickness between typical and atypical AD 
are shown as A) statistical difference map, and B) percent difference map. The colour scale of the statistical difference map represents FDR-corrected p 
values thresholded at a 0.05 significance level whereas the colour bar for percent difference represents magnitude of cortical thickness group difference 
expressed as a percentage of mean thickness across both groups (adjusted for age, gender and scanner). Red and yellow represent lower cortical thickness 
in the typical AD group, whereas blue represents lower cortical thickness in the atypical AD group. 
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4.3.3 Comparison 2: AD-FTD vs. FTLD 
Compared with controls, AD-FTD patients showed lower cortical thickness in the left superior 
temporal lobe, as well as bilaterally in the posterior cingulate gyrus, precuneus, left posterior 
parietal lobe and bilateral frontal pole (Figure 4.4A). The FTLD group showed widespread 
thinning with the most prominent reductions found bilaterally in the anterior temporal lobe 
(Figure 4.4B). The intersection map reveals regions in which both AD-FTD and FTLD show 
reduced cortical thickness compared with controls which include the bilateral posterior 
cingulate gyrus, left superior temporal lobe and left medial temporal lobe (Figure 4.4C).  
 
Differences in cortical thickness between AD-FTD and FTLD in a direct comparison did not 
reach statistical significance after FDR correction. However, percent difference maps show 
tendencies of reduced thickness bilaterally in the anterior temporal lobe and frontal lobe 
regions in the FTLD group compared with AD-FTD, whereas the AD-FTD group showed lower 
cortical thickness in left posterior parietal regions, bilaterally in the precuneus, posterior 
cingulate gyrus and, perhaps surprisingly, frontal pole compared with FTLD (Figure 4.5A). 
 
The classification analysis of AD-FTD vs. FTLD produced a classification accuracy of 79.4% 
with 95% confidence intervals [62.1%, 91.3%]. Of the AD-FTD patients 54.5% [23.4%, 83.3%] 
were correctly classified (sensitivity), whereas 91.3% [72.0%, 98.9%] of the FTLD patients 
were correctly classified (specificity). The area under the receiver operating characteristic 
(ROC) curve is 0.87 (Figure 4.6). Areas in which reduced cortical thickness contributed most 
to the classification of AD-FTD were shown bilaterally in the posterior cingulate gyrus, 
posterior parietal lobe, precuneus, medial temporal lobe, and frontal pole (Figure 4.5B). In 
contrast, regions which contributed most towards a classification of FTLD were shown 
bilaterally in frontal lobe regions and the lateral temporal lobe. 
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Figure 4.4: Differences and similarities in reduced cortical thickness in AD-FTD and FTLD compared with controls. Differences in cortical thickness 
are shown between A) AD-FTD and controls, and B) FTLD and controls. The colour scale represents FDR-corrected p values thresholded at a 0.05 
significance level. Red and yellow represent lower cortical thickness in the patient group, whereas blue represents lower cortical thickness in the controls.     
C) Intersection map showing regional differences in cortical thickness between AD-FTD and controls, and FTLD and controls. Blue represents areas which 
are reduced in the AD-FTD group only, green represents regions which are reduced in FTLD only, and orange shows areas which are reduced in both AD-
FTD and FTLD compared with controls. 
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Figure 4.5: Differences in reduced cortical thickness between AD-FTD and FTLD. A) Regional differences in cortical thickness between AD-FTD and 
FTLD shown as percent difference map. The colour bar represents magnitude of cortical thickness group difference expressed as a percentage of mean 
thickness of both groups (adjusted for age, gender and scanner). Red and yellow represent lower cortical thickness in the FTLD group, whereas blue 
represents lower cortical thickness in the AD-FTD group. B) Classification map showing regions that were most influential in making a classification between 
AD-FTD and FTLD. Red represents areas where low cortical thickness indicates FTLD, whereas blue shows areas where lower cortical thickness indicates 
AD-FTD.  
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 Figure 4.6: ROC curve for classification of AD
between sensitivity and specificity. The ROC curve is plotted by varying the decision 
threshold. The low sensitivity reported in the results arises from unbalanced
which allow high accuracy from high specificity. The ROC curve shows that relatively high 
sensitivity and specificity are simultaneously achievable if the threshold is altered. AUC 
under the curve, acc - accuracy.
 
 
4.4 Discussion 
This study describes the patterns of cortical thinning in pathologica
FTLD. Patients with AD pathology and a typical amnestic presentation during life showed 
reduced cortical thickness bilaterally in the medial temporal lobe, posterior cingul
precuneus, posterior parietal regions, and frontal lobe. The association of an amnestic 
presentation of AD with medial temporal lobe atrophy was expected
al., 2006; Teipel et al., 2006)
cortex and precuneus concurs with increasing recognition that atrophy as well as 
hypometabolism in these regions is characteristic of AD
see also chapter 2, section 2.5.2)
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A similar pattern of cortical thinning, compared with controls, was found in patients with AD 
pathology who had a different ante-mortem clinical diagnosis; however, thinning was less 
widespread, perhaps reflecting the mix of ‘focal’ presentations of AD in this group. A direct 
comparison between these two patient groups revealed greater loss in left posterior temporal 
lobe and left occipital lobe regions in the typical AD group compared with atypical AD. The 
fact that this difference is diminished after correcting for disease duration and MMSE may 
suggest that these differences simply reflect severity differences. However, mean disease 
duration was almost identical between groups. Disease progression in typical and atypical 
forms of AD may vary which means that disease duration is not a very accurate marker of 
disease severity. MMSE is also an imperfect indicator of disease severity in dementias with 
different cognitive profiles, and the high mean MMSE in atypical AD subjects is largely driven 
by the PCA subjects included.  
 
The intersection analysis illustrates the commonality of cortical thinning in typical and atypical 
AD. Cortical thickness was reduced in both the typical and atypical AD groups, compared with 
controls, bilaterally in the medial temporal lobe, posterior cingulate gyrus, precuneus, 
posterior parietal lobe and frontal pole. Cortical thinning in these regions appears to indicate 
the presence of AD pathology irrespective of clinical presentation. Cortical thinning in the 
medial temporal lobe in typical and atypical AD is consistent with the presence of memory 
deficits at the time of scan in both groups. Our general AD-specific findings are in accordance 
with previous imaging studies which investigated differences in cortical thickness (Du et al., 
2007; Lerch et al., 2005) and grey matter volume using VBM (Baron et al., 2001; Busatto et 
al., 2003) in typical forms of AD. 
 
A strong involvement of the posterior cingulate gyrus in AD has been shown in a number of 
structural (Barnes et al., 2007a; Baron et al., 2001; Boxer et al., 2003; Jones et al., 2006) and 
functional imaging studies (Lustig et al., 2003). Most functional imaging studies (PET, SPECT 
and fMRI) have reported reduced activity in this region in early stages of the disease 
(Johnson et al., 1998; Matsuda, 2001; Minoshima et al., 1997). The regions showing reduced 
cortical thickness in pathologically-confirmed AD patients in our study are consistent with 
those associated with the ‘default mode’ network (Greicius et al., 2004). Our finding adds to 
the growing number of studies suggesting that functional imaging findings are not as 
dissociated from atrophy as was once thought; temporal associations, however, remain 
unclear (Villain et al., 2008).  
 
The involvement of the frontal lobe in AD, and more specifically of the prefrontal cortex and 
frontal pole, remains controversial. A number of studies have shown reduced cortical 
thickness (Du et al., 2007; Lerch et al., 2005) and grey matter volumes (Baron et al., 2001; 
Busatto et al., 2003; Davatzikos et al., 2008) in this region. However, a number of studies 
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have failed to show involvement of any frontal areas (Whitwell and Jack, Jr., 2005). The 
current study, with the advantage of pathology confirmation, does support frontal pole atrophy 
in AD. There is always the theoretical possibility that this could be an artefact of the analysis 
technique, however, after careful visual inspection of this area in each subject we could not 
see any signal drop off or any kind of fault in the FreeSurfer surfaces which would explain 
reduced cortical thickness in this region. 
 
The second subject group comparison revealed that patients with AD pathology and a clinical 
diagnosis of FTD during life (either behavioural or language variant) had a thinner cortex in 
the medial temporal lobe, posterior parietal regions, posterior cingulate gyrus and frontal pole 
than patients with FTLD pathology. In contrast, patients with FTLD pathology showed reduced 
cortical thickness predominantly in anterior temporal and frontal lobe regions. The highly 
significant reduction in the anterior temporal lobe in the FTLD group is possibly driven by the 
high proportion of semantic dementia patients in this group who are known to have marked 
atrophy in this region (Boxer et al., 2003; Chan et al., 2001b; Rosen et al., 2002). The 
patterns of cortical thinning observed in the FTLD group are consistent with previous 
histopathological and volumetric MRI studies (Broe et al., 2003; Grossman et al., 2004; 
Rosen et al., 2002; Whitwell et al., 2005a).  
 
Although differences in the direct comparison between AD-FTD and FTLD did not reach 
statistical significance, tendencies of cortical thinning as shown in the percent difference 
maps are consistent with the patterns observed in the control comparisons. Thinner cortex in 
the posterior cingulate gyrus, parietal lobe and frontal pole suggests the presence of AD 
pathology, whereas cortical thinning in the anterior temporal lobe and frontal lobe regions 
suggests the presence of FTLD pathology. Our classification algorithm showed that subjects 
could be correctly classified on the basis of the scans alone in 79% of cases despite having 
had similar (FTD) clinical diagnoses in life. The ROC curve illustrates that although the 
original sensitivity is relatively low, this is probably driven by the imbalance in subject 
numbers between the two groups. The high area under the curve reveals that the classifier 
performs well, and a more favourable balance of sensitivity and specificity could be obtained 
by altering the threshold. The pattern of cortical thinning shown to separate the two patient 
groups best was consistent with that observed in the direct comparison between AD-FTD and 
FTLD. 
 
One strength of this study is that all AD and FTLD cases had pathological confirmation. This 
is particularly important considering that accuracies for the clinical diagnosis of AD can vary 
between 60-90% (Brayne et al., 2009; Jellinger, 2006). Consequently, a number of individuals 
included in studies of AD will inevitably have a different type of pathology. A post-mortem 
study further revealed 30% of patients diagnosed with a language subtype of FTLD had AD 
pathology (Knibb et al., 2006). It is noteworthy, however, that the inclusion of only 
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pathologically-confirmed cases inevitably limits subject numbers, reducing the power to detect 
differences between disease groups. Furthermore, the fact that patients went to post-mortem 
might suggest a more atypical presentation, even in the typical amnestic AD patients. 
However, all patient notes were reviewed confirming a typical clinical phenotype in these 
cases. The young onset of these post-mortem proven cases may mean that results are less 
generalisable to an older AD population in that older-onset typical AD cases naturally have 
more years for ageing processes to occur and may have increased co-morbidities and 
pathologies (e.g. white matter disease). Pathology confirmation was not obtained for the 
whole control group and it may be that some controls had a neurological condition but were 
asymptomatic. This is, however, unlikely and would only have reduced the ability to detect 
differences.  
 
Another limitation is the variety in image acquisition which has been shown to affect thickness 
measures (Han et al., 2006). Analyses were therefore adjusted for scanner type. It should 
also be noted that there was an imbalance in scanner type between groups, with scanner ‘A’ 
being present only in the control and typical AD group. However, excluding subjects imaged 
using scanner ‘A’ from the analyses gave very similar results. Our groups were matched for 
disease duration, but not for disease severity as measured by MMSE. As expected, MMSE 
scores varied significantly between individual groups owing to the weighting of questions 
towards memory and orientation. 
 
4.5 Chapter conclusion 
In summary, this chapter describes patterns of cortical thickness in patients with AD 
pathology but different clinical presentations. Common areas of lower cortical thickness were 
found in patients with AD pathology despite different clinical symptoms. These areas included 
the medial temporal lobe, posterior cingulate gyrus, precuneus, posterior parietal cortex and 
frontal pole. In contrast, lower cortical thickness in the anterior temporal lobe and frontal lobe 
regions is indicative of the presence of FTLD pathology in patients with a clinical presentation 
of FTD. Furthermore, patients with a frontal presentation during life and AD pathology at post-
mortem show lower cortical thickness in posterior regions than patients with FTLD pathology. 
These findings suggest that atrophy in posterior regions of the brain might be indicative of the 
presence of AD pathology irrespective of clinical syndrome. Assessing atrophy in posterior 
regions might therefore aid the distinction between AD and FTLD. This finding provides a 
motivation for developing methods of assessing posterior atrophy that could be applied 
relatively simply to the individual patient’s scan. The next chapter will present a tool with 
which posterior atrophy can be easily assessed in a clinical setting.  
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5. POSTERIOR CEREBRAL ATROPHY IN THE ABSENCE OF MEDIAL TEMPORAL LOBE 
ATROPHY IN PATHOLOGICALLY-CONFIRMED AD 
 
 
5.1 Chapter introduction 
The presence of medial temporal lobe atrophy is an important hallmark of AD (Basso et al., 
2006; Fox and Schott, 2004; Teipel et al., 2006; see also chapter 2, section 2.5.2). New AD 
research diagnostic criteria (Dubois et al., 2007) propose that the presence of memory loss 
together with medial temporal lobe atrophy on MRI are sufficient to make a diagnosis of 
prodromal AD. However, atrophy in the medial temporal lobe is also present in FTLD and 
normal ageing (Chan et al., 2001b; Fjell et al., 2009; Frisoni et al., 1996; Galton et al., 2001). 
The previous chapter, together with a number of other studies, emphasize the presence of 
atrophy in posterior areas of the brain such as precuneus and posterior cingulate gyrus in AD 
(Jones et al., 2006; Karas et al., 2007). Atrophy in these regions has further been suggested 
to be more of a feature of early-onset AD (EOAD) than late-onset AD (LOAD) (Frisoni et al., 
2007; Ishii et al., 2005a; Shiino et al., 2008), and conversely medial temporal atrophy may be 
a less sensitive marker of AD in younger patients. 
 
Since quantitative volumetric measurements are not yet available for routine clinical use, 
visual rating scales are increasingly used to assess global atrophy (Scheltens et al., 1997), 
MTA (Scheltens et al., 1992), and white matter changes (Wahlund et al., 2001). The MTA 
scale (chapter 3, section 3.5.3.1.1) has been shown to discriminate well between AD and 
healthy controls, and to predict the conversion from MCI to AD (Korf et al., 2004; Scheltens et 
al., 1992; Scheltens et al., 1995). We have recently developed a visual rating scale for 
posterior atrophy (PA), which includes the posterior cingulate gyrus, precuneus and parietal 
lobes. 
 
This chapter first describes the development and validation of the PA scale which was 
conducted in collaboration with the VU Medical Centre in Amsterdam. It then describes a 
study in which MTA and PA ratings were assessed in pathologically-confirmed AD and FTLD 
patients. This study aimed i) to assess the inter- and intra-rater agreement of the MTA and PA 
scale in a large cohort of pathologically-proven AD and FTLD patients, and controls; ii) to 
investigate associations of visual rating scores with manual volumetric measures, iii) to 
assess the utility of MTA and PA scales in distinguishing between pathologically-confirmed 
AD and controls as well as FTLD which may be misdiagnosed as AD; and iv) to assess the 
discriminatory ability of visual ratings according to age at onset. 
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5.2 Development and validation of the PA rating scale 
 
5.2.1 Development of the PA scale 
MRI scans of 25 patients with probable AD were selected from the VU Medical Centre 
Amsterdam database, and were used to determine posterior regions that were most affected 
in AD. The same areas were then assessed in 10 control subjects to determine whether these 
regions are more affected in AD and therefore are likely to represent atrophy. Based on these 
findings the following anatomical regions were selected: the posterior cingulate sulcus, 
precuneus, parieto-occipital sulcus and the cortex of the parietal lobes.  
 
The PA scale rates atrophy on a 4-point scale (Figure 5.1): grade 0 represents closed 
posterior cingulate and parieto-occipital sulci and closed sulci of the parietal lobes and 
precuneus; grade 1 includes a mild widening of the posterior cingulate and parieto-occipital 
sulci, with mild atrophy in the parietal lobes and precuneus; grade 2 represents substantial 
widening of the posterior cingulate and parieto-occipital sulci, with marked atrophy in the 
parietal lobes and precuneus; and grade 3 represents end-stage atrophy with evident 
widening of the posterior cingulate and parieto-occipital sulci and knife-blade atrophy in the 
parietal lobes and precuneus. When there was a difference between scores in the different 
planes (e.g. score 1 for the sagittal view and score 2 for the axial view), the highest score was 
given.  
 
PA was scored on T1-weighted images viewed in the sagittal, axial and coronal planes. 
Separate scores for the left and right hemispheres were obtained. The following anatomical 
features were rated in the three different planes: 
a) Sagittal plane: Evaluation of widening of the posterior cingulate and parieto-occipital sulci, 
and atrophy in the precuneus in the paramedian-sagittal plane.  
b) Axial plane: Evaluation of widening of the posterior cingulate sulcus and sulcal dilatation in 
the parietal lobes.  
c) Coronal plane: Evaluation of widening of the posterior cingulate and parietal sulci.  
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Figure 5.1: Posterior visual rating scale. T1-weighted sagittal, axial and coronal images as 
examples for each grade of the PA scale. A) grade 0=no atrophy; B) grade 1=minimal 
atrophy, C) grade 2=moderate atrophy; and D) grade 3=severe atrophy. PCS - posterior 
cingulate sulcus, PRE - precuneus, PAR - parietal lobe, POS - parieto-occipital sulcus. L - left 
hemisphere, R - right hemisphere, A - anterior, P - posterior. 
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5.2.2 Validation of the PA scale 
 
5.2.2.1 Subjects and analysis 
118 subjects were selected from the VU Medical Centre Amsterdam database based on their 
clinical diagnosis. The selection included 60 AD patients, 20 age-matched patients with other 
dementias (10 FTLD and 10 DLB patients) and 38 age-matched patients with subjective 
memory complaints but no cognitive impairment (acting as the control group in this study). All 
patients underwent a standard battery of investigations including a patient and informant-
based medical history, physical and neurological examination including the MMSE and MR 
imaging. The clinical diagnosis of probable AD, FTLD and DLB was made according to 
current diagnostic criteria (McKeith et al., 1996; McKhann et al., 1984; Neary et al., 1998), 
based purely on clinical characteristics. MR imaging was performed on a 3T MR scanner 
(Signa HDxt, General Electric, Milwaukee) using a sagittal T1-weighted 3D fast spoiled 
gradient echo (FSPGR) sequence. PA as well as MTA ratings were obtained in all 118 
subjects by three different raters (Esther Koedam, Mike Wattjes, and myself). All raters were 
blinded to clinical diagnosis. Twenty-nine MRI scans were rated twice by two raters. Inter- and 
intra-rater agreement was calculated using quadratically weighted kappas (Cohen, 1968). 
Linear regression was used to assess relationships between PA rating scores and age and 
MMSE score. PA and MTA ratings were dichotomized into normal and abnormal, with a mean 
score (left and right hemisphere) of >1 being considered abnormal. 
 
5.2.2.2 Results 
Intra-rater kappa scores (determined in 29 scans for two raters) were 0.93 (rater 1) and 0.95 
(rater 2). Inter-rater agreement (determined in 118 scans for three raters) was best between 
rater 1 and rater 2 (kappa=0.84), followed by agreement between rater 2 and 3 (kappa=0.70) 
and lowest between rater 1 and rater 3 (kappa=0.65). The average weighted kappa value for 
inter-rater agreement was 0.73.  
 
Mean scores for the PA rating scale were significantly higher in the AD group (mean=1.6; 
SD=0.9) compared with controls (mean=0.6; SD=0.7, p<0.01) and other dementias 
(mean=0.8; SD=0.8, p<0.01). PA scores did not differ between other dementias and controls. 
There was no evidence of a significant association of PA ratings with age, however, a strong 
relationship was found with MMSE score (p<0.01). 
 
28% of AD patients had prominent PA (scores>1) without evident MTA (score≤1), whereas 
only 15% had prominent MTA without marked PA. Twenty-seven percent of the AD patients 
had only minimal MTA and PA. Most controls (88%) and patients with other dementias (i.e. 
FTLD and DLB, 45%) had normal scores for MTA and PA. 
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5.2.2.3 Conclusion 
This study revealed good intra- and inter-rater agreement for the PA scale. The AD group 
showed higher PA scores compared with controls and patients with other dementias, 
suggesting that the PA scale may be useful for discriminating AD from normal ageing and 
other neurodegenerative diseases. Whilst this study provided first insights into the 
reproducibility and validity of the new PA scale, it is only with pathologically-proven cases that 
one can be sure of the predictive value of different atrophy measures such as MTA or PA 
ratings in different types of dementia. The following study was conducted to validate the PA 
scale in pathologically-confirmed AD and FTLD subjects, and to assess its clinical utility to 
distinguish between AD and FTLD as well as normal ageing. 
 
5.3 Visual ratings in pathologically-confirmed AD and FTLD 
 
5.3.1 Subjects 
Patients were selected retrospectively from a database (Dementia Research Centre) of 
pathologically- and genetically-confirmed subjects. This identified 152 subjects who had 
undergone volumetric MR imaging (see Figure 5.2): 62 patients with ‘definite’ AD (55 
pathologically- and 7 genetically confirmed) according to NINCDS-ADRDA criteria (McKhann 
et al., 1984, Appendix 1) and 40 patients with FTLD (all pathologically-confirmed). 50 healthy 
age- and gender-matched controls were also included. Demographics are presented in Table 
5.1. 44% of the control subjects, 45% of the AD and 50% of the FTLD patients were included 
in the study described in the previous chapter. The clinical notes were retrospectively 
reviewed by a clinician to determine whether the clinical presentation was predominantly an 
amnestic, behavioural, language presentation or a PCA syndrome. 
 
5.3.2 MRI acquisition and processing 
Images were acquired as described in chapter 3 (section 3.5.1) and Appendix 5. All scans 
were spatially-normalized into MNI 305 atlas space (Mazziotta et al., 1995) with a six dof 
registration. 
 
5.3.3 Regional volumes in subset of subjects 
Manual delineations of the hippocampus and posterior cingulate gyrus had been obtained in a 
subset of 38 subjects (11 controls, 19 AD, 8 FTLD, matched for age and gender) as part of a 
previous study (Barnes et al., 2007a). Demographic details as well as manual delineation 
protocols are described in Barnes et al. (2007a). Volumes in mm3 were measured and 
analysed separately for the left and right hemisphere. TIVs were also available for the same 
subjects derived according to a previously described protocol (Whitwell et al., 2001). 
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5.3.4 Rating scales 
All scans were assessed by two raters (Esther Koedam and myself) blind to diagnoses. MTA 
and PA were rated as described in sections 3.5.3.1.1 and 5.2.1 respectively, once by each 
rater for the whole cohort (152 subjects), and twice for the subset of 38 subjects for which 
there were cingulate and hippocampal volumes available. 
 
5.3.5 Statistical analysis 
A flowchart showing which subjects were used for the different parts of the analysis is 
presented in Figure 5.2. 
 
5.3.5.1 Inter- and intra-rater reliability 
Inter-rater reliability between the two raters for the MTA and PA scales was assessed using 
scores from the whole cohort of 152 subjects whereas intra-rater reliability for both scales was 
assessed in the subset of 38 subjects. Reliability was measured using quadratically weighted 
kappas  (Cohen, 1968). Bias-corrected and accelerated 95% bootstrap confidence intervals 
(CI) for kappa were found using 10,000 bootstrap samples. 
 
5.3.5.2 Anatomical correlates 
Relationships between volumes and rating scores were assessed by calculating mean 
volumes (in mm3) and standard deviations (SDs) of hippocampal volumes per MTA grade, 
and posterior cingulate gyrus volumes per PA grade. Ratings of both raters were averaged, 
resulting in half grades (i.e. 0.5, 1.5 etc). In order to ensure reasonable subject numbers for 
each grade, volumes were averaged for grades 0 and 0.5; 1 and 1.5; 2 and 2.5, and all ≥3. 
Furthermore, MTA and PA scores were dichotomized into normal and abnormal scores, with 
a score of >1 being considered abnormal. Mean volumes for normal and abnormal scores as 
well as percent differences in volumes between normal and abnormal scores are presented. 
Differences between grades were further assessed statistically by using ordinal logistic 
regression with the rating score (MTA and PA) as dependent variable and corresponding 
volume (hippocampal and posterior cingulate gyrus) as independent variable, adjusting for 
age, gender and TIV.  
 
5.3.5.3 Group comparisons 
MTA and PA ratings scores were first analysed in pathologically-confirmed sporadic AD 
(N=44) and compared with pathologically-confirmed sporadic FTLD (N=27) and controls (see 
Figure 5.2). In order to assess the effect of age at onset on visual ratings, the sporadic AD 
group was then split into pathologically-confirmed EOAD (age at onset <65, N=33) and 
pathologically-confirmed LOAD (age at onset ≥65years, N=11), and compared with younger 
(N=33) and older controls (N=14), matched for age at time of scan and gender to the EOAD 
and LOAD groups, respectively. Differences between early and late-onset FTLD patients 
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were not examined since the number of late-onset FTLD patients was too small (N=4) to 
conduct a meaningful comparison 
 
5.3.5.3.1 Atrophy patterns 
Mean scores and SDs of MTA and PA ratings were calculated and differences in scores 
between groups were assessed using a Mann-Whitney / Wilcoxon rank-sum test. MTA and 
PA scores were further dichotomized into normal and abnormal, with a score of >1 being 
considered abnormal. Ratings of both raters were averaged.  
 
5.3.5.3.2 Classification analysis and added value 
In order to assess the diagnostic accuracy of the MTA and PA scales for discriminating 
between groups, areas under the ROC, denoted AUC, were estimated. The AUC measures 
the ability of a score to discriminate between groups, and ranges from 0.5 (no predictive 
value) to 1 (perfect discrimination). The added value of MTA and PA was assessed by 
combining MTA and PA in a logistic regression model. Differences in AUCs between 
combined and single rating scales are reported as well as 95% Wald-type CIs (1,000 
bootstrap samples) and p-values based on a z-test of the difference in AUCs, using the 
bootstrap standard error. This was performed with the user-written Stata command comproc 
(Janes et al., 2009). These analyses were also based on the average of ratings from two 
raters. 
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Figure 5.2: Overview of subject groups included in each analysis. FAD and spAD - familial and sporadic Alzheimer’s disease; famFTLD and spFTLD - 
familial and sporadic Frontotemporal lobar degeneration; EOAD and LOAD - early- and late-onset Alzheimer’s disease. 
62 AD
(44 spAD, 18 FAD)
40 FTLD
(27spFTLD, 13 famFTLD)
Total N = 152
44 spAD
50 Controls Inter-rater reliability 
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5.4 Results 
 
5.4.1 Subjects 
Subject demographics are presented in Table 5.1. Of the 62 AD patients, 48 had a post-
mortem confirmation of AD, 7 had had a brain biopsy, and 7 had diagnostic genetic testing. 
The AD group consisted of 44 sporadic cases, and 18 familial cases. All sporadic AD patients 
had pathological confirmation of disease. Of the 44 sporadic AD cases, 19 patients had a 
typical amnestic presentation during life, whereas 10 had a PCA syndrome, 9 had a language 
presentation, and 4 had a behavioural presentation. There were insufficient clinical details to 
determine the presenting clinical features for 2 subjects. Furthermore, of the 44 sporadic 
cases, 33 patients had an age at onset <65 years (EOAD), whereas 11 had an age at onset 
of ≥65 years (LOAD). All of the familial AD subjects had an amnestic presentation during life. 
Of the 18 familial AD subjects, 11 had both genetic testing and post-mortem confirmation of 
disease, and 7 had a genetic diagnosis only. The familial AD cohort comprised 9 individuals 
with a Presenilin 1 mutation and 8 with an amyloid precursor protein (APP) gene. One 
individual had pathologically confirmed AD but screened negative for mutations currently 
known to cause familial AD. As she had a strong family history suggesting autosomal 
dominant inheritance of AD and a very young age at symptom onset of 36, this subject was 
included in the familial cohort. 
 
Of the 40 FTLD patients included in this study, 36 had post-mortem confirmation of FTLD, 
and 4 had a brain biopsy. Twenty of the FTLD cases had a behavioural syndrome during life, 
and 20 had a language presentation. Twenty-seven patients were sporadic cases, whereas 
13 had a family history of FTLD. Of the 27 sporadic cases, 9 were tau-positive (Pick’s 
pathology) and 18 were tau-negative (13 TDP1, 3 ubiquitin-positive with unknown TDP status, 
1 with neuronal intermediate filament inclusion disease (NIFID), and 1 with DLDH). 23 had an 
age at onset <65 years, and 4 had an age at onset of ≥65 years. Of the 13 familial cases, 7 
were tau-positive and 6 were ubiquitin-positive (5 TDP43-positive and 1 TDP43-negative). 
Seven familial patients had a microtubule-associated protein tau (MAPT) mutation, 3 had a 
progranulin (PGRN) mutation, and in 3 subjects with a history suggestive of FTLD a genetic 
mutation was not identified. 
 
There was no evidence of differences across the three main groups (controls, AD, FTLD) for 
age and gender, and for the FTLD and AD groups no significant difference in distribution of 
sporadic and familial cases, age at disease onset, disease duration, or time to death (Table 
5.1). However, the AD subjects had a lower MMSE than the FTLD group (p<0.001). Scanner 
distribution was not significantly different between AD and FTLD (p=0.3), however, the 
controls had a greater number of scans on scanner ‘A’ (p=0.002). 
 
- 86 - 
There was no significant difference in age and gender between EOAD (mean age (SD): 58.8 
(6.6) years, 61% male) and younger controls (mean age (SD): 56.5 (7.4) years, 58% male). 
Similarly, there was no evidence of a significant difference in age or gender between LOAD 
(mean age (SD): 73.0 (5.4) years, 64% male) and older controls (mean age (SD): 72.7 (5.0) 
years, 64% male). The EOAD and LOAD groups had a mean MMSE score of 16.7 and 19.1, 
respectively (p=0.5), and a mean disease duration of 4.2 years and 2.8 years, respectively 
(p=0.02). 
- 87 - 
Table 5.1: Subject demographics. 
 
  Controls AD FTLD p 
N 50 62 40 N/A 
Age in years, mean (SD) 59.7 (11.3) 58.2 (10.6) 59.2 (8.9) 0.7 ¶ 
Gender male / female 29 / 21 34 / 28 26 / 14 0.6 § 
Sporadic / familial N/A 44 / 18 27 / 13 0.8 § 
MMSE, mean (SD) ± 29.1 (1.1) 17.2 (6.8) 22.9 (5.2) <0.0001 ¶ 
Age at onset in years, mean (SD) N/A 54.2 (10.8) 55.0 (8.7) 0.7 ¶ 
Disease duration in years, mean (SD) ‡ N/A 3.9 (2.9) 4.2 (2.1) 0.6 ¶ 
Time to death in years, mean (SD) † N/A 5.6 (2.8) 6.4 (3.3) 0.2 ¶ 
Scanner A / B / C / D 14 / 27 / 8 / 1 7 / 37 / 15 / 3 1 / 26 / 9 / 4 0.002 § 
±
 available in: 15 controls, 53 AD, 28 FTLD; ‡ time between first symptoms (onset) and scan; † time between scan and death, available in: 53 AD and 35 
FTLD; ¶ ANOVA; § Fischer's exact test; A, B, C, D: different 1.5T scanners (Appendix 5); N/A - not applicable 
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5.4.2 Inter- and intra-rater reliability 
Both the MTA and PA scales had good inter- and intra-rater reliability. Inter-rater kappa 
scores for the MTA scale were 0.88 for left, 0.86 for right, and 0.91 for mean of both 
hemisphere scores (Table 5.2). Inter-rater kappa scores for the PA scale were 0.83 for left, 
0.82 for right, and 0.84 for mean of left and right hemisphere scores. Intra-rater kappa scores 
ranged from 0.83 to 0.91 for the MTA, and from 0.87 to 0.89 for the PA scale. 
 
Table 5.2: Inter- and intrarater kappa scores for MTA and PA scale. 
Scale Side Inter-rater (N=152) Intra-rater (N=38) 
    
  EK ML 
MTA LH 0.88 (0.84, 0.92)  0.90 (0.84, 0.96) 0.91 (0.84, 0.96) 
 RH 0.86 (0.80, 0.90) 0.87 (0.77, 0.94) 0.83 (0.71, 0.92) 
  Mean LH&RH 0.91 (0.87, 0.93) 0.90 (0.83, 0.95) 0.90 (0.83, 0.95) 
PA LH 0.83 (0.76, 0.88) 0.88 (0.77, 0.96) 0.88 (0.74, 0.96) 
 RH 0.82 (0.75, 0.87) 0.88 (0.78, 0.95) 0.87 (0.74, 0.95) 
  Mean LH&RH 0.84 (0.77, 0.89) 0.89 (0.79, 0.95) 0.88 (0.76, 0.96) 
 
 
5.4.3 Anatomical correlates 
Higher MTA scores were associated with smaller hippocampal volumes (Table 5.3, Figure 
5.3) which differed significantly across all MTA grades in both hemispheres (p=0.001). A 
similar relationship was found for posterior cingulate gyrus volumes and grades of the PA 
scale in the right hemisphere (p=0.004), however, not in the left hemisphere (p=0.3).  
 
 
Table 5.3: Manual volumes per rating scale grade. Shown are hippocampal volumes per 
MTA grade, and volumes of the posterior cingulate gyrus per PA grade. 
  
Hpc volumes per MTA grade PCG volumes per PA grade 
  LH RH LH RH 
Grade ‡ N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD) 
0 & 0.5 19 2598 (534) 18 2732 (544) 18 2449 (685) 17 2809 (459) 
1 & 1.5 9 2182 (403) 12 2419 (290) 14 2197 (818) 13 2591 (798) 
2 & 2.5 5 1892 (196) 7 2115 (707) 6 2021 (520) 8 1900 (540) 
≥ 3 5 1985 (526) 1 1488 (0) 0 - 0 - 
Mean volumes and SDs are shown in mm3; ‡ mean of grades from two raters; Hpc - 
Hippocampus, PCG - posterior cingulate gyrus; LH - left hemisphere, RH - right hemisphere  
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Figure 5.3: Scatter plots illustrating volumes per rating scale grade. Shown are hippocampal volumes per MTA rating (top), and posterior cingulate gyrus 
volumes per PA rating (bottom), for left and right hemispheres. 
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Mean hippocampal volume for subjects with abnormal MTA scores (>1) was 21.0% lower 
than for those with normal MTA scores in the left hemisphere (1992mm3 versus 2520mm3), 
and 17.5% lower in the right hemisphere (2214mm3 versus 2685mm3). Similarly, 
dichotomizing PA scores into normal and abnormal, mean posterior cingulate gyrus volume of 
subjects with abnormal PA scores was 21.7% lower than for those with normal PA ratings in 
the left (1936mm3 versus 2471mm3), and 23.3% lower in the right hemisphere (2149mm3 
versus 2800mm3).  
 
 
5.4.4 Visual ratings in AD and FTLD 
 
5.4.4.1 Atrophy patterns 
MTA ratings were significantly greater in the FTLD group compared with controls (p<0.0001) 
and AD (p=0.002 for left hemisphere; p=0.03 for mean left and right, Table 5.4). MTA ratings 
were also significantly higher in the AD group compared with controls (p<0.0001). Ratings for 
the PA scale were greater in the AD group compared with controls (p<0.001) and FTLD 
(p=0.004 for right hemisphere; p=0.02 for mean left and right). PA ratings were also 
significantly higher in the FTLD group compared with controls in the left hemisphere (p=0.03). 
The MTA/PA ratio was around 0.5 in the control group, 1 in the AD group and 2 in the FTLD 
group. 
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Table 5.4: Rating scores for controls, AD and FTLD. Means and SDs of MTA and PA scores are shown for each group, as well as p values for differences 
between groups. 
Scale Side Controls 
(N=50) 
AD              
(N=44) 
FTLD         
(N=27) 
Controls vs. 
AD 
Controls vs. 
FTLD 
AD vs. 
FTLD 
    Mean (SD) Mean (SD) Mean (SD) p p p 
MTA LH 0.44 (0.58) 1.43 (1.08) 2.37 (1.13) <0.0001 <0.0001 0.002 
  RH 0.37 (0.56) 1.24 (0.98) 1.37 (1.00) <0.0001 <0.0001 0.7 
  Mean LH&RH 0.41 (0.53) 1.34 (0.95) 1.87 (0.89) <0.0001 <0.0001 0.03 
  
             
PA LH 0.77 (0.64) 1.40 (0.83) 1.13 (0.67) 0.0002 0.03 0.2 
  RH 0.77 (0.68) 1.45 (0.81) 0.91 (0.65) 0.0001 0.3 0.004 
  Mean LH&RH 0.77 (0.62) 1.43 (0.77) 1.02 (0.62) 0.0001 0.1 0.02 
LH - left hemisphere, RH - right hemisphere 
- 92 - 
Dichotomizing MTA and PA scores into normal and abnormal revealed different patterns of 
atrophy in each group (Table 5.5). The majority (72%) of the control subjects had normal 
atrophy scores (i.e. normal MTA and PA), 30% of the AD patients had PA in the absence of 
abnormal MTA (i.e. abnormal PA, normal MTA), whereas only 7% of the FTLD group had 
abnormal PA score and normal MTA. 63% of the FTLD patients had a normal PA with an 
abnormal MTA score. The demographical data for the four different AD subgroups (Table 5.6) 
further show that the PA only AD group is younger in age than AD subjects with MTA only, 
however, this difference was not statistically significant. 
 
Table 5.5: Atrophy patterns in controls, AD and FTLD. Shown are proportion of subjects in 
percent who had no atrophy, MTA only, PA only, and both MTA and PA, based upon a cut-off 
score of >1 for the PA and MTA visual rating scales. 
  
Controls AD FTLD 
No atrophy 72% 18% 4% 
MTA only 6% 18% 63% 
PA only 18% 30% 7% 
MTA & PA 4% 34% 26% 
 
 
Table 5.6: Demographics of AD patients according to atrophy pattern. 
  
No atrophy MTA only PA only MTA & PA p value 
N 8 8 13 15 - 
Age, mean (SD) in years 63.3 (5.5) 66.7 (11.6) 60.6 (7.0) 61.0 (10.0) 0.3 
Gender % male 63% 75% 46% 67% 0.6 
MMSE, mean (SD) † 16.8 (6.7) 18.8 (6.3) 17.0 (6.1) 15.9 (7.9) 0.8 
Age at onset, mean (SD) in 
years 58.4 (3.6) 63.4 (12.2) 56.9 (6.9) 57.6 (10.2) 0.3 
 
 
5.4.4.2 Classification analysis 
Whilst discrimination abilities for separating AD from control subjects were good for both MTA 
and PA scales (0.80 and 0.74, respectively, for mean left and right), they improved 
significantly when both scales were combined (0.87 mean left and right, Table 5.7). In 
contrast, adding the PA to the MTA scale did not improve accuracy for separating FTLD from 
controls (p=0.4). For the discrimination between AD and FTLD, combining both scales 
improved classification accuracy to 0.73 (mean left and right). The greatest improvement was 
found in the right hemisphere, where adding the PA to the MTA scale significantly increased 
accuracy to 0.72 (p=0.02).  
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Table 5.7: Classification analysis for AD, FTLD and controls. AUCs for classification of controls, AD and FTLD, for single and combined rating scales, as 
well as differences in AUCs between combined and single rating scales, 95% CI and p values. 
 
Group Side MTA PA MTA & PA Adding PA to MTA Adding MTA  to PA 
    AUC AUC AUC Difference (95% CI) p Difference (95% CI) p 
C vs. AD LH 0.77 0.72 0.86 0.08 [0.01, 0.16] 0.02 0.14 [0.05, 0.23] 0.002 
 RH 0.76 0.74 0.83 0.06 [0.00, 0.16] 0.07 0.09 [0.02, 0.16] 0.01 
  Mean LH&RH 0.80 0.74 0.87 0.07 [0.01, 0.14] 0.03 0.13 [0.04, 0.22] 0.004 
C vs. FTLD LH 0.92 0.65 0.92 0.00 [-0.02, 0.02] 1.0 0.28 [0.15, 0.40] <0.001 
 RH 0.81 0.57 0.80 -0.01 [-0.04, 0.03] 0.7 0.23 [0.08, 0.39] 0.003 
  Mean LH&RH 0.93 0.61 0.92 -0.01 [-0.03, 0.01] 0.4 0.30 [0.17, 0.44] <0.001 
AD vs. FTLD LH 0.72 0.60 0.74 0.02 [-0.03, 0.08] 0.5 0.15 [0.02, 0.28] 0.03 
 RH 0.53 0.70 0.72 0.19 [0.02, 0.35] 0.02 0.02 [-0.05, 0.08] 0.6 
  Mean LH&RH 0.66 0.66 0.73 0.08 [-0.02, 0.17] 0.1 0.07 [-0.03, 0.18] 0.2 
LH - left hemisphere, RH - right hemisphere. 
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5.4.5 The effect of age at onset on visual ratings in AD 
 
5.4.5.1 Atrophy patterns in EOAD and LOAD 
Both EOAD and LOAD showed significantly higher MTA scores compared with younger and 
older controls, respectively, with MTA scores being significantly higher in LOAD than EOAD 
(p=0.02 for right, p=0.04 for mean left and right, Table 5.8). In addition, EOAD showed 
significantly greater PA scores compared with younger controls (p=0.0001), whereas no 
significant difference in PA scores between LOAD and older controls was found. 
 
Dichotomizing MTA and PA scores into normal and abnormal revealed that over one third of 
EOAD patients (33%) had PA only, whereas almost half of the LOAD patients (46%) had MTA 
only (Table 5.9). The majority of the younger controls (81%) had no atrophy, whereas over 
half of the older controls (57%) had either MTA, PA or both MTA and PA. These data suggest 
that abnormal PA scores may only have diagnostic implications in younger patients and are 
less specific in elderly people. 
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Table 5.8: Group differences between EOAD, LOAD and younger and older controls. Shown are the means and SDs of MTA and PA scores in younger 
and older controls, EOAD and LOAD, as well as p values for differences between groups. 
Group and comparison 
  
MTA PA 
  
  LH RH Mean LH&RH LH RH Mean LH&RH 
Younger controls (N=33) Mean (SD) 0.38 (0.53) 0.29 (0.43) 0.33 (0.44) 0.65 (0.58) 0.71 (0.56) 0.68 (0.53) 
EOAD (N=33) Mean (SD) 1.29 (1.04) 1.05 (0.95) 1.17 (0.92) 1.42 (0.79) 1.45 (0.81) 1.44 (0.76) 
Younger controls vs. EOAD p 0.0002 0.001 0.0001 0.0001 0.0001 0.0001 
  
         
Older controls (N=14) Mean (SD) 0.68 (0.67) 0.64 (0.77) 0.66 (0.69) 1.14 (0.66) 1.07 (0.85) 1.11 (0.72) 
LOAD (N=11) Mean (SD) 1.86 (1.12) 1.82 (0.87) 1.84 (0.88) 1.32 (0.96) 1.45 (0.85) 1.39 (0.84) 
Older controls vs. LOAD p 0.01 0.003 0.002 0.7 0.3 0.5 
  
         
EOAD vs. LOAD p 0.1 0.02 0.04 0.7 0.8 0.7 
LH - left hemisphere, RH - right hemisphere 
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Table 5.9: Atrophy patterns in younger and older controls, EOAD and LOAD. Shown are 
proportion of subjects in percent who had no atrophy, MTA only, PA only, and both MTA and 
PA. 
  
Younger controls Older controls EOAD LOAD 
No atrophy 81% 43% 24% 0% 
MTA only 3% 14% 9% 46% 
PA only 12% 36% 33% 18% 
MTA & PA 3% 7% 33% 36% 
 
 
5.4.5.2 Classification analysis 
Combining MTA and PA ratings significantly improved the separation of EOAD from younger 
controls to 0.89 (mean left and right, Table 5.10). In contrast, adding the PA to the MTA scale 
did not significantly improve separation of LOAD from older controls (p=0.5), whereas adding 
the MTA to the PA scale did result in a greater separation (p=0.01). Discriminatory ability of 
the MTA scale was higher for the separation of LOAD from older controls than EOAD from 
younger controls. In contrast, the PA scale showed a better discrimination for the EOAD from 
younger control classification than LOAD vs. older controls. Whilst these differences were not 
statistically significant, the magnitude of these differences, in particularly for the PA scale, 
was relatively high. 
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Table 5.10: Classification analysis for EOAD and LOAD, as well as younger and older controls. AUCs for each group for single and combined rating 
scales, as well as differences in AUCs between combined and single rating scales, 95% confidence intervals (CI) and p values. 
Group Side MTA PA MTA & PA Adding PA to MTA Adding MTA  to PA 
  
  AUC AUC AUC Difference (95% CI) p Difference (95% CI) p 
Younger controls vs. 
EOAD 
LH 0.75 0.77 0.86 0.11 [0.02, 0.21] 0.02 0.09 [0.01, 0.17] 0.03 
RH 0.74 0.77 0.84 0.10 [0.00, 0.20] 0.05 0.07 [-0.01, 0.14] 0.07 
Mean LH&RH 0.77 0.78 0.89 0.11 [0.02, 0.21] 0.02 0.10 [0.01, 0.20] 0.03 
Older controls vs. 
LOAD 
LH 0.81 0.55 0.89 0.07 [-0.06, 0.21] 0.3 0.34 [0.09, 0.60] 0.01 
RH 0.85 0.61 0.87 0.02 [-0.10, 0.14] 0.8 0.26 [0.04, 0.48] 0.02 
Mean LH&RH 0.87 0.58 0.91 0.04 [-0.07, 0.14] 0.5 0.33 [0.09, 0.57] 0.01 
EOAD vs. LOAD LH 0.65 0.54 0.65 -0.01 [-0.12, 0.10] 0.9 0.11 [-0.10, 0.32] 0.3 
RH 0.73 0.52 0.76 0.03 [-0.07, 0.13] 0.5 0.24 [0.02, 0.46] 0.03 
Mean LH&RH 0.71 0.54 0.69 -0.02 [-0.10, 0.07] 0.7 0.15 [-0.06, 0.36] 0.2 
LH - left hemisphere, RH - right hemisphere 
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5.5 Discussion 
This study demonstrates that in addition to medial temporal lobe atrophy being a feature of 
AD, prominent atrophy in posterior regions of the brain is also frequently found. Furthermore, 
in a subset of patients with pathologically-proven AD, posterior atrophy may be present in the 
absence of marked atrophy in the medial temporal lobes, particularly in younger AD patients. 
MTA is also common in FTLD whereas PA is less common. The presence of posterior 
atrophy therefore helps to distinguish AD from FTLD, and also early-onset AD patients (onset 
<65 years) from younger controls. This study, with the strength of pathological confirmation in 
all patients, therefore suggests that the presence of posterior atrophy may be a useful 
additional marker of AD pathology, over and above MTA. This investigation further presents 
and establishes a tool with which posterior atrophy can be easily and reliably assessed in a 
clinical setting. 
 
Non-memory related deficits such as visuospatial problems are increasingly recognized as 
being a feature of AD (van der Flier et al., 2010). It is perhaps therefore not surprising that an 
anatomical correlate of visuospatial deficits, namely posterior atrophy, is useful in 
distinguishing AD from FTLD. The involvement of posterior brain regions in AD seen in this 
study is in accordance with previous reports showing that AD is not only characterized by 
atrophy of the medial temporal lobe, but also of posterior regions such precuneus and 
posterior cingulate gyrus (Barnes et al., 2007a; Frisoni et al., 2007; Galton et al., 2000). 
Posterior hypometabolism has long been recognized to be characteristic of AD (Ishii et al., 
2005b; Minoshima et al., 1997). Posterior regions have also been shown to have higher levels 
of amyloid deposition early in AD (Kemppainen et al., 2007; Klunk et al., 2004). Functional 
imaging studies have further shown that the default-mode network, which includes medial 
temporal lobe regions and posterior regions, is also affected early in AD (Greicius et al., 2004; 
Zhang et al., 2010).  
 
Both the MTA and PA scales showed reasonable inter- and intra-rater kappa scores. Higher 
MTA scores corresponded to smaller hippocampal volumes on manual measurements, 
similar to previous studies (Bresciani et al., 2005; Scheltens et al., 1992; Wahlund et al., 
2000). The difference in hippocampal volumes between normal and abnormal MTA score was 
relatively high, with 21.0% in the left and 17.5% in the right hemisphere, with on average a 1 
point rise in MTA score being equivalent to around 12% reduction of hippocampal volume. It 
should be noted, however, that this difference is determined by the cut-off score used to 
define normal and abnormal MTA. It has been shown that this cut-off score is age-dependent, 
with a score of >1 being considered abnormal below the age of 75, whereas in patients >75 
years of age a score of >2 would be required to identify abnormal MTA (Scheltens et al., 
1992). Duara et al. showed that a mean MTA score of 1.33 produced optimal sensitivities and 
specificities to separate patients with AD and MCI from healthy controls (Duara et al., 2008). 
Using post-mortem MRI of very old AD patients (>85years), Barkhof et al. showed that a cut-
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off score of 2 correctly excluded subjects with no or borderline Alzheimer-type pathology 
(Barkhof et al., 2007). Since the AD group in the current study was relatively young (mean 
age 58 years), a cut-off score of >1 was used to define abnormal MTA. The same cut-off 
score was used for the novel PA scale. Further work in larger numbers of subjects is needed 
to determine if this is optimum. Higher PA scores only roughly corresponded to smaller 
volumes of the posterior cingulate gyrus, probably because the PA scale reflects more than 
just posterior cingulate atrophy. Although there was only evidence of an association in the 
right hemisphere, a test for interaction showed no evidence that the association differs by 
hemisphere (p=0.1). 
 
The presence of MTA in the FTLD group underlines the fact that hippocampal atrophy is not 
exclusive to AD, but has been widely described in FTLD as well, particularly anteriorly (Chan 
et al., 2001b; Galton et al., 2001; Mesulam, 2001; Thompson et al., 2003). Posterior atrophy 
scores, on the other hand, were significantly higher in the AD group compared with FTLD. 
This difference was driven by significantly higher PA ratings in the right hemisphere in AD 
compared with FTLD. It is perhaps surprising that a proportion of FTLD cases have quite 
prominent posterior atrophy in the left hemisphere. This is likely to be due to the language 
cases in this group where left-sided atrophy can spread posteriorly as the disease 
progresses. Higher PA ratings in the right hemisphere in AD significantly improved the 
distinction of AD from FTLD. It should be noted, however, that average scores of two raters 
were used in this study. Classification accuracies therefore may not necessarily reflect 
performance of a single rater. 
 
Interestingly, 30% of AD subjects in this study had marked PA in the absence of an abnormal 
MTA rating, whereas only 18% showed the opposite pattern. However, these results are 
based on arbitrarily chosen cut-off scores. Whilst optimal cut-off scores for different age 
groups have been investigated for the MTA (see above), further studies are required to 
identify optimal cut-off scores for the PA scale. The AD patients with PA only tended to be 
younger (in terms of age and onset) than patients with MTA only. Splitting the AD group into 
early and late-onset patients further revealed that PA ratings significantly improved the 
classification of EOAD from younger controls, whereas it did not improve the separation 
between LOAD and older controls. This suggests that atrophy in posterior regions of the brain 
is particularly important to consider when making a diagnosis in early-onset patients. 
However, this segregation with age is not exclusive; some younger AD patients may present 
with mostly MTA, while some LOAD may have mostly PA. 
 
One potential limitation is the variety in image acquisition. It is unclear how MTA and PA 
ratings are affected by different scan acquisition protocols and quality. However, it has been 
shown that MTA ratings are comparable using MRI and CT (Wattjes et al., 2009). 
Furthermore, the fact that strong patterns were still detected in different groups suggests that 
- 100 - 
visual rating tools are relatively robust to varying image quality. It should further be noted that 
only sporadic AD and FTLD cases were included in the group comparison and classification 
analyses. This was motivated by the fact that the familial AD cases were significantly younger 
than the sporadic AD cases (mean age 47.7 (SD 6.4) for familial AD and 62.3 (SD 8.9) for 
sporadic AD), and previous studies suggesting that familial AD patients can have a different 
clinical phenotype and different patterns of amyloid accumulation than sporadic AD cases 
(Knight et al., 2011; Ryan and Rossor, 2010). The exclusion of the familial cases therefore 
resulted in more homogenous groups for the group comparison analysis. Whilst some of 
these AD patients had non-amnestic clinical presentations during life and may therefore be 
considered as ‘atypical’, all of these patients had pathological confirmation of disease. Since 
pathological confirmation remains the gold standard to establish a definite diagnosis of AD, 
and since potential interventional treatments are likely to specifically target AD pathology, the 
main objective of the current study was to assess visual ratings in patients with AD pathology 
irrespective of clinical diagnosis. Further investigations assessing the relative utility of the 
visual assessment tools presented in this study should be performed in clinically-diagnosed 
older sporadic AD patients.  
 
5.6 Chapter conclusion 
In conclusion, the current study demonstrates pronounced atrophy in posterior cerebral 
regions in the absence of clear atrophy in the medial temporal lobe in patients with 
pathologically-confirmed AD. Since MTA is currently a proposed diagnostic marker for AD, 
these findings may suggest that some AD patients may not receive a diagnosis of AD if only 
MTA is considered. The presence of posterior atrophy may be a helpful additional marker for 
AD, especially in younger patients. This study further presents a tool with which posterior 
cerebral atrophy can be easily and reliably assessed in a clinical setting. Visual ratings of PA 
may improve diagnostic accuracy for distinguishing AD from FTLD, and may be valuable in 
distinguishing early-onset AD from younger controls. 
 
The findings from this and the previous chapter suggest that PA is an important feature of AD. 
This is further demonstrated by the presence of marked posterior atrophy in individuals with 
PCA. Patients with PCA therefore represent a disease population in which we can further 
characterize the mechanisms underlying the marked involvement of posterior regions in AD. 
Specifically, studying PCA will improve our understanding of how atrophy patterns vary 
between this presentation and other focal variants of AD, such as typical amnestic AD, how 
atrophy progresses over time, and how these structural changes relate to cognitive deficits. A 
better understanding of the neuroimaging and neuropsychological features of PCA may pave 
the way to address fundamental questions such as which factors drive the heterogeneity of 
phenotypes in AD.  
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6. CROSS-SECTIONAL DIFFERENCES IN CORTICAL THICKNESS AND GREY MATTER 
VOLUME IN PCA AND TYPICAL AD 
 
6.1 Chapter introduction 
Whilst the posterior atrophy of PCA (chapter 1, section 1.2.2) may often be evident from 
visual assessment of structural MR images (chapter 1, Figure 1.1), a number of image 
analysis tools have been developed with which the patterns of atrophy can be more precisely 
quantified and localized. Automated image analysis tools such as VBM can be used to assess 
differences in patterns of cerebral atrophy over the whole brain between different groups 
(chapter 2, section 2.2.1.3.3). VBM in typical AD has demonstrated grey matter loss mainly in 
the medial temporal lobe that extends into the posterior cingulate gyrus, precuneus, insula, 
temporal-parietal association cortex and prefrontal gyrus (Baron et al., 2001; Boxer et al., 
2003; Good et al., 2002; Karas et al., 2004; chapter 2, section 2.5.2). Only one study has 
assessed atrophy patterns in PCA compared with controls and typical AD using VBM 
(Whitwell et al., 2007a). The study revealed distinct patterns of grey matter loss in both the 
PCA and typical AD group compared with controls, however, the direct comparison between 
PCA and typical AD did not show any statistically significant differences after multiple 
comparison correction. Differential patterns of cortical thickness between PCA and typical AD 
have not been investigated. 
 
The aim of this study was to assess patterns of cortical thickness and grey matter loss in well-
characterized individuals with PCA, and compare these with typical, amnestic AD and with 
healthy controls. 
 
 
6.2 Methods 
 
6.2.1 Subjects 
The study involved 48 patients with PCA, 30 patients with typical AD (tAD) and 50 age- and 
gender-matched healthy controls. All subjects were identified retrospectively from a clinical 
database. Subjects had to fulfil stringent inclusion criteria as described in chapter 3, section 
3.4, and had to have at least one MRI scan. Demographics and clinical data of the subjects 
are summarized in Table 6.1. 
 
6.2.2 MRI acquisition 
Images were acquired as described in chapter 3 (section 3.5.1) and Appendix 5. 
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6.2.3 Image processing 
Cortical thickness measurements were made using FreeSurfer version 4.0.3 (chapter 3, 
section 3.5.3.2.2), and grey matter volumes were measured using SPM5 and DARTEL 
(chapter 3, section 3.5.3.2.1). 
 
6.2.4 Statistical analysis 
Regional variations in cortical thickness and grey matter volumes between the patient groups 
and the control group were assessed using a vertex-by-vertex GLM (chapter 3, section 
3.5.4.2.3). Atrophy A (cortical thickness or grey matter volume) was modelled as a function of 
group, controlling for age (mean-centred), gender, scanner and TIV, using estimated TIV 
(eTIV) from the FreeSurfer processing stream which was shown to be a reasonable estimate 
for TIV (Buckner et al., 2004), by their inclusion as covariates: A = β1 PCA + β2 tAD + β3 
controls + β4 age + β5 gender + β6 scanner + β7 eTIV + ε. The contrasts of interest were 
calculated using t-tests (two-tailed for FreeSurfer, one-tailed for VBM) between the estimates 
of the group parameters, i.e. β1 and β3 (PCA vs. controls), β2 and β3 (tAD vs. controls), and 
β1 and β2 (PCA vs. tAD). Cortical thickness and VBM maps show statistically-significant 
differences between the groups (FDR-corrected). Differences in cortical thickness between 
PCA and tAD are further presented as percent differences. 
 
Thickness values were obtained for individual regions using FreeSurfer’s Desikan parcellation 
(Desikan et al., 2006). Differences between groups were assessed on a descriptive level for 
each region by expressing mean thickness in PCA and tAD as percentage of mean control 
thickness. Differences were further assessed on a statistical level by using the same 
statistical analysis as described above (adjusting for the same covariates). This was applied 
to larger regions, namely frontal lobe, medial and lateral temporal lobes, precuneus and 
posterior parietal lobe, occipital lobe, and anterior and posterior cingulate gyri. Thickness 
estimates for these regions were obtained by averaging the thickness values of a number of 
smaller regions provided by FreeSurfer, details of which are shown in Table 6.3. 
 
6.3 Results 
 
6.3.1 Subjects 
The groups were comparable in gender distribution (p=0.5), and the PCA group was matched 
in age to the control group (p=0.6). However, the tAD group was older (p<0.005 for an effect 
of age across all groups), and there was a marked difference in MMSE between PCA and tAD 
(p<0.001), with the tAD group having, on average, a lower MMSE score than the PCA group 
despite similar disease durations (~5 years, p=0.3) at time of scan. Pathological confirmation 
was available for 5 PCA patients (4 AD, 1 AD with Lewy Bodies), 5 tAD patients (all showing 
AD pathology), and 1 control (showing a normal brain).  
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Table 6.1: Subjects demographics and clinical data. 
  
Controls PCA tAD p value 
N 50 48 30 N/A 
Gender % male 34% 40% 47% 0.5 § 
Age in years, mean (SD) 63.7 (9.6) 63.0 (6.7) † 69.2 (8.9) <0.005 ¶ 
MMSE, mean (SD) 29.3 (1.0) ¥ 21.2 (4.6) 18.4 (4.6) <0.0001 ¶ 
Disease duration in years, 
mean (range) - 4.8 (1.0, 12.0) 5.4 (1.0, 11.0) 0.3 
¶
 
§
 Fisher's exact test; ¶ ANOVA; † age of PCA group matched to age of control group; p=0.6;    
¥
 available in 32 controls. 
 
 
6.3.2 Cortical thickness 
Table 6.2 shows the adjusted differences in cortical thickness between groups which were 
obtained from the GLM. Both PCA and tAD group showed significantly lower cortical 
thickness compared with controls in most regions across the cortex except in the anterior 
cingulate gyrus. Interestingly, the PCA group showed reduced thickness in the frontal lobe 
compared with controls, which is comparable to the reductions found for the tAD-control 
comparison. Compared with tAD, the PCA group showed significantly lower thicknesses 
bilaterally in the posterior parietal lobe, precuneus and occipital lobe. There was some 
evidence for significantly lower cortical thickness in the medial temporal lobe in the tAD group 
compared with PCA.  
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Table 6.2: Adjusted differences in cortical thickness between groups, 95% confidence intervals, and significance level. 
 
Region Side PCA-C tAD-C PCA-tAD 
    Diff 95% CI Diff 95% CI Diff 95% CI 
Frontal lobe 
 
        
 
  LH -0.17 [-0.24 to -0.11] *** -0.17 [-0.24 to -0.10] *** -0.01 [-0.08 to 0.07] 
  RH -0.18 [-0.24 to -0.13] *** -0.15 [-0.22 to -0.09] *** -0.03 [-0.09 to 0.04] 
Temporal lobe 
          
 
medial LH -0.32 [-0.41 to -0.23] *** -0.42 [-0.52 to -0.32] *** 0.10 [-0.001 to 0.21] * 
  RH -0.32 [-0.41 to -0.24] *** -0.34 [-0.45 to -0.24] *** 0.02 [-0.08 to 0.12] 
lateral LH -0.28 [-0.34 to -0.21] *** -0.31 [-0.38 to -0.23] *** 0.03 [-0.05 to 0.11] 
  RH -0.27 [-0.34 to -0.20] *** -0.25 [-0.33 to -0.18] *** -0.02 [-0.10 to 0.06] 
Parietal lobe 
          
 
posterior LH -0.39 [-0.46 to -0.32] *** -0.28 [-0.36 to -0.20] *** -0.11 [-0.19 to -0.03] ** 
  RH -0.41 [-0.47 to -0.36] *** -0.23 [-0.30 to -0.16] *** -0.18 [-0.25 to -0.11] *** 
precuneus LH -0.35 [-0.42 to -0.28] *** -0.24 [-0.32 to -0.15] *** -0.12 [-0.20 to -0.03] ** 
  RH -0.41 [-0.47 to -0.34] *** -0.25 [-0.33 to -0.18] *** -0.15 [-0.23 to -0.07] *** 
Occipital lobe 
        
  
 
  LH -0.29 [-0.34 to -0.24] *** -0.17 [-0.23 to -0.10] *** -0.12 [-0.19 to -0.06] *** 
  RH -0.31 [-0.36 to -0.25] *** -0.17 [-0.23 to -0.10] *** -0.14 [-0.20 to -0.08] *** 
Cingulate gyrus 
          
 
anterior LH -0.03 [-0.13 to 0.07] -0.07 [-0.18 to 0.04] 0.04 [-0.07 to 0.16] 
  RH -0.08 [-0.17 to 0.0004] * -0.07 [-0.16 to 0.03] -0.02 [-0.12 to 0.08] 
posterior LH -0.30 [-0.38 to -0.23] *** -0.28 [-0.37 to -0.19] *** -0.02 [-0.11 to 0.07] 
  RH -0.33 [-0.40 to -0.25] *** -0.27 [-0.36 to -0.18] *** -0.05 [-0.14 to 0.04] 
* p≤0.05; ** p≤0.01; *** p≤0.005, LH - left hemisphere, RH - right hemisphere 
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6.3.2.1 Comparison of PCA and controls 
The PCA group showed widespread differences in cortical thickness, with parts of the 
orbitofrontal cortex being the only region not showing a significantly thinner cortex (Figure 
6.1A). The maps further illustrate a posterior-anterior gradient, with posterior regions showing 
greater reductions in cortical thickness than anterior regions. As shown in Table 6.3, the 
superior parietal cortex showed the greatest reduction: on average 20% lower than controls 
on the left and 22% lower on the right. 
 
6.3.2.2 Comparison of tAD and controls 
In the tAD group, lower cortical thickness was found in many regions across the whole brain, 
only sparing regions around the central sulcus, and small parts of the occipital lobe (Figure 
6.1B). Cortical thickness was thinnest in regions of the temporal lobes as well as parietal 
lobes and precuneus, followed by regions in the frontal lobe. The entorhinal cortex showed 
lowest cortical thickness compared with mean control thickness (30% reduced in the left and 
25% in the right hemisphere, Table 6.3). Reductions in cortical thickness appear to be 
marginally more marked in the left hemisphere than the right. 
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Figure 6.1: Differences in reduced cortical thickness in PCA and tAD compared with controls. A) PCA compared with controls; B) tAD compared with 
controls, for the left and right hemisphere. The colour scale for statistical difference represents FDR-corrected p values at a 0.05 significance level. Red and 
yellow (positive values) represent lower cortical thickness in the patients groups (PCA and tAD) compared with controls, whereas dark and light blue 
(negative values) represent greater cortical thickness (which yielded no statistically significant results). A - anterior, P - posterior.  
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6.3.2.3 Comparison of PCA and tAD 
The statistical difference maps for the direct comparison between the patient groups revealed 
lower cortical thickness predominantly in the superior parietal cortex in the PCA group, and 
reduced thickness in the entorhinal cortex in the tAD group (Figure 6.2). As shown in Table 
6.3, the superior parietal lobes were reduced by 7% in the left, and 12% in the right 
hemisphere in the PCA group, whereas the entorhinal cortex was reduced by 14% in the left, 
and 10% in the right hemisphere in the tAD group.  
 
Percent difference maps further revealed lower cortical thickness in the occipital lobes, 
precuneus, posterior cingulate gyrus, and fusiform gyrus in PCA compared with tAD. In 
contrast, the tAD group showed lower cortical thickness in the medial temporal lobes as well 
as lateral temporal lobe regions. However, this difference did not survive FDR correction in 
the statistical difference maps. In the PCA group cortical thickness showed marginally greater 
reductions in the right hemisphere compared with the left, whereas in the tAD group thickness 
was slightly more reduced in the left hemisphere. 
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Figure 6.2: Differences in reduced cortical thickness in PCA compared with tAD. The colour scale for statistical difference (A) represents FDR-corrected 
p values at a 0.05 significance level, whereas the colour bar for percent difference (B) represents magnitude of cortical thickness difference. Red and yellow 
(positive values) represent lower cortical thickness in PCA compared with tAD, whereas dark and light blue (negative values) represent lower cortical 
thickness in tAD compared with PCA. A - anterior, P - posterior.  
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Table 6.3: Differences in cortical thickness in PCA and tAD. Cortical thickness values for 
PCA, tAD and difference between PCA and tAD are represented as percentage of mean 
control thickness in the regions automatically parcellated by FreeSurfer according to Desikan 
et al. (Desikan et al., 2006). 
Region 
  
%PCA/Controls 
mean (SD) 
%tAD/Controls 
mean (SD) 
% (PCA-AD) 
/Controls 
Frontal lobe left hemisphere     
  
  Frontal pole 88.1 (13.9) 88.0 (13.9) 0.1 
  Orbitofrontal gyrus 1 96.0 (8.5) 93.3 (6.6) 2.7 
  Inferior frontal gyrus 2 94.2 (9.3) 91.8 (6.0) 2.4 
  Middle frontal gyrus 3 90.6 (9.0) 90.4 (7.3) 0.2 
  Superior frontal gyrus 92.8 (7.8) 92.1 (7.6) 0.7 
  Precentral gyrus 88.7 (9.8) 90.4 (7.6) -1.7 
          
Frontal lobe right hemisphere 
      
  Frontal pole 88.7 (13.5) 90.6 (9.7) -1.9 
  Orbitofrontal gyrus 1 95.8 (7.5) 93.5 (7.6) 2.3 
  Inferior frontal gyrus 2 93.7 (7.6) 92.7 (6.6) 1.0 
  Middle frontal gyrus 3 90.3 (7.6) 92.1 (7.5) -1.8 
  Superior frontal gyrus 92.5 (7.2) 91.9 (7.5) 0.6 
  Precentral gyrus 87.4 (8.8) 92.2 (8.2) -4.8 
          
Temporal lobe left hemisphere 
      
       Medial temporal lobe       
  Entorhinal cortex 84.6 (15.2) 70.4 (16.5) 14.2 
  Parahippocampal gyrus 91.3 (13.6) 85.5 (11.4) 5.8 
  Fusiform gyrus 87.0 (8.0) 87.8 (9.5) 9.2 
       Lateral temporal lobe       
  Transverse temporal gyrus 88.0 (8.9) 86.6 (8.5) 1.4 
  Banks of superior temporal sulcus 84.1 (10.5) 85.2 (10.8) -1.1 
  Superior temporal gyrus 91.7 (8.1) 86.8 (6.9) 4.9 
  Middle temporal gyrus 90.9 (9.8) 86.9 (7.9) 4.0 
  Inferior temporal gyrus 90.5 (10.3) 87.9 (7.8) 2.6 
  Temporal pole 88.5 (14.5) 82.3 (17.9) 6.2 
          
Temporal lobe right hemisphere 
      
       Medial temporal lobe       
  Entorhinal cortex 85.5 (15.0) 75.1 (19.6) 10.4 
  Parahippocampal gyrus 88.3 (12.3) 87.6 (13.3) 0.7 
  Fusiform gyrus 87.0 (8.1) 89.3 (8.0) -2.3 
       Lateral temporal lobe       
  Transverse temporal gyrus 89.7 (11.4) 90.2 (9.2) -0.5 
  Banks of superior temporal sulcus 84.9 (9.9) 88.1 (10.1) -3.2 
  Superior temporal gyrus 91.1 (9.2) 88.6 (7.5) 2.5 
  Middle temporal gyrus 90.4 (8.0) 89.5 (9.5) 0.9 
  Inferior temporal gyrus 91.4 (9.0) 91.8 (8.0) -0.4 
  Temporal pole 89.2 (12.0) 83.3 (17.9) 5.9 
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Table 6.3 continued. 
Region 
  
%PCA/Controls 
mean (SD) 
%tAD/Controls 
mean (SD) 
% (PCA-AD) 
/Controls 
Parietal lobe left hemisphere 
    
  
  Postcentral gyrus 91.2 (9.0) 91.2 (7.2) 0 
  Supramarginal gyrus 85.7 (9.5) 87.1 (7.0) -1.4 
  Precuneus 83.4 (9.0) 88.4 (8.8) -5.0 
       Posterior parietal lobe       
  Inferior parietal lobe 83.7 (9.4) 84.9 (8.6) -1.2 
  Superior parietal lobe 79.6 (10.9) 87.0 (8.0) -7.4 
          
Parietal lobe right hemisphere 
      
  Postcentral gyrus 88.9 (8.6) 92.1 (7.8) -3.2 
  Supramarginal gyrus 84.6 (8.0) 90.0 (8.2) -5.4 
  Precuneus 80.7 (8.8) 87.8 (8.1) -7.1 
       Posterior parietal lobe       
  Inferior parietal lobe 82.5 (6.9) 87.7 (8.7) -5.2 
  Superior parietal lobe 77.6 (9.5) 89.6 (7.1) -12.0 
          
Occipital lobe left hemisphere 
      
  Lateral occipital gyrus 83.0 (11.3) 89.4 (7.4) -6.4 
  Cuneus 84.6 (11.5) 88.5 (7.1) -3.9 
  Lingual gyrus 86.0 (8.2) 91.0 (6.6) -5.0 
          
Occipital lobe right hemisphere 
      
  Lateral occipital gyrus 81.3 (10.3) 89.7 (7.1) -8.4 
  Cuneus 82.2 (11.3) 89.2 (8.7) -7.0 
  Lingual gyrus 85.3 (10.3) 91.7 (7.2) -6.4 
          
Cingulate gyrus left hemisphere 
      
       Anterior cingulate gyrus       
  Rostral anterior cingulate gyrus 98.8 (13.7) 97.5 (10.4) 1.3 
  Caudal anterior cingulate gyrus 99.4 (12.0) 95.8 (12.0) 3.6 
       Posterior cingulate gyrus       
  Posterior posterior cingulate gyrus 91.3 (9.4) 93.3 (7.8) -2.0 
  Isthmus posterior cingulate gyrus 83.0 (11.4) 82.7 (7.5) 0.3 
          
Cingulate gyrus right hemisphere 
      
       Anterior cingulate gyrus       
  Rostral anterior cingulate gyrus 96.1 (11.1) 97.2 (10.7) -1.1 
  Caudal anterior cingulate gyrus 98.1 (11.7) 96.7 (11.9) 1.4 
       Posterior cingulate gyrus       
  Posterior posterior cingulate gyrus 89.6 (10.6) 92.7 (7.9) -3.1 
  
Isthmus posterior cingulate gyrus 82.0 (10.8) 83.2 (9.6) -1.2 
1
 average of lateral and medial orbitofrontal regions, 2 average of pars opercularis, pars 
orbitalis and pars triangularis, 3 average of caudal and rostral midfrontal regions 
 
 
 
 
- 111 - 
6.3.3 Voxel-based morphometry 
 
6.3.3.1 Comparison of PCA and controls 
In the PCA group widespread grey matter differences were shown compared with controls, 
with the most significant reductions found in regions of the occipital and parietal lobe, followed 
by regions in the temporal lobe (Figure 6.3 left, Table 6.4). No significant reductions in grey 
matter volume were observed for the reverse contrast.  
6.3.3.2 Comparison of tAD and controls 
In the tAD group, grey matter reductions were shown across the whole brain, with the most 
significant grey matter loss found in the parietal and temporal regions (Figure 6.3 right, Table 
6.4). No significant reductions in grey matter volume were found in the control group 
compared with tAD. 
 
6.3.3.3 Comparison of PCA and tAD 
Direct comparison between PCA and tAD revealed lower grey matter volume in bilateral 
posterior parietal regions and parts of the occipital lobe (Figure 6.4, Table 6.4). Unthresholded 
maps further revealed lower grey matter volumes in the medial temporal lobe in the tAD group 
compared with PCA, however, this reduction did not reach statistical significance following 
correction for multiple comparisons. 
 
6.3.3.4 Posterior-anterior gradient 
A clear posterior-anterior gradient was shown in the PCA group compared with controls and 
tAD (Figure 6.5). Regions in the temporal and frontal lobes showed similar levels of grey 
matter differences in both PCA and tAD compared with controls and therefore these were not 
found to be significantly different in the direct PCA<tAD comparison. 
 
 
Table 6.4: Location of cluster maximum for each group comparison. 
 
 
 
 
 
Voxel coordinates are in millimetres after conversion from DARTEL into MNI stereotactic 
space. Results are corrected for multiple comparisons (p<0.05). 
 
 
 
Comparison Region Hemisphere T value Cluster size pFDR value
x y z
PCA < Control Occipital lobe Left -33 -64 -1 13.6 254462 <0.0001
tAD < Control Temporal lobe Left -47 -36 -6 9.8 142790 <0.0001
PCA < tAD Occipital lobe Right 29 -78 -0 6.2 43421 <0.0001
MNI coordinates
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Figure 6.3: Differences in reduced grey matter in PCA and tAD compared with controls. Maps show t-scores (FDR-corrected at p<0.05), with warmer 
colours indicating statistically lower grey matter volumes in the PCA group (left) and the tAD group (right) compared with controls. The crosshair in each 
contrast is set to the global maximum, which is in the left occipital lobe in the PCA group, and in the left temporal in the tAD group. L - left hemisphere, R -  
right hemisphere, A - anterior, P - posterior.  
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Figure 6.4: Differences in grey matter volume in the PCA group compared with tAD. 
Map shows t-scores (FDR-corrected at p<0.05), with warmer colours indicating statistically 
lower grey matter volumes in the PCA group compared with tAD. The crosshair is set to the 
global maximum in the right occipital lobe. L - left hemisphere, R -  right hemisphere, A - 
anterior, P - posterior.  
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Figure 6.5: Posterior-anterior gradient for each group comparison. Presented are coronal slices from posterior (P) to anterior (A) for differences in grey 
matter volume in PCA compared with controls (upper panel), tAD compared with controls (middle panel), and PCA compared with tAD (lower panel). Scale 
bars represent t-values, with warmer colours representing statistically greater differences between groups. Note that y-coordinates here relate to the DARTEL 
average template, not to MNI space. L - left hemisphere, R - right hemisphere.  
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6.4 Discussion 
This study reports patterns of grey matter loss and cortical thinning in a large series of PCA 
patients. Cortical thickness and grey matter volumes were compared with tAD patients and 
healthy controls. Distinct and dissociated patterns of loss were seen in PCA and tAD. The 
PCA group showed thinner cortex predominantly in occipital and posterior parietal regions 
compared with controls, whereas the tAD group showed a thinner cortex mainly in medial 
temporal lobe regions. A direct comparison between PCA and tAD further revealed 
significantly thinner cortex most marked in the right superior parietal lobe in the PCA group 
compared with tAD, and the left entorhinal cortex in the tAD group compared with PCA. 
These results indicate an interesting greater involvement of the right hemisphere in the PCA 
group compared with tAD which might be driven by the relatively high proportion of patients 
with predominantly right hemisphere deficits in the PCA group. It would be important to see if 
this is just a feature of the PCA group in this study (e.g. an artefact of inclusion criteria) or if 
this reflects a true difference in cerebral vulnerability of the right hemisphere in PCA. 
 
The VBM analysis revealed similar patterns of differences in grey matter volume to those 
observed in cortical thickness. A direct comparison between PCA and tAD showed significant 
differences in grey matter volume in occipital lobe and posterior parietal regions in the PCA 
group compared with tAD, with the right hemisphere being marginally more affected than the 
left. However, there were no areas where grey matter volume was significantly lower in the 
tAD group compared with PCA.  
 
These findings are in accordance with a previous volumetric imaging study using VBM. 
Whitwell et al. found greater grey matter atrophy in primary visual and visual association 
cortices in PCA compared with controls, and reduced grey matter in the medial temporal lobe 
in the typical AD group compared with controls (Whitwell et al., 2007a). However, no 
significant FDR-corrected differences in grey matter were found for the direct comparison 
between PCA and typical AD. The stronger differences between the disease groups shown in 
our study may be due to the larger size of the PCA group as well as to differences in the 
inclusion criteria applied to the PCA and tAD group. Therefore the current study strengthens 
the evidence base suggesting not only a clinical but also a neuroimaging distinction between 
these typical and atypical presentations of AD when assessing a single time point. This study 
also validates the use of cortical thickness measures as a method for quantifying and 
localising cortical loss in PCA. The posterior pattern of grey matter loss and cortical thinning is 
further in accordance with PET and SPECT studies showing marked hypoperfusion and 
hypometabolism in posterior regions in PCA (Bokde et al., 2001; Freedman et al., 1991; 
Nestor et al., 2003; Ross et al., 1996; Wakai et al., 1994). 
 
Strengths of the current study include the size of the PCA group as well as the well-defined 
inclusion criteria for both the PCA group and the tAD group (chapter 3, section 3.4). Unlike 
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some previous studies where patients were selected purely on clinical grounds, the PCA 
subjects in this study conformed to specific behavioural criteria and in particular were clearly 
distinguished from tAD patients on the basis of relatively intact episodic memory functions. By 
only including individuals who met these selection criteria the potential overlap between 
groups was reduced. Many patients with tAD also show parietal deficits and episodic memory 
can be impaired in PCA patients later in the disease course. In addition, only PCA patients 
with AD as the most probable diagnosis were included, since patients with clinical features 
suggesting DLB, CBD or prion disease at presentation may have non-AD pathology. It should 
be noted that the tAD group reflects the most common amnestic presentation of AD and did 
not include any atypical (such as frontal or language) AD presentations. 
 
It is generally difficult to match PCA and tAD groups for disease severity as disease 
progression and duration in PCA are still not very well understood. In this study, both disease 
groups showed similar ranges of disease duration, suggesting that both groups included 
patients with mild to severe impairments. As expected, mean MMSE scores differed between 
the two disease groups owing to the weighting of questions towards memory and orientation. 
Furthermore, pathological confirmation was only available in five PCA patients (at time of 
writing) which represents a limitation to this study since some PCA patients may have other, 
non-AD pathologies as the underlying cause (Tang-Wai et al., 2004; Victoroff et al., 1994). 
 
Atrophy patterns were analysed using two computational image analysis tools which 
assessed differences in thickness and grey matter volume across the whole brain without 
making any a priori assumptions about which regions may or may not be affected by the 
disease. Each technique gives complementary information regarding brain structures in both 
patient groups. Whilst VBM provides grey matter volumes for subcortical regions for which no 
cortical thickness estimates are available, cortical thickness measures provided by FreeSurfer 
are more easily interpretable than the probabilistic grey matter volumes in VBM. The 
retrospective nature of this study meant that scans were obtained from different scanners, 
though these were all the same field strength and model, and statistical models were adjusted 
for scanner type.  
 
Although techniques such as cortical thickness offer a measure of cortical rather than whole 
brain atrophy, they inevitably lack the resolution to identify changes in cell structure integrity 
at anything more than a regional level. Nevertheless, the evidence presented here of very 
significant occipital cortex thinning extending into the striate cortex, provides justification for  
further studies investigating the specific cognitive phenomena in PCA (e.g. prolonged colour 
after-images, visual crowding) and regional atrophy patterns (Chan et al., 2001a; Crutch and 
Warrington, 2007). 
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6.5 Chapter conclusion 
This chapter presents significant cross-sectional differences in cortical thickness and grey 
matter volume in PCA compared with typical amnestic AD. Regions showing lower cortical 
thickness and grey matter volumes in the PCA group compared with tAD include the superior 
parietal lobe and areas of the visual cortex. In contrast, cortical thickness was lower in the 
entorhinal cortex in the typical AD group compared with PCA. These distinct patterns of 
atrophy may have diagnostic utility and may help identify posterior variants of AD. This means 
that in the appropriate clinical context AD should not be discounted simply because of 
relatively preserved medial temporal lobes and the presence of parietal lobe atrophy. Whilst 
cross-sectional imaging studies are useful in revealing characteristic patterns of atrophy 
which may aid clinical diagnosis, it is only through longitudinal studies that progression of 
atrophy in these patients can be assessed. Longitudinal changes in atrophy patterns in PCA 
and typical AD will be described in the next chapter. 
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7. LONGITUDINAL CHANGES IN GREY MATTER VOLUMES AND CORTICAL 
THICKNESS IN PCA 
 
7.1 Chapter introduction 
Longitudinal image analysis is particularly useful in assessing the progression of atrophy over 
time within an individual, and may increase power by allowing adjustment of tissue loss by 
initial volume (chapter 2, section 2.2.2). In particular, longitudinal investigations are needed to 
assess whether the focal cross-sectional patterns of atrophy (as presented in the previous 
chapter) remain confined to these regions or whether they become more global. Areas of 
greatest change may not be the areas that are most atrophied initially. The anatomical extent 
and amount of change in grey matter volume and cortical thickness in PCA is not well 
understood. Results from longitudinal studies of PCA may allow for a better understanding of 
the natural history of both PCA and AD. 
 
The aim of the current study was to assess longitudinal changes in whole brain volume, grey 
matter volume, and cortical thickness in PCA, and compare these with structural changes 
over time in groups of typical amnestic AD (tAD) patients and healthy controls. Specifically, 
two possible outcomes were predicted: patterns of atrophy progression are either i) focal, with 
PCA showing greater atrophy changes in posterior regions compared with controls and tAD, 
and tAD showing greater atrophy changes in medial temporal lobe regions compared with 
controls and PCA, leading to significantly different patterns of atrophy changes between PCA 
and tAD, or ii) atrophy changes are global, with PCA and tAD showing widespread changes of 
atrophy compared with controls, and only subtle differences in the direct comparison of PCA 
and tAD. Understanding the progression of atrophy in PCA may improve diagnosis and the 
quality of prognostic information given to patients.  
 
7.2 Methods 
 
7.2.1 Subjects 
The study included 17 PCA and 16 tAD patients, and 18 healthy controls. All subjects were 
identified retrospectively from a clinical database. Demographics and clinical data of the 
subjects are summarized in Table 7.1. Subjects had to fulfil specific inclusion criteria as 
described in chapter 3, section 3.4, and had to have at least two MRI scans on the same 
scanner approximately 1 year apart. All PCA and tAD patients (100%) as well as 12 control 
subjects (67%) were included in the cross-sectional study described in the previous chapter. 
The clinical notes of all PCA patients were reviewed by a clinician to identify initial symptoms 
and clinical findings (Table 7.2). All patients underwent comprehensive clinical and 
neuropsychological assessment. An overview of the proportion of PCA and tAD patients 
showing impaired performance (<5th %ile) on neuropsychological tests of memory, 
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arithmetic, naming, spelling, speed (letter cancellation), and visuospatial and visuoperceptual 
processing is provided in Table 7.3. 
 
7.2.2 MRI acquisition 
Images were acquired as described in chapter 3 (section 3.5.1) and Appendix 5. Scans of all 
subjects were acquired on the same scanner, and scan acquisition was consistent between 
time points for each subject.  
 
7.2.3 Registration of repeat to baseline image 
Both baseline and repeat brain regions were delineated (chapter 3, section 3.5.2.1) and the 
repeat brain images were registered to baseline images using 12dof registration (Woods et 
al., 1998). A differential bias correction (DBC) was applied to the registered baseline and 
repeat images using a kernel radius of 5 voxels, in order to correct for differences in intensity 
inhomogeneity artefacts between the two images (Lewis and Fox, 2004).  
 
7.2.4 BSI 
The registered and DBC-corrected scan pairs were used to calculate volume changes using 
the BSI algorithm (KN-BSI, Leung et al., 2010). 
 
7.2.5 Fluid-registration 
The registered and DBC-corrected scan pairs were cropped using subject-specific masks to 
exclude non-brain regions (e.g. neck and eye), whilst including lateral ventricular CSF, grey 
matter, white matter and a layer of brain-surface CSF. Fluid registrations (chapter 2, section 
2.2.2.2) were run until a stopping criterion based on the derivative of the cost function of the 
registration was reached (Barnes et al., 2007b). The amount of voxel-level expansion or 
contraction was extracted from each resulting deformation field by computing the determinant 
of the Jacobian at each voxel (i.e. the determinant of the gradient of the deformation field). 
The Jacobian-determinants were then log-transformed, and the resulting ‘voxel-compression 
map’ for each subject was stored. 
 
7.2.6 Longitudinal VBM 
The voxel-compression maps as well as the baseline images were converted to NIFTI format 
in order to process them using SPM8. The baseline images were first processed in the 
standard way (chapter 3, section 3.5.3.2.1). The transformation parameters required to warp 
the original segments to the final template (i.e. rigid alignment plus DARTEL warping) were 
applied to the grey matter segments, as well as to the voxel-compression map images in 
order to normalise them to the group-wise average template. The warped grey matter 
segments were then thresholded at a value of 0.5 to produce binary masks that were then 
used to multiply the voxel-compression map images to generate separate grey matter voxel-
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compression maps for each subject. These grey matter voxel-compression maps were 
smoothed using an isotropic Gaussian kernel of 6mm FWHM. 
 
7.2.7 Longitudinal cortical thickness 
Images were first processed using the standard cross-sectional FreeSurfer pipeline, version 
4.5.0 (chapter 3, section 3.5.3.2.2). Baseline and repeat images were then processed using 
the longitudinal FreeSurfer processing stream (chapter 2, section 2.2.2.2). Cortical thickness 
was smoothed to approximate a 20mm FWHM Gaussian kernel. All images were visually 
inspected and editing was performed on the cross-sectional baseline and repeat images, as 
well as on the template images.  
 
7.2.8 Statistical analysis 
Differences in measures of atrophy between groups were analysed using a GLM with a three-
level group factor, and adjusting for age, gender as well as interval between time points. 
 
7.2.8.1 BSI 
BSI measures were annualised and differences in rates of atrophy between groups were 
analysed using a GLM with age and gender included as covariates.  
 
7.2.8.2 Longitudinal VBM 
Longitudinal volume changes were analysed using a GLM, adjusting for age, gender and 
interval between time points. Statistical significance of the group differences was tested using 
FDR-correction at p<0.05. Results are displayed as overlays on a study-specific template 
which was created by normalizing all original images using the DARTEL transformations and 
calculating the average of the warped brain images. Group differences are presented either 
as statistical difference maps (FDR-corrected) or as effect size maps (using Pearson 
correlation coefficients). 
 
7.2.8.3 Longitudinal cortical thickness 
Longitudinal differences were assessed by producing thickness change values at each vertex 
by subtracting the baseline from the repeat. A linear regression model was then applied to 
assess group differences, adjusting for age, gender and interval between time points. 
Statistical significance was tested using an FDR-correction at p<0.05. Non-significant results 
are displayed as raw differences between groups in mm. 
 
7.2.8.4 SVM 
An SVM (chapter 3, section 3.5.4.2.6) was used in order to assess how well patterns of grey 
matter volume derived from the VBM analysis and patterns of cortical thickness data obtained 
from FreeSurfer can separate the three groups (controls, PCA and tAD). 
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7.2.8.5 Relative variability of changes 
A post-hoc analysis was performed in order to assess the variability relative to mean changes 
over time within specific regions of grey matter. The motivation for this was to establish 
whether the lack of significant differences in cortical thickness changes between subject 
groups was owing to a relatively high variance or relatively low mean changes. Seven regions 
were selected from the FreeSurfer processing stream based on regions that showed the 
greatest differences in the VBM and FreeSurfer analyses between PCA/tAD and controls. 
These regions were the entorhinal cortex, fusiform gyrus, inferior and superior parietal cortex, 
precuneus, isthmus of cingulate gyrus and cuneus, all in both hemispheres. We assessed 
fluid-derived grey matter volume change alongside FreeSurfer-derived volume and thickness 
changes in these regions. Grey matter volume changes were measured by importing the 
FreeSurfer regions into the same space as the Jacobian voxel-compression maps, and 
calculating mean grey matter volume change in mm3 within these regions by integrating the 
Jacobians. Cortical thickness and volume changes were measured by extracting thicknesses 
(in mm) and volumes (in mm3) directly from FreeSurfer and subtracting the repeat 
thickness/volume from the baseline thickness/volume. Mean (SD) differences in volume and 
thickness changes between subject groups together with their ratio (mean difference/SD) 
were assessed. For this comparison a pooled SD was used derived from the GLM which was 
weighted according to the subject groups.  
 
7.3 Results 
 
7.3.1 Subjects demographics 
As shown in Table 7.1, there was no evidence of a difference in gender distribution or age 
between the PCA and control group (p>0.8, both tests). However, the tAD group was older 
compared with controls and PCA (both p<0.001). As expected there was a significant 
difference in baseline and follow-up MMSE between PCA and controls (p<0.0001), and tAD 
and controls (p<0.0001), however, no significant difference was found between PCA and tAD 
(p=0.2 at baseline, p=0.3 at follow-up). Both PCA and tAD showed a similar decline in MMSE 
from baseline to follow-up (2.6 points in PCA, 2.4 points in tAD with similar, ~1-year, intervals 
between time points). Furthermore, no significant differences were found for TIV (p=0.8 
across groups, p>0.5 between groups). Whole brain volume at baseline and follow-up, 
adjusted for TIV, was significantly different across groups (p<0.0001 for both baseline and 
follow-up) and between patient groups and controls (p<0.001 for both PCA and tAD), with 
both patient groups having significantly lower brain volumes (12-15%) than the controls. No 
significant differences in baseline and follow-up whole brain volume were found between PCA 
and tAD (p=0.7 at baseline, p=0.8 at follow-up). 
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Table 7.1: Subject demographics. 
  
Controls PCA tAD p ¶ 
N 18 17 16 N/A 
Gender male / female 7 / 11 6 / 11 7 / 9 0.9 § 
Age in years at baseline, 
mean (SD) 64.0 (5.0) 64.3 (4.7) 72.6 (7.1)
†‡
* <0.001 
Interval between time points 
in months, mean (SD) 12.4 (0.6) 12.0 (1.1) 11.6 (0.9) 0.06 
Disease duration in years at 
baseline, mean (SD) N/A 5.1 (2.4) 4.7 (3.1) 0.7 
MMSE at baseline, mean (SD) 29.4 (0.7)# 21.4 (5.2)†** 19.3 (3.8)†** <0.0001 
MMSE at follow-up, mean 
(SD) 29.3 (1.1)
#
 18.8 (5.9)†** 16.9 (4.0)†** <0.0001 
Total intracranial volume at 
baseline in ml, mean (SD) 1477.9 (131.9) 1466.7 (153.3) 1448.5 (140.1) 0.8 
Whole brain volume at 
baseline in ml, mean (SD) 1118.7 (103.1) 983.2 (121.4)
†
* 965.4 (96.2)†* <0.0001 ¥ 
Whole brain volume at follow-
up in ml, mean (SD) 1120.3 (98.3) 966.1 (129.2)
†
* 949.0 (98.2)†* <0.0001 ¥ 
¶
 ANOVA (except gender); § Fischer's exact test; # available for 10 controls; † compared with 
controls; ‡ compared with PCA; * p<0.001; ** p<0.0001; ¥ adjusted for TIV 
 
7.3.2 Clinical and neuropsychology data 
The most commonly reported initial symptoms (Table 7.2) in the PCA group were difficulties 
with arithmetic (71%) as well as spelling (41%) and locating objects (41%). Whilst a high 
proportion of PCA patients also reported difficulties with ‘memory’ (47%), a much lower 
proportion showed impaired performance on memory tasks on formal neuropsychological 
testing at visit 1 (29%, Table 7.3). The most commonly reported clinical feature in the PCA 
group was difficulties handling objects (praxis, 47%)), followed by visual disorientation (24%).  
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Table 7.2: Frequency of first reported symptoms and clinical features in PCA group. 
INITIAL SYMPTOMS % DEFICITS PRESENT 
Calculation 71% 
Memory 47% 
Spelling 41% 
Locating objects 41% 
Reading 35% 
Perceiving distances/depth 35% 
Word-finding 35% 
Writing 24% 
Facial recognition 18% 
Identifying objects 12% 
CLINICAL FEATURES   
Praxis 47% 
Visual disorientation 24% 
Myoclonus 6% 
Extrapyramidal signs 6% 
 
 
Neuropsychological testing (Table 7.3) revealed that all PCA patients showed impaired 
performance on the letter cancellation task (100%), and the majority of PCA patients also 
showed visuospatial (88% at visit 1) and visuoperceptual difficulties (82% at visit 1). In the 
tAD group, besides impaired performance on visual and verbal memory tasks (as defined by 
inclusion criteria), patients showed difficulties with visuoperceptual processing (81%) and 
arithmetic (81%). The PCA group showed a decline in performance on all tests, with a 
particularly marked drop in performance on the verbal memory task. A decline in performance 
was also revealed in the tAD group except on visual memory, letter cancellation, arithmetic 
and visuoperceptual processing tests. Formal statistical testing (chi-square test) of changes in 
performance between visit 1 and visit 2 in each group did not reveal significant differences. 
However, comparing performance at visit 1 between PCA and tAD revealed that the PCA 
group performed significantly better on the verbal memory task (p<0.001) and arithmetic 
(p=0.01), whereas performance in the PCA group was significantly worse on tasks of 
visuospatial processing (p=0.01) and the letter cancellation task (p=0.02) compared with tAD. 
 
 
 
- 124 - 
Table 7.3: Proportion of PCA and tAD patients showing deficits on neuropsychological 
tests. 
COGNITIVE DEFICITS ¶ PCA tAD 
VISIT 1 ‡ VISIT 2 VISIT 1 VISIT 2 
Memory (verbal) 1 29% *** 47% 100% 100% 
Memory (visual) 1 - - 100% 94% 
Visuospatial 2 88% ** 94% 44% 81% 
Visuoperceptual 3 82% 88% 81% 81% 
Naming 4 59% 71% 56% 81% 
Arithmetic 5 35% ** 41% 81% 75% 
Speed 6 100% * 100% 69% 63% 
Spelling †7 50% 60% - - 
¶
 Proportion (%) of subjects performing <5th %ile; ‡ Chi-square test comparing baseline 
assessments between PCA and tAD; * p≤0.05; ** p≤0.01; *** p≤0.001; 1 Short Recognition 
Memory Test (Warrington, 1996) or Easy Recognition Memory Test for words (Clegg and 
Warrington, 1994); 2 VOSP Number location test (Warrington and James, 1991); 3 VOSP 
Object Decision or VOSP Silhouettes test (Warrington and James, 1991); 4 Graded Naming 
test, verbal version of this test in 10 PCA patients (Warrington, 1997); 5 Graded Difficulty 
Arithmetic test (Jackson and Warrington, 1986); 6 Letter cancellation test (Willison and 
Warrington, 1992); 7 Graded Difficulty Spelling test (Baxter and Warrington, 1994); † available 
in 10 PCA subjects 
 
 
7.3.3 BSI 
Table 7.4 shows the means and SDs of the annualized brain atrophy rates in controls, PCA 
and tAD as well as adjusted group differences and significance levels. BSI is reported in ml as 
well as percent of whole brain volume at baseline. TIV was not significant when included as a 
covariate in this model (p=0.3 for ml, and p=0.7 for percentage BSI). Atrophy rates were 
significantly different between the patient groups and controls (p<0.0001 for both PCA and 
tAD), and across all groups (p<0.0001). The PCA group showed higher atrophy rates 
compared with tAD, however, this difference was not statistically significant (p=0.08).  
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Table 7.4: Overview atrophy rates (BSI) in controls, PCA and tAD. 
  
  
BSI annualized,       
in ml 
BSI annualized, % of 
whole brain volume at 
baseline 
Means and SD Controls (N=18) 4.0 (4.5) 0.3 (0.4) 
PCA (N=17) 22.3 (6.0) 2.3 (0.7) 
tAD (N=16) 18.1 (7.4) 1.9 (0.8) 
Adjusted differences 
and confidence 
intervals 
Controls vs. PCA 18.4 [14.4, 22.3]* 2.0 [1.6, 2.4]* 
Controls vs. tAD 16.8 [12.0, 21.6]* 1.8 [1.3, 2.3]* 
PCA vs. tAD 1.6 [-3.2, 6.4] 0.2 [-0.3, 0.7] 
p (across all groups) 
  <0.0001 <0.0001 
* p<0.0001 
 
7.3.4 Controls vs. PCA longitudinal changes 
The longitudinal grey matter change analysis revealed global grey matter loss in PCA 
compared with controls (Figure 7.1A, Figure 7.2A, Figure 7.3A), with the most significant 
atrophy progression in temporal and parietal lobe regions, as well as areas in the frontal lobe. 
The cortical thickness analysis also showed global thinning in the PCA group, however, 
thinning in most areas did not survive FDR-correction. Cortical thickness maps therefore 
show raw differences in mm (Figure 7.4). 
 
7.3.5 Controls vs. tAD longitudinal changes 
The VBM analysis revealed global grey matter volume loss in tAD compared with controls 
(Figure 7.1B, Figure 7.2B, Figure 7.3B), with the most significant atrophy progression found in 
temporal and parietal lobe regions in tAD. Widespread cortical thinning was also found in the 
longitudinal cortical thickness comparison, none of which, however, survived FDR-correction 
(Figure 7.4).  
 
7.3.6 PCA vs. tAD longitudinal changes 
The direct comparison of longitudinal changes in grey matter volume and cortical thickness 
between PCA and tAD did not return statistically significant results after FDR-correction. 
Differences in grey matter volume change are therefore presented as effect size (Pearson 
correlation coefficient, Figure 7.1C, Figure 7.2C, Figure 7.3C), and differences in cortical 
thinning are shown in mm (Figure 7.4). The PCA group showed greater grey matter volume 
losses in the left medial temporal lobe, as well as bilaterally in the supramarginal and inferior 
parietal lobe, head of the caudate nucleus and frontal lobe regions compared with tAD. In 
contrast, the tAD group showed greater grey matter volume losses bilaterally in anterior, 
middle and superior temporal lobe regions, frontal lobe regions including the frontal pole, 
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precuneus, superior parietal lobe, and thalamus compared with PCA. Similarly, the cortical 
thickness difference maps show greater cortical thinning bilaterally in the medial temporal and 
medial frontal lobe regions, as well as right parietal lobe regions in PCA compared with tAD, 
and greater thinning bilaterally in anterior and lateral temporal lobe regions as well as left 
superior parietal lobe in tAD compared with PCA. However, the size of these effects was 
small and statistically non-significant. 
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Figure 7.1: Longitudinal changes in grey matter volume, coronal view. Differences in grey matter atrophy are shown for A) PCA compared with controls, 
B) tAD compared with controls, and C) PCA compared with tAD. The colour bar for the control comparisons (A and B) show t-values for FDR-corrected 
results (p<0.05) with warmer colours indicating greater volume loss in PCA and tAD compared with controls, whereas the colour bar for the PCA vs. tAD 
comparison (C) shows correlation coefficients, with warmer colours indicating greater volume loss in PCA compared with tAD, and cooler colours 
representing the reverse contrast. DARTEL coordinates for the slices shown are (from left to right): y=20, y=-15, y=-45, y=-60, y=-80. 
A – Controls vs. PCA change
B – Controls vs. tAD change
C – PCA vs. tAD change
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Figure 7.2: Longitudinal changes in grey matter volume, sagittal view. Differences in grey matter atrophy are shown for A) PCA compared with controls, 
B) tAD compared with controls, and C) PCA compared with tAD. The colour bar for the control comparisons (A and B) show t-values for FDR-corrected 
results (p<0.05) with warmer colours indicating greater volume loss in PCA and tAD compared with controls, whereas the colour bar for the PCA vs. tAD 
comparison (C) shows correlation coefficients, with warmer colours indicating greater volume loss in PCA compared with tAD, and cooler colours 
representing the reverse contrast. DARTEL coordinates for the slices shown are (from left to right): x=10, x=20, x=30, x=40, x=50. 
A – Controls vs. PCA change
B – Controls vs. tAD change
C – PCA vs. tAD change
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Figure 7.3: Longitudinal changes in grey matter volume, axial view. Differences in grey matter atrophy are shown for A) PCA compared with controls, B) 
tAD compared with controls, and C) PCA compared with tAD. The colour bar for the control comparisons (A and B) show t-values for FDR-corrected results 
(p<0.05) with warmer colours indicating greater volume loss in PCA and tAD compared with controls, whereas the colour bar for the PCA vs. tAD comparison 
(C) shows correlation coefficients, with warmer colours indicating greater volume loss in PCA compared with tAD, and cooler colours representing the 
reversed contrast. DARTEL coordinates for slices shown are (from left to right): z=-5, z=10, z=25, z=45. 
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Figure 7.4: Longitudinal changes in cortical thickness. Differences in cortical thinning is shown for A) PCA compared with controls, B) tAD compared with 
controls, and C) PCA compared with tAD. The colour bar represents raw differences in mm, with warmer colours indicating greater cortical thinning in PCA 
and tAD compared with controls (A and B), and PCA compared with tAD (C), whereas cooler colours represent the reversed contrast. 
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7.3.7 Support vector machine 
The results of the classification analysis (accuracies, sensitivities and specificities) are 
presented in Table 7.5. Using the cortical thickness change data from FreeSurfer, the SVM 
produced accuracies of 65.7% for classifying PCA from controls, and 73.5% for classifying 
tAD from controls, whereas using grey matter volume loss data from the VBM analysis 
classification accuracies for PCA and tAD from controls were 97.1% and 94.1%, respectively. 
The direct classification of PCA and tAD gave mixed results. Classification accuracy using 
cortical thickness was 63.6% [95% CI 45.1, 79.6]. The confidence intervals indicate that this 
accuracy is not significantly different from chance. In contrast, accuracy using grey matter 
volumes was 72.7% [95% CI 54.5, 86.7], which represents a reasonable classification 
accuracy which was significantly different from chance. 
 
Furthermore, regions in which loss of grey matter and cortical thickness contributed most to 
the classification of PCA and tAD (Figure 7.5) are very similar to those found in the difference 
maps (Figure 7.1C, Figure 7.2C, Figure 7.3C and Figure 7.4C). These results may suggest 
that, although structural differences between PCA and tAD are subtle and statistically non-
significant, using a voxel-by-voxel VBM analysis they are sufficiently strong to train a machine 
learning algorithm and provide reasonable classification accuracy between the two groups. 
 
 
Table 7.5: Classification analysis. Shown are accuracies, specificities and sensitivities with 
95% confidence intervals in percent for each group comparison and method. 
Groups Method Accuracy Specificity Sensitivity 
Controls vs. PCA 
FreeSurfer 65.7 [47.8, 80.1] 72.2 [46.5, 90.3] 58.8 [32.9, 81.6] 
VBM 97.1 [85.1, 99.9] 100.0 [81.5, 100.0] 94.1 [71.3, 99.9] 
Controls vs. tAD 
FreeSurfer 73.5 [55.6, 87.1] 77.8 [52.4, 93.6] 68.8 [41.3, 89.0] 
VBM 94.1 [80.3, 99.3] 100.0 [81.5, 100.0] 87.5 [61.7, 98.5] 
PCA vs. tAD 
FreeSurfer 63.6 [45.1, 79.6] 64.7 [38.3, 85.8] 62.5 [35.4,  84.8] 
VBM 72.7 [54.5, 86.7] 70.6 [44.0, 89.7] 75.0 [47.6, 92.7] 
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Figure 7.5: VBM and cortical thickness maps for classification of PCA vs. tAD. The classification maps show regions that were most influential in making 
a classification between the two groups, using grey matter volumes (left) and cortical thickness (right). Red represents areas where grey matter volume loss 
and cortical thinning indicates PCA, whereas blue shows areas where grey matter volume loss and cortical thinning indicates tAD. 
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7.3.8 Relative variability of changes  
Table 7.6 presents the mean differences between patient group (PCA and tAD) and controls, 
as well as pooled SD and ratios of mean difference divided by pooled SD. Ratios were higher 
for the grey matter volume data from the fluid registration method (average ratio 2.6 and 1.9 
for PCA and tAD, respectively) than the ratios for the cortical volume (average ratio 0.3 and 
0.5 for PCA and tAD, respectively) and cortical thickness (average ratio 0.7 for both PCA and 
tAD). This may indicate that although FreeSurfer measures greater mean changes in patient 
groups than controls, this difference is also relatively more variable. 
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Table 7.6: Variability of fluid and FreeSurfer measures. Presented are mean differences, pooled SDs and ratios of difference/pooled SD for grey matter 
volume, cortical volume and cortical thickness between PCA and controls, and tAD and controls. 
 
 
 
Region Left / 
Right 
PCA - Controls tAD - Controls 
Fluid - volume FS - volume FS - thickness Fluid - volume FS - volume FS - thickness 
diff in 
mm3 
SD diff / SD 
diff in 
mm3 
SD diff / SD 
diff in 
mm 
SD diff / SD 
diff in 
mm3 
SD diff / SD 
diff in 
mm3 
SD diff / SD 
diff in 
mm 
SD diff / SD 
Entorhinal L 41.5 20.4 2.0 54.4 205.6 0.3 30.0 188.4 0.2 29.5 15.2 1.9 148.8 415.6 0.4 20.1 170.5 0.1 
  R 39.4 20.4 1.9 -12.8 237.6 -0.1 81.9 67.0 1.2 19.5 35.3 0.6 360.4 432.1 0.8 128.8 172.6 0.7 
Fusiform L 241.8 75.4 3.2 99.6 360.4 0.3 18.7 63.1 0.3 188.0 60.2 3.1 124.9 370.4 0.3 30.7 63.6 0.5 
  R 212.6 58.9 3.6 238.9 269.0 0.9 43.4 75.4 0.6 191.7 65.8 2.9 346.1 325.4 1.1 60.5 70.3 0.9 
Inferiorparietal L 261.4 82.6 3.2 184.1 464.2 0.4 36.9 50.0 0.7 218.0 68.9 3.2 38.2 463.2 0.1 45.7 42.2 1.1 
  R 313.5 97.2 3.2 223.4 463.0 0.5 54.8 56.1 1.0 254.3 137.2 1.9 336.4 360.1 0.9 39.7 46.8 0.8 
Superiorparietal L 235.0 93.0 2.5 3.7 684.4 <0.1 32.9 42.6 0.8 188.7 94.0 2.0 219.9 387.9 0.6 45.3 46.2 1.0 
  R 217.7 83.7 2.6 161.2 452.1 0.4 53.8 46.3 1.2 194.6 110.8 1.8 374.5 463.8 0.8 55.2 46.2 1.2 
Precuneus L 175.0 45.9 3.8 135.7 233.1 0.6 44.5 46.8 0.9 161.4 74.9 2.2 58.3 227.8 0.3 29.6 44.4 0.7 
  R 181.9 55.7 3.3 141.0 237.2 0.6 27.9 49.4 0.6 123.4 78.2 1.6 154.9 224.1 0.7 32.2 42.9 0.8 
Isthmuscingulate L 43.6 24.9 1.8 -5.4 143.8 <-0.1 28.1 54.4 0.5 35.6 17.1 2.1 105.8 156.9 0.7 9.9 65.2 0.2 
  R 23.1 21.1 1.1 7.5 172.3 <0.1 75.0 65.3 1.1 28.8 23.4 1.2 28.0 172.2 0.2 39.1 68.2 0.6 
Cuneus L 35.5 18.7 1.9 17.4 211.8 0.1 36.8 72.0 0.5 30.4 17.2 1.8 81.3 244.6 0.3 29.4 59.3 0.5 
  R 35.1 18.8 1.9 3.9 203.5 <0.1 38.2 67.0 0.6 26.1 24.9 1.0 17.0 234.7 0.1 44.2 71.3 0.6 
Mean ratio    2.6    0.3   0.7   1.9    0.5   0.7 
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7.4 Discussion 
This study investigates the progression of atrophy in PCA compared with typical AD and 
healthy controls. Compared with controls, at 5 years disease duration both PCA and tAD 
showed widespread grey matter loss including changes in medial temporal and frontal lobe 
regions in PCA, and posterior regions in tAD. Differences between PCA and tAD were subtle, 
reaching statistical significance only when using a multi-variate classification approach.  
 
Cross-sectional studies have shown marked focal patterns of atrophy in PCA and tAD 
(chapter 6 and Whitwell et al., 2007a) suggesting that at some point during the disease 
atrophy changes are confined to posterior regions in PCA, and medial temporal lobe regions 
in tAD. The widespread pattern of grey matter loss in the PCA and tAD groups compared with 
controls may therefore suggest that initial focal patterns of atrophy changes become more 
global as the diseases progress. This is in accordance with previous reports showing that 
anterograde memory functions, linguistic skills and frontal lobe functions, which are 
sometimes strikingly preserved in the earlier stages of PCA, gradually deteriorate as some 
patients progress to a more global dementia state (Levine et al., 1993) making their 
presentation ultimately indistinguishable from that found in typical AD (DellaSala et al., 1996). 
 
Whilst differences in grey matter volume changes and cortical thinning between PCA and tAD 
were small with respect to size of effect and non-significant in the VBM and FreeSurfer 
analyses, the patterns of atrophy are interesting. As atrophy progression spreads across the 
cortex, the PCA group shows slightly greater rates of atrophy in medial temporal lobe areas 
than tAD, and conversely, tAD showed slightly more atrophy progression in lateral parts of the 
temporal lobe compared with PCA. Whilst the involvement of individual regions in this 
comparison may provide useful information about the progression of structural changes in 
these groups, differences between PCA and tAD have to be interpreted with caution since 
they are very small and non-significant using the mass-univariate VBM and FreeSurfer 
approach. Statistically significant global changes in grey matter volume in both disease 
groups compared with controls, however, suggest that, whilst regions of greatest total tissue 
loss in both groups remain those typically associated with these diseases (i.e. posterior 
regions in PCA, medial temporal lobe regions in tAD), atrophy becomes more global as the 
diseases progress.  
 
Whole brain atrophy rates, as measured using the BSI, were approximately 5 times higher in 
both PCA and tAD than in controls. Atrophy rates in the PCA group were slightly higher than 
in the tAD group, however, the age- and gender-adjusted difference of 0.2 percentage points 
was not statistically significant. The mean volume loss found in the tAD group was 
comparable with those found in previous studies of around 2% per year (Evans et al., 2010; 
Freeborough and Fox, 1997; Schott et al., 2005). 
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Although subject numbers in this study are relatively high given the rarity of PCA, it is possible 
that this study was not sufficiently powered to detect statistically significant longitudinal 
differences between the PCA and tAD groups using the mass-univariate VBM and FreeSurfer 
approach. However, the global patterns of atrophy changes in PCA and tAD compared with 
controls point to a global progression of atrophy in these disease groups. Studies including 
milder cases of PCA are required to fully understand the evolution of PCA from the very 
earliest symptomatic stages. The recruitment of milder PCA patients closer to symptom onset 
is often difficult since early visual symptoms are often mistaken as being ophthalmological 
rather than neurological. To date, only one study has assessed early structural changes in an 
individual with PCA who volunteered as a healthy control subject in a longitudinal study 
investigating subjective memory complaints (Kennedy et al., 2011). During the 5 year follow-
up, this patient showed a gradual decline in posterior cortical functions including 
visuoperceptual, visuospatial and literacy impairments in the context of intact verbal episodic 
memory. The imaging data (presented in Appendix 3) revealed atrophy which was initially 
most marked in inferior temporal and posterior parietal cortices before spreading to occipital 
cortices and subsequently to more anterior regions. 
 
Although most baseline images selected for both patient groups (77% for PCA, 75% for tAD) 
were the first scan available for each subject, the mean disease durations were already 5 
years. Disease durations reported in this study are comparable with those reported in 
previous cross-sectional studies of PCA where posterior atrophy patterns have been shown, 
e.g. Mendez et al. (2002): PCA 4.5 years, AD 4.2 years; Whitwell et al. (2007a): PCA 4.0 
years, AD 4.7 years; Schott et al. (2006): PCA 3.8 years, AD 4.4 years; and McMonagle et al. 
(2006): PCA 4.5 years. It would also be interesting to study progression of atrophy over 
multiple time points. This may reveal areas which atrophy earlier vs. later in the disease as 
well as whether atrophy accelerates or slows down selectively across the brain. Larger group 
studies will also permit more detailed assessment of the variance within the wider PCA 
population and in particular whether a small number of individuals retain a truly focal pattern 
of atrophy until late in the disease.  
 
The cognitive and clinical features of the PCA patients included in this study are consistent 
with those typically reported in PCA studies (see chapter 1, section 1.2.2.6). A large 
proportion of PCA subjects showed visuospatial and visuoperceptual deficits, as well as 
dyscalculia, dysgraphia, dyspraxia and visual disorientation. A number of patients also 
reported difficulties with their memory as initial symptom. It should be noted, however, that 
these subjective memory complaints may not necessarily reflect difficulties with episodic 
memory per se, but rather may indicate other non-amnestic cognitive symptoms which are 
difficult for the patient to articulate (Kennedy et al., 2011). This may explain the relatively 
smaller proportion of individuals with PCA who showed impaired memory performance on 
formal neuropsychological testing 5 years after symptom onset.  
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Only the VBM analysis returned statistically significant results for the patient group (PCA and 
tAD) vs. control comparisons. The lack of significant results in the FreeSurfer analysis 
appears to be due to a higher variability of mean changes in cortical thickness over time 
relative to the analogous statistic for grey matter volume changes. To test this hypothesis a 
post-hoc analysis was performed which assessed the variability of grey matter volumes from 
the fluid-registration method, and cortical thickness and cortical volume from FreeSurfer in a 
specific set of regions. Variability in grey matter volume was found to be lower than that of 
cortical thickness changes, which could be due to the different metrics used here (volume vs. 
thickness). However, both cortical thickness and cortical volume (both derived from 
FreeSurfer) show higher relative variabilities compared with changes in grey matter volume 
measured using Jacobian integration from the voxel-compression maps which may suggest a 
more fundamental difference between the two methods. The fluid-based method used in this 
study is a ‘direct’ measure of change, i.e. change is measured ‘directly’ from the two 
registered serial scans. In contrast, FreeSurfer represents a less ‘direct’ approach which 
measures cortical thickness changes by subtracting two measured thicknesses. A previous 
study has shown that the variability in ‘direct’ estimates of whole brain volume change is 
smaller than that in ‘indirectly’ estimated differences calculated by brain volume subtraction 
(Frost et al., 2004). 
 
Although studies have shown that AD is the underlying pathology in the majority of PCA 
patients (Hof et al., 1997; Levine et al., 1993), a small number of patients may be attributable 
to non-AD pathologies. In this study, pathological confirmation was only available in 1 PCA 
patient (AD with additional Lewy Body pathology) and 4 tAD patients (all AD pathology). 
Future studies using datasets of pathologically proven AD with PCA and typical presentations 
would be helpful in informing us of the different degenerative trajectories of patients with 
typical and atypical AD phenotypes. 
 
7.5 Chapter conclusions 
In conclusion, these data show that although PCA and tAD are known to have different cross-
sectional atrophy patterns (as presented in the previous chapter), at 5 years symptom 
duration atrophy progression is widespread throughout the cortex including medial temporal 
lobe areas in PCA and posterior regions in tAD when compared with controls. Whilst 
differences in patterns of tissue loss between PCA and tAD were small and non-significant, 
the fact that these were sufficient to enable a multivariate classification analysis to achieve 
statistically significant group separation may encourage further studies which assess 
longitudinal structural changes in larger subject groups. Future studies using potentially milder 
patients may further elucidate differences in the natural history of PCA and tAD and may 
provide early markers of change for PCA. Finally, in the current study the fluid-VBM approach 
was more sensitive in detecting longitudinal changes than the relatively novel longitudinal 
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processing stream in FreeSurfer, probably due to the relatively higher inter-subject variability 
of the cortical thickness measures, which greatly reduced the power to detect significant 
differences. 
 
Whilst understanding the neuroimaging signature of PCA in relation to normal ageing and 
typical AD is a crucial step towards characterizing atypical variants of AD, structural changes 
need to be examined in relation to cognitive changes in these patients. Although PCA is often 
regarded as being relatively homogeneous in terms of atrophy and cognitive symptoms, some 
studies have suggested the existence of different subtypes in PCA, each showing different 
deficits. However, the existence of these variants of PCA is disputed. This will be investigated 
in the next chapter. 
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8. HETEROGENEITY OF VISUAL DEFICITS AND CORTICAL THICKNESS PATTERNS IN 
PCA 
 
8.1 Chapter introduction 
Although PCA is often considered a relatively homogeneous syndrome, clinical experience 
indicates that a degree of heterogeneity exists in the behavioural and neuroimaging profiles of 
PCA patients. It has been suggested that separate parietal (dorsal), occipitotemporal 
(ventral), and primary visual (striate cortex; caudal) forms of PCA exist (Galton et al., 2000; 
Ross et al., 1996, see chapter 1, section 1.2.2.1). However, these claims are based upon the 
observation of patterns of impairment in single cases. Furthermore, the most detailed 
neuropsychological study of PCA to date found evidence of object perception deficits, faces 
and colours in a proportion of the patients tested, but overall the pattern of impairments was 
suggestive of greater deficits of the dorsal than ventral visual processing streams as no pure 
ventral stream syndromes were detected (McMonagle et al., 2006). 
 
One limitation in understanding PCA and evaluating the relationship between PCA and typical 
AD is that very few studies have assessed the integrity of fundamental, basic visual 
processes supported by striate and extrastriate occipital cortices (e.g. basic form, colour, 
motion and location processing). Without testing these basic visual functions, it is difficult to 
determine whether higher-order object and space perception deficits are attributable to 
parietotemporal tissue loss, or in fact result from a more fundamental deafferentation of such 
areas owing to occipital lobe disease. A second limitation is that no studies reported to date 
have systematically evaluated both neuropsychological deficits and patterns of brain atrophy 
using quantitative, unbiased methods in a large group of patients.  
 
The current study was designed to address these limitations with the motivation to more 
precisely characterize AD-associated syndromes such as PCA in order to identify factors 
driving the distribution and spread of pathology underpinning typical and atypical clinical 
presentations of AD. The study investigated a relatively large sample of patients with PCA 
using detailed neuropsychological evaluation and systematic measurement of cortical 
thickness. The primary hypothesis was that higher-order visual deficits in PCA are associated 
with specific and separable patterns of basic visual processing impairments. The secondary 
hypothesis was that different patterns of posterior behavioural dysfunction are associated with 
distinct patterns of atrophy. These hypotheses were addressed by: i) characterizing the basic 
visual, space and object perceptual processing abilities of patients with PCA; ii) identifying 
associations between specific basic visual functions and measures of higher-order object and 
space perception; and iii) assessing whether PCA patients with predominant object and space 
perception impairments show greater cortical thinning in dorsal (superior parietal) and ventral 
(occipitotemporal) regions. 
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8.2 Methods 
 
8.2.1 Subjects 
The behavioural part of the study involved 21 patients with PCA. Demographics and clinical 
data of the subjects are summarized in Table 8.1. For the imaging part of the study, 20 PCA 
patients were included (11 female, 9 male, mean (SD) age: 63.0 (8.5) years), as well as a 
group of 20 healthy control subjects for comparison (11 female, 9 male, mean (SD) age: 61.9 
(10.6) years). The groups (20 PCA vs. controls) were matched for gender (p=1), age (p=0.7) 
and scanner distribution (p=0.7). All subjects fulfilled the inclusion criteria described in chapter 
3 (section 3.4.1). 
 
8.2.2 Background neuropsychological assessment 
Each patient completed a background neuropsychological battery at the time of the current 
experimental investigations, including tests of general cognitive function (Folstein et al., 
1975), verbal recognition memory (Warrington, 1996), word comprehension (Warrington et 
al., 1998), naming from verbal description (Randlesome (unpublished)), cognitive estimates 
(Shallice and Evans, 1978), calculation (Crutch (unpublished)), spelling (Baxter and 
Warrington, 1994), gesture production (Crutch (unpublished)), and auditory-verbal short term 
memory (digit span, Wechsler, 1987). In addition, patients were administered tests of visual 
acuity (Cortical Visual Screening Test (CORVIST), James et al., 2001), space perception 
(Warrington and James, 1991, Appendix 4), and object perception (Warrington, 1996; 
Warrington and James, 1988, Appendix 4).  
 
8.2.3 Experimental investigations of basic visual processing 
The following detailed experimental investigations were administered in order to assess the 
contribution of basic form, colour, motion and location processing to the object and space 
perception deficits observed in the PCA cohort (see Appendix 4 for example items for each 
test). 
Form I: Form detection: VOSP Shape Detection test (Warrington and James, 1991) 
examining figure-ground discrimination. Stimuli (N=20) were random black patterns, half with 
a degraded ‘X’ superimposed. Patients were requested to state whether an ‘X’ was present. 
Form II: Form coherence: Adapted from Braddick et al., the stimuli (N=80) consisted of 
static arrays of 3000 randomly oriented short line segments (Braddick et al., 2000). In half the 
arrays, a percentage of the line segments in an 11.8° central region were coherently oriented 
tangentially to concentric circles. In the remaining arrays, all line segments were arranged 
randomly. There were 4 levels of difficulty: 90%, 70%, 50% and 30% coherence. Patients 
were requested to state whether a ‘circle’ was present in each stimulus. 
Form III: Form discrimination: The stimuli (N=60) for this boundary detection task, adapted 
from Efron, were a square (50 x 50mm) or an oblong matched for total flux (Efron, 1968). 
There were 3 levels of difficulty: oblong edge ratio 1:1.63 (Level I), 1:1.37 (Level II), and 
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1:1.20 (Level III). The task was to discriminate whether each shape presented was a square 
or an oblong.  
Colour discrimination: The stimuli (N=60) were pairs of matte colour chips presented 
adjacently. The colours were selected from the Munsell colour system and had a fixed value 
and chroma (6/6). There were 3 difficulty levels based on varying the distance between hue-
pairs on the Munsell hue scale. The task was to determine whether the hues in each pair 
were the same or different.  
Motion coherence: Using the same experimental paradigm as the form coherence task, the 
stimuli (N=80) were arrays of 3000 0.1° high contra st dots drifting in random linear directions 
(5.12°/s). In half the arrays, the direction of mot ion of a percentage of dots in an 11.8° central 
region was coherently circular. In the remaining arrays, all the dots moved in random 
directions. There were 4 levels of difficulty: 90%, 70%, 50% and 30% coherence. Patients 
were requested to state whether a ‘moving circle’ was present in each stimulus. 
Point localisation: The stimuli (N=8) were A3 laminated white cards with a single, randomly 
positioned black dot (5mm diameter). The position of each dot was revealed for 3s before the 
stimulus was covered by a second blank A3 card, and participants were requested to mark 
the position of the dot on the blank sheet using a pen in their dominant hand. Target-response 
discrepancy was measured. 
 
 
8.2.4 Neuropsychological data analysis 
8.2.4.1 Correlations  
Performance on each level of each experimental task was recorded as a raw score, and a 
total score calculated for multi-level tasks. In the calculation of total scores, performance at 
untestable levels and scores of <10 were assigned a chance score of 10/20. Correlations 
were based on total scores.  
 
8.2.4.2 Syndrome subgroups  
Two behavioural subgroups were generated on the basis of object perception and space 
perception composite scores which were obtained from the mean performance across the 
Fragmented letters/Object decision and Number location/Dot counting scores, respectively, 
transformed onto linear scales of 0-100 representing minimum and maximum values of the 
range of PCA group performance. The Object subgroup (N=11) showed lower object than 
space perception composite scores, whilst the Space subgroup showed the reverse tendency 
(Figure 8.1). Pair-wise comparisons between the Object and Space subgroups on each of the 
demographic and behavioural measures were conducted using Wilcoxon-Mann-Whitney 
ranksum statistics.  
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Figure 8.1: Classification of behavioural subgroups. Illustrated are A) split between 
Space and Object subgroups, and B) range of scores for each subgroup for each composite 
score and MMSE. Blue - Space subgroup; red - Object subgroup. Composite scores were 
generated for space perception (VOSP Number Location and Dot Counting) and object 
perception (VOSP Fragmented Letters and Object Decision) by transforming raw scores 
proportionally onto a linear scale of 0-100, where 0 and 100 represent the minimum and 
maximum values of the range of PCA group performance on a given task. Composite scores 
are means of the transformed scores. 
 
8.2.5 Image acquisition and analyses 
Images were acquired from all patients and controls, however, one PCA patient (Space 
subgroup) had to be excluded due to an artefact on the scan. Therefore 20 patients and 20 
control subjects were included for the imaging analysis. Scans were acquired at two different 
scanners (chapter 3, section 3.5.1, and Appendix 5). Controls and patients were matched for 
scanner: 14 patients and 14 controls were scanned on a 1.5T GE Signa scanner, and 6 
patients and 6 controls were scanned on a Siemens Trio TIM 3T. The average time between 
psychological assessment and scan was 27.7 days (SD 72.2 days). In the subgroup analysis, 
8/9 scans in the Space subgroup and 6/11 scans in the Object subgroup were acquired on 
the 1.5T scanner.  
 
8.2.5.1 Cortical thickness 
Cortical thickness measurements were made using FreeSurfer version 4.3.0 (chapter 3, 
section 3.5.3.2.2).   
A B
Space 
perception
Object 
perception
Co
m
po
s
ite
 
sc
o
re
O
bje
ct
 
–
sp
ac
e
 
di
ffe
re
n
ce
 
sc
o
re
MMSE
M
M
SE
 
s
co
re
Space subgroup Object subgroup
Co
m
po
s
ite
 
sc
o
re
O
bje
ct
 
–
sp
ac
e
 
di
ffe
re
n
ce
 
sc
o
re
M
M
SE
 
s
co
re
- 143 - 
8.2.5.2 Statistical analysis 
Regional cortical thickness variations between controls and the two syndrome subgroups 
were assessed using a vertex-by-vertex GLM (chapter 3, section 3.5.4.2.3). Cortical thickness 
(C) was modelled as a function of group, controlling for age (mean-centred), gender, and 
scanner: C = β1 (Controls) + β2 (Space) + β3 (Object) + β4 age + β5 gender + β6 scanner + 
ε. The comparisons between individual PCA subgroups were further corrected for average 
cortical thickness (mean-centred) by inclusion as covariate. Statistical difference maps for 
comparisons with controls show FDR-corrected p values thresholded at a 0.05 significance 
level, whereas maps for the comparisons between individual subgroups present uncorrected 
statistical differences (p<0.05) and percent differences.  
 
8.2.5.3 Support vector machine 
An SVM (chapter 3, section 3.5.4.2.6) was trained to classify the controls and PCA subjects, 
and the resultant SVM scores were subsequently labelled according to Space (dorsal) and 
Object (ventral) PCA subgroups. A second SVM was trained directly to separate Space and 
Object subgroups. 
 
 
8.3 Results 
 
8.3.1 Neuropsychological analysis 
 
Details of background neuropsychological test scores as well as percentage of patients failing 
each task are shown in Table 8.1. Verbal recognition memory (short RMT) and verbal 
comprehension (concrete synonyms) were generally well preserved, but the majority of 
patients showed deficits in calculation, praxis and short-term memory (digit span). In 
particular, 95% of patients failed one or both space perception tasks, and 100% of patients 
failed at least two object perception tasks.  
 
Means and standard deviations for the performance on each experimental task of basic visual 
processing are shown in Table 8.2. All 21 patients (100%) failed at least 1 of the 6 
experimental tests of basic visual processing (with 90% failing at least 2 tasks, and 81% 
failing at least 3 tasks). Therefore, there was not a single case of higher-order object or space 
agnosia in the current sample to which a basic visual processing deficit did not potentially 
contribute.  
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Table 8.1: Overview scores of background neuropsychological assessment. Mean and 
SD scores are presented for the PCA patient group as well as number of subjects scoring <5th 
%ile. 
  PCA N below  Normative 
  Mean(SD) 5th %ile Mean(SD) 
Age 63.5 (7.7) - - 
Gender male / female 9 / 12 - - 
Disease duration (years) 5.0 (2.6) - - 
GENERAL FUNCTION 
   
MMSE (/30) 21.5 (3.4) - - 
Short RMT (words; /25) 20.1 (2.8) 5 (24%) 23.5 (2.1) 
Concrete synonyms (/25) 21.3 (3.1) 1 (5%) 20.8 (3.0) 
Naming (/20) 13.6 (5.1) 12 (57%) 18.9 (1.5) 
Cognitive estimates 12.0 (6.6) 15 (71%) 3.6 (1.9) 
DOMINANT PARIETAL 
   
Calculation (/20) 11.9 (3.6) 18 (86%) 20.7 (3.1) 
Spelling (/20) 10.5 (6.6) 6 (29%) - 
Gesture production (/15) 12.2 (3.0) 14 (67%) 15.0 (0.0) 
Digit span (N forwards) 5.7 (1.4) 15 (71%) † Range 5-9 
SPACE PERCEPTION 
   
Number location (/10) 3.1 (3.2) 19 (90%) 9.4 (1.1) 
Dot counting (/10) 4.8 (3.2) 17 (81%) 9.9 (0.2) 
OBJECT PERCEPTION 
   
Fragmented letters (/20) 5.1 (4.8) 21 (100%) 18.8 (1.4) 
Object decision (/20) 11.6 (4.8) 15 (71%) 17.7 (1.9) 
Unusual views (/20) 2.7 (3.0) 21 (100%) 17.1 (3.0) 
Usual views (/20) 11.5 (6.2) 18 (86%) 19.7 (0.5) 
† Below mean normal performance. 
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Table 8.2: Experimental assessment of basic visual processing skills. Mean and SD 
scores are presented for the PCA patient group as well as number of subjects scoring <5th 
%ile and relevant control samples.  
  PCA N below  Normative 
  Mean (SD) 5th %ile Mean(SD) 
FORM DETECTION 
   
Score (/20) 17.2 (2.3) 14 (67%) 19.9 (0.3)a 
FORM COHERENCE 
   
90% coherence (/20) 19.1 (1.8) 8 (38%) 20.0 (0.0) 
70% coherence (/20) 19.3 (1.3) 7 (33%) 19.9 (0.3) 
50% coherence (/20) 17.9 (2.3) 11 (52%) 19.9 (0.4) 
30% coherence (/20) 14.0 (3.1) 18 (86%) 19.4 (0.9) 
Total score (/80) 69.3 (8.5) 18 (86%) 79.9 (0.9)b 
FORM DISCRIMINATION 
   
Level 1 (/20) 18.2 (3.5) - - 
Level 2 (/20) 17.2 (2.9) - - 
Level 3 (/20) 12.3 (5.4) 14 (67%) 19.1 (2.1)c 
Total score (/60) 48.0 (8.6) - - 
COLOUR 
   
Level 1 (/16) 15.4 (1.4) 5 (24%) 16.0 (0.2) 
Level 2 (/16) 14.6 (2.0) 11 (52%) 16.0 (0.1) 
Level 3 (/16) 13.7 (2.6) 13 (62%) 16.0 (0.0) 
Total score (/48) 43.7 (5.5) 14 (67%) 47.9 (0.2)d 
MOTION COHERENCE 
   
90% coherence (/20) 19.1 (1.8) 6 (29%) 20.0 (0.0) 
70% coherence (/20) 18.2 (2.1) 14 (67%) 19.9 (0.3) 
50% coherence (/20) 17.2 (2.5) 12 (57%) 19.7 (1.1) 
30% coherence (/20) 13.5 (2.9) 18 (86%) 19.3 (0.9) 
Total score (/80) 69.1 (6.1) 18 (86%) 78.9 (1.8)e 
POINT LOCALISATION 
   
Mean error (cm) 2.6 (2.5) 12 (60%) 0.8 (0.3)f 
Normative data samples: a Warrington and James (1991; N=60); Keilty (unpublished; bN=14; 
cN=39; eN=16); dConnell (unpublished; N=54); fRandlesome (unpublished; N=83). 
 
8.3.1.1 Correlations 
Pair-wise correlations and significance values between the 6 experimental tests of basic 
visual processing and tests of higher-order space and object perception as well as general 
cognition and tests of parietal, non-visual skills are shown in Table 8.3. Three basic visual 
tests (form detection, form coherence, colour) were significantly correlated with both higher-
order object and space perception. However, form discrimination correlated significantly only 
with object perception, whilst point localisation correlated significantly only with space 
perception. Furthermore, none of the basic visual processing tasks correlated with non-visual 
parietal functions (calculation and spelling), or tests of memory and general cognition (with 
the exception of a spurious negative colour-MMSE correlation). 
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Table 8.3: Pair-wise correlations between basic visual processing and general cognition, parietal non-visual tasks, and higher-order object and 
space perception tasks. 
 
BASIC VISUAL PROCESSING 
Form 
detection 
Form 
coherence 
Form 
discrimination 
Colour Motion Location 
GENERAL 
FUNCTION 
MMSE 0.09 -0.26 0.13 -0.44 * -0.05 -0.28 
Recognition memory 0.03 -0.01 0.02 -0.29 -0.01 -0.36 
DOMINANT 
PARIETAL 
Calculation 0.02 0.05 0.08 -0.06 -0.04 0.30 
Spelling -0.18 0.06 0.28 -0.14 0 0.16 
SPACE 
PERCEPTION 
Number location 0.64 *** 0.58**** 0.31 0.52 * 0.26 0.49 * 
Dot counting 0.68 **** 0.48 * 0.3 0.58 ** 0.28 0.61 *** 
OBJECT 
PERCEPTION 
Fragmented letters 0.44 * 0.34 0.52 * 0.36 0.10 0.37 
Object decision 0.26 0.41 0.61 ** 0.77 **** -0.18  0.36 
Unusual views 0.39 0.47 * 0.45 * 0.47 * 0.36 0.37 
Usual views 0.37 0.58 ** 0.74 **** 0.71 **** 0.15 0.31 
* p≤0.05; ** p≤0.01; *** p≤0.005 **** p≤0.001 
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8.3.1.2 Syndrome subgroups 
There were no significant differences between the subgroups in terms of age (Object: 62.0 
(7.4) years, Space: 64.3 (10.0) years), gender (Object: 46% male, Space: 44% male), MMSE 
(Object: 21.4 (2.8), Space: 21.8 (4.4)), disease duration (Object: 4.9 (2.7) years, Space: 4.6 
(2.3) years) or on any of the individual neuropsychological tests. 
 
8.3.2 Cortical thickness analysis 
8.3.2.1 Syndrome subgroups (Object and Space) comparisons 
Differences in cortical thickness between the two putative PCA subgroups (Space and Object) 
and controls are shown in Figure 8.2. The Space (dorsal) subgroup compared with controls 
showed significantly lower cortical thickness predominantly bilaterally in the occipital lobe and 
the posterior parietal lobe, as well as the precuneus, occipitotemporal gyrus and medial 
temporal lobe, with relative sparing of the orbitofrontal gyrus (Figure 8.2A). Similar results 
were shown in the Object (ventral) subgroup versus controls comparison, however, cortical 
thinning showed more focal differences, including thinner cortex bilaterally in the inferior 
parietal lobe and fusiform gyrus, with relative sparing of medial occipital lobe and frontal lobe 
regions (Figure 8.2B). Figure 8.3 presents differences in cortical thickness for the direct 
comparison between Object and Space subgroups. The Space subgroup compared with the 
Object subgroup showed reduced cortical thickness in the right occipital and medial temporal 
lobe, and bilaterally in the inferior and superior parietal lobe (Figure 8.3A). However, these 
differences did not survive FDR-correction. No statistically significant differences were found 
in the Object subgroup compared with the Space subgroup.  
 
The less widespread reduction in cortical thickness in the Object subgroup, despite matching 
for age and disease duration, suggested that this group overall had a relatively thick cortex 
(possibly owing to premorbid differences and/or lesser disease severity). This motivated the 
use of correction for average cortical thickness for the direct comparison between Object and 
Space subgroup. Figure 8.3B shows percent differences in cortical thickness over and above 
global thinning between the two subgroups. The Space subgroup compared with the Object 
subgroup showed reduced cortical thickness bilaterally in the occipital, inferior parietal and 
medial temporal lobe. In contrast, the Object subgroup showed reduced cortical thickness in 
the right fusiform gyrus, right lateral inferior temporal lobe and frontal lobe regions.  
 
These cortical thickness maps provide some evidence that thickness of the cortex varies in a 
predictable manner between the two behaviourally-defined subgroups, as seen most clearly 
in the right lateral percentage map in Figure 8.3B. More specifically, there was an indication of 
greater thinning in occipital and superior parietal (dorsal) regions in patients with greater 
impairment of Space perception, and greater thinning of inferior temporal (ventral) regions in 
patients with greater impairment of Object perception. However, putting issues of statistical 
power to one side, the scarcity of regions showing significant thickness differences between 
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the two subgroups suggests substantial anatomical overlap, making a separation into distinct 
subgroups less clear.  
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Figure 8.2: Differences in cortical thickness between controls and PCA subgroups. Regional variation in cortical thickness shown in A) Space subgroup 
compared with controls, and B) Object subgroup compared with controls. The colour scale represents FDR-corrected p values at a 0.05 significance level. 
Red and yellow (positive values) represent lower cortical thickness in the PCA subgroups compared with controls whereas dark and light blue (negative 
values) represent the reverse contrasts. A - anterior, P - posterior. 
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Figure 8.3: Difference in cortical thickness between Space and Object subgroups. A) shows uncorrected p values at a 0.05 significance level, and B) 
shows percent difference maps after correcting for average cortical thickness. Warmer colours show regions thinner in the Space subgroup compared with 
the Object subgroup whereas cooler colours represent the opposite comparison. A - anterior, P - posterior. 
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8.3.2.2 Support vector machine: 
The classification analysis produced a near complete separation between the controls and the 
PCA patients (Figure 8.4), with 97.5% accuracy [95% CI 86.8 - 99.9%]. In contrast, no clear 
separation into the two putative subgroups was found, with the SVM-weighted scores 
showing great overlap between subgroups. The SVM trained specifically to separate Object 
and Space subgroups yielded a low accuracy with confidence interval spanning chance 
performance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.4: SVM-weighted scores for each subject. Left: Illustration of separation between 
the controls and PCA group; right: no separation between the two putative PCA subgroups 
(Space and Object). 
 
 
8.4 Discussion 
This study investigated basic and higher-order visual function in a relatively large sample of 
patients with PCA using both detailed neuropsychological assessments and quantitative 
measures of cortical thickness. Considering that the primary deficits in PCA are visual, it is, 
perhaps, surprising that previous studies have failed to examine the nature of basic visual 
deficits in more detail or to consider their influence upon higher-order visual processing. In 
this study it is shown that basic visual functions are affected in the vast majority of PCA 
patients, and that the severity of deficit in these basic visual skills predicts the pattern of 
higher-order object and space perception observed. The current study also demonstrates that 
- 152 - 
the severity of space and object perception difficulties can partially predict the degree of 
cortical thinning in dorsal and ventral posterior cortical regions, however, the neuroimaging 
evidence garnered from the current study is insufficient to justify the specification of distinct 
PCA subtypes. 
 
8.4.1 Basic visual deficits predict the nature of higher-order perceptual deficits in PCA 
The first hypothesis addressed in the current study was that higher-order visual deficits in 
PCA are associated with specific and separable patterns of basic visual processing. Object 
and space perception problems are reported commonly in PCA and yet it is unknown whether 
these problems constitute true visual agnosias or result from impaired sensory processing, 
because the integrity of basic visual processes (e.g. form, colour, motion and location) have 
not been assessed systematically in previous neuropsychological studies of PCA. 
Furthermore, although atrophy and pathological changes have been found in striate and 
extrastriate occipital cortex, it is unknown whether mechanisms supporting these fundamental 
components of vision are uniformly affected in PCA or can be selectively disrupted in line with 
models of the human visual system (e.g. Deyoe et al., 1996; Goodale and Milner, 1992; 
Ungerleider and Mishkin, 1982; Wandell et al., 2007). 
 
The neuropsychological data revealed that every PCA patient was impaired on at least one 
basic visual processing task. Thus, no evidence of ‘pure’ visual agnosia was found, with the 
data suggesting that basic visual processing deficits contribute to the object and space 
agnosias commonly reported in PCA patients. The correlation analysis further revealed that 
basic visual processing impairments have a significant impact upon the nature of higher-order 
visual dysfunctions: whilst form detection, form coherence and colour performance were 
correlated with both object and space perception, form discrimination predicted object but not 
space perception, and point localisation predicted only space but not object perception. 
Together, these findings provide the first evidence that higher-order visual deficits in PCA are 
associated with different patterns of basic visual processing impairment. Furthermore in 
contrast to their influence on higher-order perceptual functions, basic visual processing 
dysfunction had no significant impact upon non-visual parietal functions (e.g. calculation, 
spelling), despite the equivalent proximity of the critical cortical regions. Models of the 
evolution of AD and related disorders contrast pathological proliferation between contiguous 
brain regions with network-based progression, in which functional and anatomical 
connections between non-contiguous brain areas play an important role in determining the 
spread and development of tissue pathology (e.g. Palop et al., 2006; Seeley et al., 2009). The 
current evidence of associations between occipital dysfunction and some but not other forms 
of parietal dysfunction may therefore support network models, and reflect network dysfunction 
and disconnection. Basic visual processing deficits also did not correlate with recognition 
memory, MMSE or disease duration, providing some evidence that involvement of basic 
visual processing, considered to be mediated primarily by more posterior occipital regions, 
- 153 - 
may reflect a different locus of pathology in some individuals rather than merely greater 
disease severity. 
 
8.4.2 Variation in patterns of cortical thinning 
The study further assessed the hypothesis that different types of behavioural dysfunction are 
associated with distinct patterns of structural change in posterior cortical regions. More 
specifically, it was hypothesised that PCA patients with predominant spatial perception 
problems (Space subgroup) would be associated with greater posterior parietal cortical 
thinning, and that patients with predominant object perception problems (Object subgroup) 
would be associated with greater inferior temporal cortical thinning. In line with this 
hypothesis, the Space subgroup showed thinning particularly in the occipital and inferior 
parietal lobes, and the Object subgroup showed particular thinning in the fusiform gyrus and 
inferior temporal lobe. Trends toward lower cortical thickness in ventral (Object Subgroup) 
and dorsal (Space subgroup) regions were apparent in independent subgroup-controls 
comparisons (Figure 8.2) and between-subgroup comparisons (Figure 8.3).  
 
However, whilst these neuroimaging findings provide some evidence for differential patterns 
of tissue loss in the dorsal and ventral regions of different PCA patients, the majority of 
differences detected between subgroups were only found as percent differences. 
Furthermore, the indirect comparisons between each subgroup and the control population 
(Figure 8.2) showed multiple common areas of tissue loss across the subgroups. This 
observation was confirmed by the SVM analysis, with SVM-weighted scores showing 
considerable overlap between subgroups (Figure 8.4), while almost perfectly separating 
controls from patients. Thus overall the neuroimaging findings are indicative of a degree of 
heterogeneity within the PCA population but do not motivate a clinical characterisation of 
distinct PCA subtypes. 
 
Previous neuropsychological analyses of PCA have claimed good evidence to support the 
description of caudal (occipital) and dorsal (parietal) subtypes of PCA, but have failed to find 
convincing evidence for a ventral (occipito-temporal) subtype (McMonagle et al., 2006). In the 
current study, individual examples of a ventrally-focussed syndrome have been found, for 
example one patient failed all object perception tests and passed all space perception tests. 
However, this patient’s cognitive profile constituted merely the most extreme value on a 
continuous range of object-space difference scores, with several patients showing moderate, 
mild or no differences between object and space perception tasks (see Figure 8.1). Clinical 
experience suggests that the majority of PCA patients complain of or exhibit both space and 
object processing difficulties from early in the disease course, but as demonstrated in Figure 
8.1 the relative severity of these deficits can be quite variable. 
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8.4.3 Continuous variation within PCA 
The current study yields evidence of both similarities and differences amongst the PCA 
patients. At one level, the PCA cohort is collectively quite different from individuals with typical 
AD: relatively preserved memory, impaired perceptual skills and predominant posterior 
deficits and atrophy (chapter 6). At a more fine-grain level, detailed assessment reveals that 
PCA patients differ in the severity of their basic visual, object and space perception deficits 
and the extent to which occipital, superior parietal and inferior temporal cortical regions are 
affected. However, these more fine-grain differences do not reflect discrete, definable 
syndromic subtypes of PCA. Rather, the manual classification of neuropsychological profiles 
(Figure 8.1) and the automated classification of cortical thickness patterns (Figure 8.4) are 
more suggestive of continuous variation within the syndrome of PCA. The data in the present 
study are insufficient to support the existence of discrete dorsal and ventral sub-syndromes 
within PCA, although patients at the outer limits of such continuous variability can indeed 
possess markedly different phenotypes (Galton et al., 2000). Instead, those putative subtypes 
are more likely to represent points in a continuously varying topological distribution of cortical 
dysfunction, which may in turn reflect the distribution of underlying pathology. A similar notion 
has recently been expressed in a study of progressive PNFA to describe the relationship 
between putative PNFA subtypes such as progressive apraxia of speech and LPA; namely 
that individual patients with such phenotypes represent ‘points at the edges of a space of 
continuous variability within PNFA’ (Knibb et al., 2009, p2744). 
 
If PCA phenotypes do represent different points in a space of continuous variation, this has 
implications for studies investigating the factors which drive the variation both within and 
between the different ‘typical’ and ‘atypical’ presentations of AD and related disorders. It may 
be more appropriate to consider how a population of patients varies on a particular 
continuous marker of topology (e.g. measures of basic visual function as a marker of occipital 
cortical loss) rather than dichotomising the population into symptomatic categories (e.g. 
‘typical AD’, PCA), the boundaries of which may be poorly defined. Such continuous rather 
than categorical techniques may be used to determine the role of molecular and 
environmental factors in driving the topological focus of pathology (e.g. anterior-posterior, 
superior-inferior, unilateral-bilateral) and their interaction with other structural and 
physiological constraints. It should also be noted that the anterior-posterior and dorsal-ventral 
distinctions considered to date also fail to capture the pronounced asymmetry apparent in the 
neuropsychological and neuroimaging profiles of many individuals with PCA (e.g. Freedman 
et al., 1991; Snowden et al., 2007b). Without considering this lateral dimension of pathological 
distribution, it will also be difficult to establish the relationship between PCA and atypical 
variants of AD and related disorders such as LPA which is characterised by highly 
asymmetric atrophy of the dominant hemisphere (Gorno-Tempini et al., 2004). 
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8.4.4 Limitations of the current study 
With regard to the neuropsychological aspects of the study several possible limitations should 
be considered. Firstly, visual fields were not tested formally in the PCA patients. Many 
showed problems on informal clinical field assessment, but clinical experience of PCA 
suggests that an inability to detect the presence or movement of a stimulus in the periphery 
during clinical examination is often more accurately attributed to visual disorientation and 
attentional problems rather than a field defect per se. Secondly, the division between visual 
processes labelled ‘basic’ and ‘higher’ is relative rather than absolute; it cannot be denied that 
for example that the boundary detection skills critical to the ‘basic’ form detection task are 
also necessary for the ‘higher’-order fragmented letter task. Thirdly, whilst the space and 
object perception tests (mainly from the VOSP) employed in the current study are routinely 
used in clinical and research practice, there is little direct evidence to demonstrate differential 
dependence upon dorsal and ventral visual streams. Therefore alternative tasks with greater 
or more demonstrable localising power may yield a more accurate classification of ‘dorsal’ 
and ‘ventral’ subgroups. 
 
From the neuroimaging and diagnostic perspectives, one limitation of this study is that scans 
were obtained from two different scanners with different field strengths which may have an 
effect on thickness measures (Han et al., 2006). Statistical models were therefore adjusted for 
scanner type. Furthermore, subject numbers, particularly in the subgroup analysis, were 
relatively small leading to a lack of power to detect statistically significant results after 
correcting for multiple comparisons. Replication of this study with a larger cohort of patients 
may increase the power to detect differences between the behaviourally-defined subgroups. 
Although all the patients in the current study have a clinical diagnosis of probable AD, another 
limitation is the lack of pathological confirmation. A further issue which applies to most studies 
of degenerative disease relates to controlling for the variable of disease severity when 
conducting between-group comparisons. There were no significant differences between the 
two behaviourally-defined subgroups on measures of general cognitive function, although 
measures such as the MMSE are of limited utility in this population of patients. Furthermore, 
cortical thickness comparisons were corrected for mean cortical thickness in order to adjust 
for potential premorbid differences and/or differences in disease severity.  
 
8.5 Chapter conclusion 
This study aimed to investigate the nature of visual impairments in PCA, in particular the 
contribution of deficits of basic visual processing to higher-order object and space processing 
impairments. The neuropsychological data revealed specific correlations between basic and 
higher-order visual deficits, however, no correlations were found with non-visual parietal skills 
suggesting the specific involvement of visual networks in PCA. Furthermore, the cortical 
thickness analysis revealed trends towards lower cortical thickness in occipitotemporal 
(ventral) and occipitoparietal (dorsal) regions in patients with visuoperceptual and visuospatial 
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deficits, respectively. However, there was also great overlap in the patterns of cortical thinning 
in these two subgroups of PCA.  
 
The great heterogeneity of the visual deficits in PCA and the overlap in patterns of cortical 
thickness therefore provide only limited support for the existence of distinct phenotypical 
subtypes in PCA. Rather it may be more appropriate to consider different presentations of 
PCA as points on a continuum of phenotypical variation. This conclusion may be applicable to 
AD as a whole, with different phenotypes, including amnestic, visual and aphasic phenotypes, 
representing points in a space of continuous variation, rather than distinct subtypes of AD. For 
the purpose of most research studies, including the studies presented in this thesis, the 
inclusion criteria chosen to define groups such as PCA and typical amnestic AD are designed 
to minimize the overlap between these groups, i.e. to maximize the separation between them, 
allowing the identification of those features that are most characteristic for each group. Future 
studies, however, need to address the degree of overlap between different variants of AD in 
order to understand the nature of the heterogeneity of phenotypical presentations in AD. 
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9. THESIS CONCLUSIONS 
 
9.1 Chapter introduction 
With ageing populations, AD is a growing health and socio-economic problem, greatly 
affecting the quality of life for the patient and the carers. Increasing international efforts 
therefore aim to identify markers which may aid diagnosis and track disease progression. 
Structural neuroimaging techniques have become widely used tools to diagnose dementia, 
discriminate neurodegeneration from normal ageing, differentiate between degenerative 
diseases, and track the progression of disease by providing detailed, quantitative and 
increasingly automated measures of whole and regional brain volume as an index of 
neurodegeneration. Imaging markers may therefore provide sensitive outcome measures for 
testing the efficacy of drugs aimed at slowing disease progression.  
 
AD is most commonly associated with memory loss and atrophy in the medial temporal lobes 
(chapter 1, section 1.2.1). The prominence of these two markers in AD is reflected by their 
inclusion in proposed research diagnostic criteria for AD (Dubois et al., 2007), which argue 
that the presence of memory loss and medial temporal lobe atrophy is sufficient to make a 
diagnosis of prodromal AD. However, atrophy in the medial temporal lobe is also present in 
other neurodegenerative diseases, such as FTLD (chapter 2, section 2.5.4), and normal 
ageing (chapter 2, section 2.5.1). In addition increasing numbers of studies have stressed the 
importance of atrophy, and metabolic and pathological changes in posterior regions in typical 
AD (chapter 2, section 2.5.2). Furthermore, atypical clinical presentations have been 
highlighted in AD, in which memory is not the primary deficit and which tend to have a 
younger age at onset (van der Flier et al., 2010), such as PCA and LPA (chapter 1, section 
1.2.1.3).  
 
This thesis aimed to investigate the nature of the heterogeneity of different phenotypes in AD 
by using two different approaches: a) by studying atrophy patterns in patients with 
pathological confirmation of AD with different clinical presentations during life, and b) by 
characterizing patterns of atrophy and visual deficits in a form of atypical AD: PCA. With both 
these approaches comparisons were made with healthy controls and additionally for PCA 
comparisons were made with amnestic, typical AD. 
 
Increasing the clinical and scientific community’s knowledge of atypical variants in particular is 
important in order to help identify the biological factors which drive this heterogeneity in AD, 
which may lead to a better understanding of AD as a whole. Better understanding should also 
improve the support, care and education that can be given to the patients, carers and 
healthcare professionals. 
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9.2 Posterior atrophy is a common finding in patients with AD pathology 
This thesis first investigated patterns of cortical thickness in patients with AD pathology with 
different clinical diagnoses during life (including typical amnestic, visual, aphasic and 
behavioural phenotypes) (chapter 4). Regions with reduced cortical thickness in patients with 
AD pathology compared with controls were found to be the medial temporal lobe, as well as 
posterior regions such as posterior cingulate gyrus, precuneus and the posterior parietal 
cortex. Lower cortical thickness was also shown in the frontal pole. Compared with patients 
with FTLD pathology, subjects with AD pathology who had a clinical presentation of FTD 
during life also showed lower cortical thickness in posterior regions (precuneus, posterior 
parietal lobe, and posterior cingulate gyrus), frontal pole and superior temporal lobe. The 
involvement of these regions in patients with AD pathology despite different clinical 
presentations and diagnoses during life may suggest that atrophy in these regions is 
indicative of AD pathology, at least when compared with normal ageing and patients with 
FTLD pathology. Interestingly, these areas greatly overlap with regions commonly associated 
with the default-mode network which is a highly active network, even at rest, and has been 
shown to be strongly involved in the processing of memories. It has also been found to be 
affected early in AD. The cortical thickness findings presented here therefore support models 
of AD affecting functional networks leading to atrophy in the regions described above. 
 
The posterior involvement in patients with AD is in accordance with previous reports, and has 
been further demonstrated by using visual rating scales (chapter 5). In this study, two visual 
ratings scales were used to assess atrophy in medial temporal and posterior regions in 
pathologically-confirmed AD and FTLD. It was demonstrated that a significant proportion of 
AD subjects showed prominent posterior atrophy in the absence of significant medial 
temporal lobe involvement. Ratings of posterior atrophy also improved accuracy for 
separating AD from FTLD, and proved valuable for distinguishing early-onset AD from 
younger controls. These findings stress the need to consider atrophy in posterior regions 
when making a diagnosis of AD, especially in younger patients. This is particularly important 
considering that proposed diagnostic criteria for AD (Dubois et al., 2007) include medial 
temporal lobe atrophy as a diagnostic marker, however, not posterior atrophy, which might 
mean that AD patients with prominent posterior atrophy in the absence of medial temporal 
lobe atrophy might not be given a diagnosis of AD during early disease stages. 
 
Whilst growing evidence points to a number of key regions commonly affected in patients with 
AD pathology, largely matching areas typically associated with the default-mode network, 
there are forms of AD which show strong involvement in other areas as well, such as visual 
areas in patients with PCA, and language areas in patients with LPA. Although these patient 
populations can also have other, non-AD pathologies as their underlying cause, studying 
these different phenotypes will provide insights into the nature of the heterogeneity in AD. 
Specifically, studying PCA, which is characterized by marked posterior atrophy with only 
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minimal medial temporal lobe involvement, will provide insights into the mechanisms 
underlying the marked involvement of posterior regions in AD. 
 
9.3 Characteristic cross-sectional and longitudinal patterns of atrophy in PCA 
Whilst the posterior atrophy of PCA may often be evident from visual inspection of structural 
MR images (chapter 1, Figure 1.1), using automated image analysis tools allows the exact 
localization and quantification of atrophy in PCA. Using VBM and FreeSurfer to measure 
cross-sectional (chapter 6) and longitudinal differences (chapter 7) in grey matter volume and 
cortical thickness, respectively, revealed some interesting results about the natural history of 
the disease in PCA and typical amnestic AD. The cross-sectional data revealed significantly 
lower grey matter volumes and cortical thickness in posterior regions in PCA compared with 
typical amnestic AD as expected. In contrast, amnestic AD showed significantly lower cortical 
thickness in the entorhinal cortex compared with PCA. Assuming that the majority of the 
patients included in this study have AD pathology, these findings of prominent posterior 
atrophy with minimal atrophy in the medial temporal lobes are in accordance with the patterns 
of atrophy in pathologically-confirmed AD subjects presented in chapter 4 and 5. Furthermore, 
the significant differences in grey matter volume and cortical thickness in the direct 
comparison between PCA and typical AD provide evidence that different behaviourally-
defined AD phenotypes are associated with significantly different brain atrophy patterns. 
 
However, despite these striking cross-sectional differences between PCA and typical 
amnestic AD, the longitudinal results demonstrated global changes in grey matter loss and 
cortical thinning in PCA and typical AD compared with controls over the course of 1 year, with 
only subtle differences in the direct patient group comparison. Since both disease groups had 
a disease duration of approximately 5 years, these findings suggest that initial focal patterns 
of atrophy (as demonstrated by the cross-sectional results in chapter 6) become more 
widespread as the diseases progress. These results may encourage future studies to 
investigate disease progression in prodromal and presymptomatic cases of PCA and typical 
AD to identify the processes which result in different AD phenotypes. These data may also 
point to a common path of AD progression, a theory which will need further support from 
studies investigating atrophy progression in patients with pathology-confirmation and studies 
investigating earlier disease stages. This study further demonstrated the advantage of using 
multiple techniques to analyse imaging data, particularly when a number of different 
outcomes are possible and a number of hypotheses have been posed. As has been 
demonstrated in previous studies, combining a fluid-registration approach with VBM 
represents a powerful tool to assess longitudinal changes in a disease group. The relatively 
novel longitudinal processing stream in FreeSurfer, however, did not return any statistically 
significant results. This is possibly due to the higher inter-subject variability of the cortical 
thickness measures, which greatly reduced the power to detect significant differences. The 
reason why the variability of the VBM data was lower might be due to the fact that the fluid-
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based method is a ‘direct’ measure of change, i.e. change is measured ‘directly’ from the two 
registered serial scans. In contrast, FreeSurfer represents a less ‘direct’ approach which 
measures cortical thickness changes by subtracting two measured thicknesses. 
 
9.4 PCA and AD as continuums of varying phenotypical presentations 
In addition to the heterogeneity of different phenotypes in AD, it has been suggested that 
different phenotypes also exist within PCA. Studies which have investigated the presence of 
different clinical subtypes in PCA have returned mixed results. The study presented in chapter 
8 therefore aimed to investigate further the existence of these subtypes in PCA using 
behavioural and cortical thickness measures at a single time point. The behavioural data 
revealed heterogeneous patterns of basic and higher-order visual deficits in PCA. The cortical 
thickness analysis further revealed trends towards lower cortical thickness in occipitotemporal 
(ventral) and occipitoparietal (dorsal) regions in PCA patients with visuoperceptual and 
visuospatial deficits, respectively. However, there was also great overlap in the patterns of 
cortical thinning in these two subgroups of PCA. Furthermore, classifying PCA patients on the 
basis of their cortical thickness patterns did not return a clear separation into subgroups. 
These findings therefore provide only limited support for the existence of very distinct 
subtypes in PCA; rather they suggest a spectrum of varying phenotypical presentations in 
PCA. Considering different presentations of PCA as points on a continuum of phenotypical 
variation may also have implications for how we view the variation of different phenotypes in 
AD as whole. The variation within and between typical and atypical presentations of AD may 
therefore also represent a spectrum rather than distinct categories.  
 
9.5 Clinical implications 
An increasing number of studies emphasize the importance of posterior atrophy in AD, a 
finding supported by the studies presented in this thesis. Atrophy in posterior regions may 
therefore be a useful additional marker for AD and certainly should not be ignored in the 
clinical and radiological assessment of patients with cognitive decline. Growing awareness of 
the posterior involvement as well as the presence of atypical, non-amnestic phenotypes in AD 
is reflected by renewed suggestions for a revision of the AD diagnostic criteria (Dubois et al., 
2010), acknowledging non-memory related deficits (e.g. visuospatial problems) as being a 
feature of AD. 
 
Furthermore, the characterisation of the structural and cognitive features of specific atypical 
variants of AD, such as PCA, should lead to a better understanding of the nature of the 
heterogeneity in AD. As importantly this should also help to raise awareness amongst 
scientists, medical practitioners and society in general of the existence of these unusual 
syndromes. This is particularly important in under-diagnosed variants such as PCA in which 
initial visual symptoms are often mistaken as being of ophthalmological rather than 
neurological origin resulting in a great delay or even a complete lack of diagnosis in these 
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patients. This is not only frustrating for the patients and their carers, but also means that 
treatments which might be available might be missed because patients are already too 
severely impaired. Understanding the evolution of the disease in different variants of AD may 
further improve diagnosis and the quality and accuracy of prognosis given to patients and 
their carers. Finally, it is important to develop tools which allow the characterisation of the 
cognitive deficits and the structural damage in patients on a routine basis in a clinical setting. 
Visual rating scales have been shown to represent a convenient method to assess atrophy in 
a clinical environment. 
 
9.6 Future directions 
Whilst this thesis aimed to improve our understanding and characterisation of atypical 
variants of AD, it has also revealed a number of issues and questions which remain to be 
addressed in future studies. For example, it is currently unknown which factors drive the 
heterogeneity of different phenotypes in AD. It has been suggested that the default-mode 
network, which is affected early in AD, is particularly vulnerable to AD pathology due to its 
high metabolic activity throughout life (Buckner et al., 2005). This and its strong involvement 
in memory processing might explain the great prevalence of the amnestic phenotype in AD. 
However, it remains unclear how the default-mode network is affected in non-amnestic 
variants of AD, and what makes other networks, such as visual and language networks, more 
vulnerable to pathology and atrophy in some people but not others. Factors driving the 
selective vulnerability of visual and language networks in PCA and LPA, respectively, may 
include genetic predisposition, higher vascular burden or even developmental damage or 
predisposition as has been suggested in patients with PPA who were shown to have a high 
rate of developmental language disorders (Rogalski et al., 2008). 
 
Another question which remains is how disease progresses in different variants of AD. It has 
been suggested that the sites of earliest change in AD includes posterior regions such as the 
posterior cingulate cortex, retrosplenial and lateral parietal cortex (Buckner et al., 2005; 
Migliaccio et al., 2009). It may even be that these regions are affected as early or even earlier 
than the medial temporal lobe. The common involvement of posterior regions in patients with 
AD pathology, as presented in chapter 4 and 5 in this thesis, might support this theory. 
Further studies, however, are needed to address the question of the sites of earliest 
involvement. There is of course no fundamental reason for suggesting that all variants of AD 
have common areas of disease origin in terms of increased pathology, decreased metabolism 
or increased atrophy. In fact, it is likely that in this regard, like in so many others, AD 
demonstrates heterogeneity. 
 
The study of early disease in some variants of AD remains problematic: the inclusion of milder 
cases of PCA is difficult since early visual symptoms are often not recognized as being of 
neurological origin. Furthermore, since potential therapeutic drugs are likely to target specific 
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pathological processes such as amyloid, it is also important to identify possible markers which 
may help to distinguish between PCA subjects with different pathological causes, such as AD, 
CBD and DLB. The utility of amyloid imaging and cerebrospinal markers of pathology remains 
to be fully explored in this disease presentation. 
 
9.7 Chapter conclusion 
The studies described in this thesis contribute to the growing interest in characterising and 
understanding atypical variants of AD. Atrophy in posterior regions is common to many 
variants of AD and is particularly striking in patients with PCA. This brain region therefore 
needs to be considered when making a diagnosis of AD, particularly in younger patients. 
Studying atypical presentations such as PCA is important in order to understand the nature of 
the heterogeneity of clinical phenotypes in AD. Moreover, their study may shed light on issues 
relevant to AD more generally. 
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APPENDIX 1 - NINCDS-ADRDA CRITERIA FOR AD 
 
Criteria for probable Alzheimer’s disease given by the National Institute of Neurological and 
Communicative Disorders and the Alzheimer’s Disease and Related Disorders Association 
(NINCDS-ADRDA) (McKhann et al., 1984). 
 
I) The diagnosis of PROBABLE Alzheimer’s disease include: 
a) Dementia established by clinical examination and documented by the Mini-Mental Test; 
Blessed Dementia Scale, or some similar examination, and confirmed by neuropsychological 
tests 
b) Deficits in two or more areas of cognition 
c) Progressive worsening of memory and other cognitive functions 
d) No disturbance of consciousness 
e) Onset between 40 and 90, most often after age 65 
f) Absence of systemic disorders or other brain diseases that in and of themselves could 
account for the progressive deficits in memory and cognition 
 
II) The diagnosis of PROBABLE Alzheimer’s disease is supported by: 
a) Progressive deterioration of specific cognitive functions such as language (aphasia), motor 
skills (apraxia), and perceptions (agnosia) 
b) Impaired activities of daily living and altered patterns of behaviour 
c) Family history of similar disorders, particularly if confirmed neuropathologically 
d) Normal lumbar puncture as evaluated by standard techniques 
e) Normal pattern or non-specific changes in EEG, such as increased slow-wave activity 
f) Evidence of cerebral atrophy on CT with progression documented by serial observation 
 
III) Other clinical features consistent with the diagnosis of PROBABLE Alzheimer’s 
disease, after exclusion of causes of dementia other than Alzheimer’s disease, include:  
a) Plateaus in the course of progression of the illness 
b) Associated symptoms of depression, insomnia, incontinence, delusions, illusions, 
hallucinations, catastrophic verbal, emotional, or physical outbursts, sexual disorders, and 
weight loss 
c) Other neurologic abnormalities in some patients, especially with more advanced disease 
and including motor signs such as increased muscle tone, myoclonus, or gait disorder 
d) Seizures in advanced disease 
e) CT normal for age 
 
IV) Features that make the diagnosis of PROBABLE Alzheimer’s disease uncertain or 
unlikely include: 
a) Sudden, apoleptic onset 
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b) Focal neurologic findings such as hemiparesis, sensory loss, visual field deficits, and 
incoordination early in the course of the illness 
c) Seizures or gait disturbance at the onset or very early in the course of the illness 
 
V) Clinical diagnosis of POSSIBLE Alzheimer’s disease: 
a) May be made on the basis of the dementia syndrome, in the absence of other neurologic, 
psychiatric, or systemic disorders sufficient to cause dementia, in the presence of variations in 
the onset, in the presentation, or in clinical course 
b) May be made in the presence of a second systemic or brain disorder sufficient to produce 
dementia, which is not considered to be the cause of the dementia 
c) Should be used in research studies when a single, gradually progressive severe cognitive 
deficit is identified in the absence of other identifiable cause 
 
VI Criteria for the diagnosis of DEFINITE Alzheimer’s disease are: 
a) The clinical criteria for probable Alzheimer’s disease 
b) Histopathological evidence obtained from biopsy or autopsy 
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APPENDIX 2 - PROPOSED DIAGNOSTIC CRITERIA FOR PCA  
 
I Proposed clinical diagnostic criteria for PCA (Mendez et al., 2002) 
  
1) Core diagnostic features (all must be present) 
a) Insidious onset and gradual progression 
b) Presentation with visual complaints with intact primary visual functions 
c) Evidence of predominant complex visual disorder on examination; elements of Balint’s 
syndrome; visual agnosia; dressing apraxia; environmental disorientation 
d) Proportionally less impaired deficits in memory and verbal fluency 
e) Relatively preserved insight with or without depression 
 
2) Supportive diagnostic features 
a) Presenile onset 
b) Alexia 
c) Elements of Gerstmann’s syndrome 
d) Ideomotor apraxia 
e) Physical examination within normal limits 
f) Investigations 
 - Neuropsychology: predominantly impaired perceptual deficits 
 - Brain imaging: predominantly occipitoparietal abnormality (especially on functional 
 neuroimaging) with relative sparing of frontal and mesiotemporal regions 
 
 
II Proposed clinical diagnostic criteria for PCA (Tang-Wai et al., 2004) 
 
1) Core features 
a) Insidious onset and gradual progression 
b) Presentation of visual complaints in the absence of significant primary ocular disease 
explaining the symptoms 
c) Relative preservation of anterograde memory and insight early in the disorder 
d) Disabling visual impairment throughout the disorder 
e) Absence of stroke or tumor 
f) Absence of early parkinsonism and hallucinations 
g) Any of the following findings:  
- Simultanagnosia with or without optic ataxia or ocular apraxia 
- Constructional dyspraxia 
- Visual field defect 
- Environmental disorientation 
h) Any of the elements of Gerstmann syndrome 
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2) Supportive features 
a) Alexia 
b) Presenile onset 
c) Ideomotor or dressing apraxia 
d) Prosopagnosia 
e) Investigations 
- Neuropsychological deficits referable to parietal and/or occipital regions 
- Focal or asymmetric atrophy in parietal and/or occipital regions on structural 
imaging 
- Focal or asymmetric hypoperfusion/hypometabolism in parietal and/or occipital 
regions on functional imaging 
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APPENDIX 3 - VISUALIZING THE EMERGENCE OF PCA 
 
Diagnosis of PCA is often delayed because of poor general knowledge of the syndrome’s 
existence, and because early visual symptoms are often mistaken as being of 
ophthalmological rather than neurological origin. Therefore, little is known about the earliest 
cognitive and structural changes in PCA. Studying the early stages of PCA is, however, 
crucial to fully understand the evolution of this disease. In a single case study, a patient with 
PCA who volunteered as a healthy control subject in a longitudinal study investigating 
subjective memory complaints was assessed. Over the course of 5 years the participant 
underwent extensive investigations including clinical, neuropsychological and neuroimaging 
assessments. Each assessment included a clinical interview with the patient and his 
informant, a standardised neuropsychological battery, and a volumetric T1-weighted MRI 
brain scan with additional T2-weighted images which were obtained on a 1.5T GE Signa 
scanner. This case has been described in detail in Kennedy et al., 2011. A summary of the 
imaging findings is presented below, which represent a good example of the application of 
fluid registration to visualize structural changes over multiple time points in an individual 
patient. 
 
Imaging findings 
During the first three years of this study, the patient’s serial MR imaging was reviewed by the 
same neuroradiologist and individually felt to be normal. After viewing registered scan pairs of 
visit 4 and 5, the neuroradiologist suggested that a progressive neurodegenerative disease 
may be present. For the purpose of this study, MR images were segmented (chapter 3, 
section 3.5.2.1, Freeborough et al., 1997) and each time point was registered to the baseline 
using the fluid algorithm described in chapter 2, section 2.2.2.2 (Freeborough and Fox, 1998). 
The resulting voxel-compression maps are shown in Figure A-1. The neuroimaging data 
revealed a marked posterior-anterior gradient of atrophy, with early changes occurring 
predominantly in inferior temporal and superior parietal regions at visit 2. Atrophy then spread 
affecting inferior parietal and occipital lobe areas at visit 3. This continued to be the focus of 
progressive atrophy but by visit 6 atrophy in anterior regions also appeared. 
 
Annualised whole brain atrophy rates (% loss per year) were also calculated using the KN-
BSI (chapter 2, section 2.2.2.2, Leung et al., 2010): -0.28% (Baseline-Visit 2), 0.83% (Visit 2-
3), 1.69% (Visit 3-4), 1.45% (Visit 4-5) and 0.99% (Visit 5-6). The initial apparent increase in 
brain volume between baseline and Visit 2 is at odds with subsequent atrophy, however, this 
is not beyond the change in volume between same day scans (Boyes et al., 2006). The mean 
atrophy rate thereafter is 0.93% which is approximately three times what would be expected 
for a healthy man of this age (chapter 2, section 2.5.1). Whilst normal variation and artefacts 
can make it difficult to interpret atrophy rates on an individual basis, particularly on one year 
alone, the patient’s rates were highly suggestive of pathological atrophy. 
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It is noteworthy that one of the regions affected early in the present case was the inferior 
temporal lobe, and continued to atrophy throughout the later stages. As discussed in chapter 
8, different subtypes of PCA have been suggested (Galton et al., 2000; Ross et al., 1996), 
with some patients exhibiting a more dorsal (i.e. parieto-occipital) phenotype, and others a 
more ventral (i.e. temporo-occipital) presentation. According to this distinction, the present 
case may represent an example of a PCA patient with a ventral phenotype. There is some 
evidence to suggest that PCA often occurs more commonly in the absence of an ApoE ε4 
allele and it has been postulated that this allows AD pathology to be directed more posteriorly. 
Our subject was an ApoE ε4 allele heterozygote which may account for the more ventral 
phenotype and striking inferior temporal lobe involvement, perhaps, suggesting that the 
present case lies somewhat between the two extremes of typical amnestic AD and typical 
visual AD (i.e. PCA). 
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Figure A-1: Fluid-registered serial MR images of a PCA patient for 6 visits. Shown is a sagittal view of the patient’s right hemisphere. Repeat scans were 
fluid-registered to the baseline image and colour-coded voxel-compression maps were produced. The scale shows the percentage volume change per voxel 
(-20% to 20%) with green and blue representing contraction and yellow and red representing expansion. 
Contraction Expansion-20% +20%0%
Baseline: Jan 04 Repeat 1: Jan 05 Repeat 2: Jan 06 Repeat 3: Dec 06 Repeat 4: Jan 08 Repeat 5: Nov 08
A P
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APPENDIX 4 - PCA NEUROPSYCHOLOGY TESTS 
 
1) Basic visual processing 
 
1.1) Form detection 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A-2: VOSP Figure-ground discrimination task. Participants were shown random 
black patterns, half with a degraded ‘X’ superimposed. They were requested to state whether 
an ‘X’ was present. 
 
1.2) Form discrimination 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A-3: Form discrimination task. The task was to discriminate whether a shape 
presented to the participant was a square or an oblong. 
Square 
‘X’ present ‘X’ not present 
Oblong - Level 1 Oblong - Level 2 
Oblong - Level 3 
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1.3) Form coherence 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A-4: Form coherence task. This and the motion coherence test were administered 
on a computer screen. In half the arrays, a percentage of the line segments in a central region 
were coherently oriented tangentially to concentric circles. In the remaining arrays, all line 
segments were arranged randomly. Patients were requested to state whether a ‘circle’ is 
present in each stimulus. The motion coherence task was similar, only difference being that 
the short line segments were dots moving around. 
 
 
No circle
90% coherence
30% coherence
50% coherence 70% coherence
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1.4) Colour discrimination 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A-5: Colour discrimination task. The stimuli were pairs of matte colour chips 
presented adjacently. The task was to determine whether the hues in each pair are the same 
or different. This example shows different colours. 
 
1.5) Point localization 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A-6: Point localization task. Stimuli were A3 laminated white cards with a single, 
randomly-position black dot. The position of each dot was revealed for 3s before the stimulus 
was covered by a second blank A3 card, and participants were requested to mark the position 
of the dot on the blank sheet using a pen in their dominant hand.  
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2) Higher-order visual processing 
 
2.1) Object perception - ventral processing 
 
2.1.1) Object decision (VOSP) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A-7: VOSP Object decision task. Participants were shown 4 silhouettes. Only one of 
them was a silhouette of a real object, the other 3 were completely made up. Participants 
were asked to point to the one they think is real. In this example the correct answer is “jug” in 
the right bottom corner. 
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2.1.2) Fragmented letters (VOSP)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A-8: VOSP Fragmented letters task. Subjects were shown incomplete letters and they were asked which letter they can see. In this example the 
letters are (from left to right): F, Z, P, K. 
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2.1.3) Unusual/usual views 
 
 
 
 
 
 
 
 
 
 
Figure A-9: Unusual/usual views. Participants were shown a number of photos of 
household objects, taken from odd angles (unusual views) and they were asked what object 
they can see. If they did not recognize the object, they were shown another photograph of the 
same object from a ‘usual’ angle. The example shown here is a “plug”. 
 
2.2) Space perception - dorsal processing 
 
2.2.1) Number location (VOSP)    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A-10: VOSP Number location task. Participants were shown two boxes. One box 
contained a black dot, the other box above it contained numbers. Participants were asked 
which number corresponded to the position of the dot. In the example shown here, the correct 
answer is “4”. 
Plug - unusual view Plug - usual view 
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 2.2.2) Dot counting (VOSP)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A-11: VOSP Dot counting task. Subjects were presented a number of black dots and 
were asked to say, as quickly as they could, how many dots they can see. In this example the 
correct answer is “7”. 
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APPENDIX 5 - IMAGE ACQUISITION PROTOCOLS 
 
The majority of scans were acquired on one of four 1.5T Signa MRI scanners (General 
Electric, Milwaukee, Wisconsin, USA) as 124 contiguous 1.5mm coronal slices. The 4 scan 
sites were as follows: 
 
1) Dave MacManus’ scanner, NMR group, Queen Square:  
This protocol was an inversion recovery (IR)-prepared fast SPGR sequence with a 256x256 
image matrix and a 24cm field of view. This scanner underwent a software upgrade in April 
2004 which consisted of new gradient drivers, a new computer operating system (Linux 
platform) and a scanner operating software upgrade from v5.8 to v11.0. Scans acquired prior 
to the upgrade have the following parameters: readout interval repetition time TR=15ms; echo 
time TE=5.4ms; inversion time TI=650ms; flip angle=15°. Scans obtained after the upgrade 
have the following parameters: readout interval TR=12ms; TE=5.2ms; TI=650ms; flip 
angle=13°.  
 
2) St Mary’s hospital, Paddington and Queen Square Imaging Centre:  
The scans were taken using a 256x126 image matrix with the field of view being 24cm; 
acquisition parameters: TE=5.4ms; readout interval TR=12ms; flip angle=15°; TI=650ms. 
 
3) Queen Square Imaging Centre:  
Scans were taken using a 256x224 image matrix with the field of view being 24cm. The 
scanning protocol used the following acquisition parameters: TE=2.3ms; readout interval 
TR=20ms; flip angle=20°; TI=450ms.  
 
4) National Hospital for Neurology and Neurosurgery:  
4.1) 1.5T scanner: This scanner used an IR-prepared SPGR with a 256x256 image matrix 
and a field of view of 24cm; acquisition parameters: TE=6.3ms; readout interval TR=14.2ms; 
flip angle=15°; TI=650ms. 
 
4.2) 3T scanner: A small number of scans were acquired on a Siemens Trio TIM 3T scanner 
using an MPRAGE sequence with a 256x256 acquisition matrix  and 28.2-cm field of view to 
provide 208 contiguous 1.1-mm-thick slices in the sagittal plane; acquisition parameters: 
TE=2.9ms, inversion interval TR=2200ms, TI=900ms. 
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GLOSSARY 
 
AD: Alzheimer’s disease 
ApoE: Apolipoprotein E 
AUC: Area under the curve 
BSI: Boundary-shift integral 
bvFTD: behavioural variant frontotemporal dementia 
CBD: Corticobasal degeneration 
CI: Confidence intervals 
CJD: Creutzfeld Jakob disease  
CORVIST: Cortical Visual Screening Test 
CSF: Cerebrospinal fluid 
CT: Computed tomography 
DLB: Dementia with Lewy Bodies 
DLDH: Dementia lacking distinctive histology 
dof: degrees-of-freedom  
DTI: Diffusion tensor imaging 
EOAD: Early-onset Alzheimer’s disease 
FDR: False discovery rate 
FTLD: Frontotemporal lobar degeneration  
FTD: Frontotemporal dementia  
FWHM: full-width at half-maximum 
GLM: General linear model 
LOAD: Late-onset Alzheimer’s disease 
LPA: Logopenic progressive aphasia 
MCI: Mild cognitive impairment 
MIDAS: Medical information display and analysis system 
MMSE: Mini-mental state examination 
MNI: Montreal Neurological Institute 
MPRAGE: magnetization-prepared rapid acquisition with gradient echo 
MRI: Magnetic resonance imaging 
MTA: Medial temporal lobe atrophy 
NINCDS-ADRDA: National Institute of Neurological and Communicative Disorders and Stroke 
and the Alzheimer's Disease and Related Disorders Association 
PA: Posterior atrophy 
PCA: Posterior cortical atrophy 
PET: Positron emission tomography 
PNFA: Progressive non-fluent aphasia 
PPA: Primary progressive aphasia 
PSP: Progressive supranuclear palsy 
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RMT: Recognition Memory Test 
ROC: Receiver operating characteristic   
ROI: Region of interest 
SemD: Semantic dementia 
SD: Standard deviation 
SPECT: Single photon emission computed tomography 
SPGR: Spoiled gradient echo 
SPM: Statistical parametric mapping 
SVM: Support vector machine 
tAD: typical Alzheimer’s disease 
TIV: Total intracranial volume 
VBM: Voxel-based morphometry 
VOSP: Visual Object and Space Perception Battery 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 184 - 
BIBLIOGRAPHY 
 
 1.  Agdeppa, E.D., Kepe, V., Liu, J., Flores-Torres, S., Satyamurthy, N., Petric, A., Cole, 
G.M., Small, G.W., Huang, S.C., Barrio, J.R., 2001. Binding characteristics of 
radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission 
tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. Journal 
of Neuroscience 21, RC189. 
 2.  Aharon-Peretz, J., Israel, O., Goldsher, D., Peretz, A., 1999. Posterior cortical atrophy 
variants of Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 10, 483-
487. 
 3.  Aizenstein, H.J., Nebes, R.D., Saxton, J.A., Price, J.C., Mathis, C.A., Tsopelas, N.D., 
Ziolko, S.K., James, J.A., Snitz, B.E., Houck, P.R., Bi, W.Z., Cohen, A.D., Lopresti, 
B.J., Dekosky, S.T., Halligan, E.M., Klunk, W.E., 2008. Frequent amyloid deposition 
without significant cognitive impairment among the elderly. Archives of Neurology 65, 
1509-1517. 
 4.  Alladi, S., Xuereb, J., Bak, T., Nestor, P., Knibb, J., Patterson, K., Hodges, J.R., 
2007. Focal cortical presentations of Alzheimer's disease. Brain 130, 2636-2645. 
 5.  Allen, J.S., Bruss, J., Brown, C.K., Damasio, H., 2005. Normal neuroanatomical 
variation due to age: The major lobes and a parcellation of the temporal region. 
Neurobiology of Aging 26, 1245-1260. 
 6.  Anderson, V.M., Bartlett, J.W., Fox, N.C., Fisniku, L., Miller, D.H., 2007. Detecting 
treatment effects on brain atrophy in relapsing remitting multiple sclerosis: Sample 
size estimates. Journal of Neurology 254, 1588-1594. 
 7.  Andrade, K., Samri, D., Sarazin, M., de Souza, L.C., Cohen, L., Thiebaut de, S.M., 
Dubois, B., Bartolomeo, P., 2010. Visual neglect in posterior cortical atrophy. BMC 
Neurology 10, 68. 
 8.  Arnold, S.E., Hyman, B.T., Flory, J., Damasio, A.R., Van Hoesen, G.W., 1991. The 
topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic 
plaques in the cerebral cortex of patients with Alzheimer's disease. Cerebral Cortex 
1, 103-116. 
 9.  Ashburner, J., 2007. A fast diffeomorphic image registration algorithm. Neuroimage 
38, 95-113. 
 10.  Ashburner, J., Friston, K.J., 2000. Voxel-based morphometry - the methods. 
Neuroimage 11, 805-821. 
- 185 - 
 11.  Ashburner, J., Friston, K.J., 2005. Unified segmentation. Neuroimage 26, 839-851. 
 12.  Bacskai, B.J., Frosch, M.P., Freeman, S.H., Raymond, S.B., Augustinack, J.C., 
Johnson, K.A., Irizarry, M.C., Klunk, W.E., Mathis, C.A., Dekosky, S.T., Greenberg, 
S.M., Hyman, B.T., Growdon, J.H., 2007. Molecular imaging with Pittsburgh 
compound B confirmed at autopsy - A case report. Archives of Neurology 64, 431-
434. 
 13.  Ball, M.J., Fisman, M., Hachinski, V., Blume, W., Fox, A., Kral, V.A., Kirshen, A.J., 
Fox, H., Merskey, H., 1985. A new definition of Alzheimer's disease: a hippocampal 
dementia. Lancet 1, 14-16. 
 14.  Barkhof, F., Polvikoski, T.M., van Straaten, E.C., Kalaria, R.N., Sulkava, R., Aronen, 
H.J., Niinisto, L., Rastas, S., Oinas, M., Scheltens, P., Erkinjuntti, T., 2007. The 
significance of medial temporal lobe atrophy: a postmortem MRI study in the very old. 
Neurology 69, 1521-1527. 
 15.  Barnes, J., Bartlett, J.W., van de Pol, L.A., Loy, C.T., Scahill, R.I., Frost, C., 
Thompson, P., Fox, N.C., 2009. A meta-analysis of hippocampal atrophy rates in 
Alzheimer's disease. Neurobiology of Aging 30, 1711-1723. 
 16.  Barnes, J., Godbolt, A.K., Frost, C., Boyes, R.G., Jones, B.F., Scahill, R.I., Rossor, 
M.N., Fox, N.C., 2007a. Atrophy rates of the cingulate gyrus and hippocampus in AD 
and FTLD. Neurobiology of Aging 28, 20-28. 
 17.  Barnes, J., Lewis, E.B., Scahill, R.I., Bartlett, J.W., Frost, C., Schott, J.M., Rossor, 
M.N., Fox, N.C., 2007b. Automated measurement of hippocampal atrophy using fluid-
registered serial MRI in AD and controls. Journal of Computer Assisted Tomography 
31, 581-587. 
 18.  Barnes, J., Mitchell, L.A., Kennedy, J., Bastos-Leite, A.J., Barker, S., Lehmann, M., 
Nordstrom, R.C., Frost, C., Smith, J.R., Garde, E., Rossor, M.N., Fox, N.C., 2010. 
Does registration of serial MRI improve diagnosis of dementia? Neuroradiology 52, 
987-995. 
 19.  Baron, J.C., Chetelat, G., Desgranges, B., Perchey, G., Landeau, B., De La Sayette, 
V., Eustache, F., 2001. In vivo mapping of gray matter loss with voxel-based 
morphometry in mild Alzheimer's disease. Neuroimage 14, 298-309. 
 20.  Basso, M., Yang, J., Warren, L., MacAvoy, M.G., Varma, P., Bronen, R.A., van Dyck, 
C.H., 2006. Volumetry of amygdala and hippocampus and memory performance in 
Alzheimer's disease. Psychiatry Research - Neuroimaging 146, 251-261. 
- 186 - 
 21.  Baumann, T.P., Duyar, H., Sollberger, M., Kuhle, J., Regeniter, A., Gomez-Mancilla, 
B., Schmidtke, K., Monsch, A.U., 2010. CSF-tau and CSF-Abeta(1-42) in posterior 
cortical atrophy. Dementia and Geriatric Cognitive Disorders 29, 530-533. 
 22.  Baxter, D.M., Warrington, E.K., 1994. Measuring dysgraphia: A graded-difficulty 
spelling test. Behavioural Neurology 7, 107-116. 
 23.  Benson, F., Davis, J., Snyder, B.D., 1988. Posterior Cortical atrophy. Archives of 
Neurology 45, 789-793. 
 24.  Bokde, A.L.W., Pietrini, P., Ibanez, V., Furey, M.L., Alexander, G.E., Graff-Radford, 
N.R., Rapoport, S.I., Schapiro, M.B., Horwitz, B., 2001. The effect of brain atrophy on 
cerebral hypometabolism in the visual variant of Alzheimer disease. Archives of 
Neurology 58, 480-486. 
 25.  Bookstein, F.L., 2001. "Voxel-based morphometry" should not be used with 
imperfectly registered images. Neuroimage 14, 1454-1462. 
 26.  Boxer, A.L., Rankin, K.P., Miller, B.L., Schuff, N., Weiner, M., Gorno-Tempini, M.L., 
Rosen, H.J., 2003. Cinguloparietal atrophy distinguishes Alzheimer disease from 
semantic dementia. Archives of Neurology 60, 949-956. 
 27.  Boyes, R.G., Rueckert, D., Aljabar, P., Whitwell, J., Schott, J.M., Hill, D.L., Fox, N.C., 
2006. Cerebral atrophy measurements using Jacobian integration: comparison with 
the boundary shift integral. Neuroimage 32, 159-169. 
 28.  Braak, H., Braak, E., 1991. Neuropathological staging of Alzheimer-related changes. 
Acta Neuropathologica 82, 239-259. 
 29.  Braak, H., Braak, E., 1995. Staging of Alzheimer's disease related neurofibrillary 
changes. Neurobiology of Aging 16, 271-278. 
 30.  Braddick, O.J., O'Brien, J.M.D., Wattam-Bell, J., Atkinson, J., Turner, R., 2000. Form 
and motion coherence activate independent, but not dorsal/ventral segregated, 
networks in the human brain. Current Biology 10, 731-734. 
 31.  Bradley, K.M., Bydder, G.M., Budge, M.M., Hajnal, J.V., White, S.J., Ripley, B.D., 
Smith, A.D., 2002. Serial brain MRI at 3-6 month intervals as a surrogate marker for 
Alzheimer's disease. British Journal of Radiology 75, 506-513. 
 32.  Brayne, C., Richardson, K., Matthews, F.E., Fleming, J., Hunter, S., Xuereb, J.H., 
Paykel, E., Mukaetova-Ladinska, E.B., Huppert, F.A., O'Sullivan, A., Dening, T., 
2009. Neuropathological correlates of dementia in over-80-year-old brain donors from 
- 187 - 
the population-based Cambridge city over-75s cohort (CC75C) study. Journal of 
Alzheimer's disease 18, 645-658. 
 33.  Bresciani, L., Rossi, R., Testa, C., Geroldi, C., Galluzzi, S., Laakso, M.P., Beltramello, 
A., Soininen, H., Frisoni, G.B., 2005. Visual assessment of medial temporal atrophy 
on MR films in Alzheimer's disease: comparison with volumetry. Aging Clinical and 
Experimental Research 17, 8-13. 
 34.  Bresjanac, M., Smid, L.M., Vovko, T.D., Petric, A., Barrio, J.R., Popovic, M., 2003. 
Molecular-imaging probe 2-(1-[6-[(2-fluoroethyl)(methyl) amino]-2-
naphthyl]ethylidene) malononitrile labels prion plaques in vitro. Journal of 
Neuroscience 23, 8029-8033. 
 35.  Broe, M., Hodges, J.R., Schofield, E., Shepherd, C.E., Kril, J.J., Halliday, G.M., 2003. 
Staging disease severity in pathologically confirmed cases of frontotemporal 
dementia. Neurology 60, 1005-1011. 
 36.  Buckner, R.L., Andrews-Hanna, J.R., Schacter, D.L., 2008. The brain's default 
network - Anatomy, function, and relevance to disease. Year in Cognitive 
Neuroscience 2008 1124, 1-38. 
 37.  Buckner, R.L., Head, D., Parker, J., Fotenos, A.F., Marcus, D., Morris, J.C., Snyder, 
A.Z., 2004. A unified approach for morphometric and functional data analysis in 
young, old, and demented adults using automated atlas-based head size 
normalization: reliability and validation against manual measurement of total 
intracranial volume. Neuroimage 23, 724-738. 
 38.  Buckner, R.L., Snyder, A.Z., Shannon, B.J., LaRossa, G., Sachs, R., Fotenos, A.F., 
Sheline, Y.I., Klunk, W.E., Mathis, C.A., Morris, J.C., Mintun, M.A., 2005. Molecular, 
structural, and functional characterization of Alzheimer's disease: evidence for a 
relationship between default activity, amyloid, and memory. Journal of Neuroscience 
25, 7709-7717. 
 39.  Busatto, G.E., Garrido, G.E.J., Almeida, O.P., Castro, C.C., Camargo, C.H.P., Cid, 
C.G., Buchpiguel, C.A., Furuie, S., Bottino, C.M., 2003. A voxel-based morphometry 
study of temporal lobe gray matter reductions in Alzheimer's disease. Neurobiology of 
Aging 24, 221-231. 
 40.  Cairns, N.J., Bigio, E.H., Mackenzie, I.R., Neumann, M., Lee, V.M., Hatanpaa, K.J., 
White, C.L., III, Schneider, J.A., Grinberg, L.T., Halliday, G., Duyckaerts, C., Lowe, 
J.S., Holm, I.E., Tolnay, M., Okamoto, K., Yokoo, H., Murayama, S., Woulfe, J., 
Munoz, D.G., Dickson, D.W., Ince, P.G., Trojanowski, J.Q., Mann, D.M., 2007. 
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar 
- 188 - 
degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. 
Acta Neuropathologica 114, 5-22. 
 41.  Campion, D., Dumanchin, C., Hannequin, D., Dubois, B., Belliard, S., Puel, M., 
Thomas-Anterion, C., Michon, A., Martin, C., Charbonnier, F., Raux, G., Camuzat, A., 
Penet, C., Mesnage, V., Martinez, M., Clerget-Darpoux, F., Brice, A., Frebourg, T., 
1999. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic 
heterogeneity, and mutation spectrum. American Journal of Human Genetics 65, 664-
670. 
 42.  Cardenas, V.A., Du, A.T., Hardin, D., Ezekiel, F., Weber, P., Jagust, W.J., Chui, H.C., 
Schuff, N., Weiner, M.W., 2003. Comparison of methods for measuring longitudinal 
brain change in cognitive impairment and dementia. Neurobiology of Aging 24, 537-
544. 
 43.  Chan, D., Anderson, V., Pijnenburg, Y., Whitwell, J., Barnes, J., Scahill, R., Stevens, 
J.M., Barkhof, F., Scheltens, P., Rossor, M.N., Fox, N.C., 2009. The clinical profile of 
right temporal lobe atrophy. Brain 132, 1287-1298. 
 44.  Chan, D., Crutch, S.J., Warrington, E.K., 2001a. A disorder of colour perception 
associated with abnormal colour after-images: a defect of the primary visual cortex. 
Journal of Neurology Neurosurgery and Psychiatry 71, 515-517. 
 45.  Chan, D., Fox, N., Scahill, R., Crum, W., Whitwell, J., Cipolotti, L., Rossor, M.N., 
2001b. Patterns of temporal lobe atrophy in semantic dementia and Alzheimer's 
disease. Journal of Neurology Neurosurgery and Psychiatry 70, 276. 
 46.  Chan, D., Fox, N.C., Jenkins, R., Scahill, R.I., Crum, W.R., Rossor, M.N., 2001c. 
Rates of global and regional cerebral atrophy in AD and frontotemporal dementia. 
Neurology 57, 1756-1763. 
 47.  Chan, D., Janssen, J.C., Whitwell, J.L., Watt, H.C., Jenkins, R., Frost, C., Rossor, 
M.N., Fox, N.C., 2003. Change in rates of cerebral atrophy over time in early-onset 
Alzheimer's disease: longitudinal MRI study. Lancet 362, 1121-1122. 
 48.  Chang, C.C., Lin, C.J., 2001. Training nu-support vector classifiers: Theory and 
algorithms. Neural Computation 13, 2119-2147. 
 49.  Charles, R.F., Hillis, A.E., 2005. Posterior cortical atrophy: clinical presentation and 
cognitive deficits compared to Alzheimer's disease. Behavioural Neurology 16, 15-23. 
 50.  Chumbley, J., Worsley, K., Flandin, G., Friston, K., 2010. Topological FDR for 
neuroimaging. Neuroimage 49, 3057-3064. 
- 189 - 
 51.  Chumbley, J.R., Friston, K.J., 2009. False discovery rate revisited: FDR and 
topological inference using Gaussian random fields. Neuroimage 44, 62-70. 
 52.  Clark, K.A., Woods, R.P., Rottenberg, D.A., Toga, A.W., Mazziotta, J.C., 2006. 
Impact of acquisition protocols and processing streams on tissue segmentation of TI 
weighted MR images. Neuroimage 29, 185-202. 
 53.  Clegg, F., Warrington, E.K., 1994. Four easy memory tests for older adults. Memory 
2, 167-182. 
 54.  Coffey, C.E., Wilkinson, W.E., Parashos, I.A., Soady, S.A., Sullivan, R.J., Patterson, 
L.J., Figiel, G.S., Webb, M.C., Spritzer, C.E., Djang, W.T., 1992. Quantitative cerebral 
anatomy of the aging human brain: a cross-sectional study using magnetic resonance 
imaging. Neurology 42, 527-536. 
 55.  Cogan, D.G., 1985. Visual disturbances with focal progressive dementing disease. 
American Journal of Ophthalmology 100, 68-72. 
 56.  Cohen, J., 1968. Weighted kappa - Nominal scale agreement with provision for 
scaled disagreement or partial credit. Psychological Bulletin 70, 213-220. 
 57.  Cohen, M.L., Burtis, B., Kwon, J.C., Williamson, J., Heilman, K.M., 2010. Action-
intentional spatial bias in a patient with Posterior Cortical Atrophy. Neurocase, 1-6. 
 58.  Cosentino, S., Scarmeas, N., Helzner, E., Glymour, M.M., Brandt, J., Albert, M., 
Blacker, D., Stern, Y., 2008. APOE epsilon 4 allele predicts faster cognitive decline in 
mild Alzheimer disease. Neurology 70, 1842-1849. 
 59.  Crutch, S.J., Warrington, E.K., 2007. Foveal crowding in posterior cortical atrophy: a 
specific early-visual-processing deficit affecting word reading. Cognitive 
Neuropsychology 24, 843-866. 
 60.  Dale, A.M., Fischl, B., Sereno, M.I., 1999. Cortical surface-based analysis - I. 
Segmentation and surface reconstruction. Neuroimage 9, 179-194. 
 61.  Davatzikos, C., Resnick, S.M., Wu, X., Parmpi, P., Clark, C.M., 2008. Individual 
patient diagnosis of AD and FTD via high-dimensional pattern classification of MRI. 
Neuroimage 41, 1220-1227. 
 62.  De Renzi, E., 1986. Slowly progressive visual agnosia or apraxia without dementia. 
Cortex 22, 171-180. 
 63.  de Souza, L.C., Lamari, F., Belliard, S., Jardel, C., Houillier, C., De, P.R., Dubois, B., 
Sarazin, M., 2011. Cerebrospinal fluid biomarkers in the differential diagnosis of 
- 190 - 
Alzheimer's disease from other cortical dementias. Journal of Neurology 
Neurosurgery and Psychiatry 82, 240-246. 
 64.  DellaSala, S., Spinnler, H., Trivelli, C., 1996. Slowly progressive impairment of spatial 
exploration and visual perception. Neurocase 2, 299-323. 
 65.  Desikan, R.S., Segonne, F., Fischl, B., Quinn, B.T., Dickerson, B.C., Blacker, D., 
Buckner, R.L., Dale, A.M., Maguire, R.P., Hyman, B.T., Albert, M.S., Killiany, R.J., 
2006. An automated labeling system for subdividing the human cerebral cortex on 
MRI scans into gyral based regions of interest. Neuroimage 31, 968-980. 
 66.  Devanand, D.P., Mikhno, A., Pelton, G.H., Cuasay, K., Pradhaban, G., Kumar, J.S.D., 
Upton, N., Lai, R., Gunn, R.N., Libri, V., Liu, X.H., van Heertum, R., Mann, J.J., 
Parsey, R.V., 2010. Pittsburgh Compound B (C-11-PIB) and Fluorodeoxyglucose (F-
18-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and 
healthy controls. Journal of Geriatric Psychiatry and Neurology 23, 185-198. 
 67.  Deyoe, E.A., Carman, G.J., Bandettini, P., Glickman, S., Wieser, J., Cox, R., Miller, 
D., Neitz, J., 1996. Mapping striate and extrastriate visual areas in human cerebral 
cortex. Proceedings of the National Academy of Sciences of the United States of 
America 93, 2382-2386. 
 68.  Diehl-Schmid, J., Grimmer, T., Drzezga, A., Bornschein, S., Perneczky, R., Forstl, H., 
Schwaiger, M., Kurz, A., 2006. Longitudinal changes of cerebral glucose metabolism 
in semantic dementia. Dementia and Geriatric Cognitive Disorders 22, 346-351. 
 69.  Drzezga, A., Grimmer, T., Henriksen, G., Stangier, I., Pemeczky, R., Diehl-Schmid, 
J., Mathis, C.A., Klunck, W.E., Price, J., DeKosky, S., Wester, H.J., Schwaiger, M., 
Kurz, A., 2008. Imaging of amyloid plaques and cerebral glucose metabolism in 
semantic dementia and Alzheimer's disease. Neuroimage 39, 619-633. 
 70.  Du, A.T., Schuff, N., Amend, D., Laakso, M.P., Hsu, Y.Y., Jagust, W.J., Yaffe, K., 
Kramer, J.H., Reed, B., Norman, D., Chui, H.C., Weiner, M.W., 2001. Magnetic 
resonance imaging of the entorhinal cortex and hippocampus in mild cognitive 
impairment and Alzheimer's disease. Journal of Neurology Neurosurgery and 
Psychiatry 71, 441-447. 
 71.  Du, A.T., Schuff, N., Kramer, J.H., Ganzer, S., Zhu, X.P., Jagust, W.J., Miller, B.L., 
Reed, B.R., Mungas, D., Yaffe, K., Chui, H.C., Weiner, M.W., 2004. Higher atrophy 
rate of entorhinal cortex than hippocampus in AD. Neurology 62, 422-427. 
- 191 - 
 72.  Du, A.T., Schuff, N., Kramer, J.H., Rosen, H.J., Gorno-Tempini, M.L., Rankin, K., 
Miller, B.L., Weiner, M.W., 2007. Different regional patterns of cortical thinning in 
Alzheimer's disease and frontotemporal dementia. Brain 130, 1159-1166. 
 73.  Du, A.T., Schuff, N., Zhu, X.P., Jagust, W.J., Miller, B.L., Reed, B.R., Kramer, J.H., 
Mungas, D., Yaffe, K., Chui, H.C., Weiner, M.W., 2003. Atrophy rates of entorhinal 
cortex in AD and normal aging. Neurology 60, 481-486. 
 74.  Duara, R., Loewenstein, D.A., Potter, E., Appel, J., Greig, M.T., Urs, R., Shen, Q., 
Raj, A., Small, B., Barker, W., Schofield, E., Wu, Y., Potter, H., 2008. Medial temporal 
lobe atrophy on MRI scans and the diagnosis of Alzheimer disease. Neurology 71, 
1986-1992. 
 75.  Dubois, B., Feldman, H.H., Jacova, C., Cummings, J.L., Dekosky, S.T., Barberger-
Gateau, P., Delacourte, A., Frisoni, G., Fox, N.C., Galasko, D., Gauthier, S., Hampel, 
H., Jicha, G.A., Meguro, K., O'Brien, J., Pasquier, F., Robert, P., Rossor, M., 
Salloway, S., Sarazin, M., de Souza, L.C., Stern, Y., Visser, P.J., Scheltens, P., 2010. 
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurology 9, 
1118-1127. 
 76.  Dubois, B., Feldman, H.H., Jacova, C., Dekosky, S.T., Barberger-Gateau, P., 
Cummings, J., Delocourte, A., Galasko, D., Gauthier, S., Jicha, G., Meguro, K., 
O'Brien, J., Pasquier, F., Robert, P., Rossor, M., Solloway, S., Stern, Y., Visser, P.J., 
Scheltens, P., 2007. Research criteria for the diagnosis of Alzheimer's disease: 
revising the NINCDS-ADRDA criteria. Lancet Neurology 6, 734-746. 
 77.  Duning, T., Warnecke, T., Mohammadi, S., Lohmann, H., Schiffbauer, H., Kugel, H., 
Knecht, S., Ringelstein, E.B., Deppe, M., 2009. Pattern and progression of white-
matter changes in a case of posterior cortical atrophy using diffusion tensor imaging. 
Journal of Neurology Neurosurgery and Psychiatry 80, 432-436. 
 78.  Efron, R., 1968. What is perception? In: Cohen, R.S., Wartofsky, M.W. (Eds.), Boston 
Studies in the Philosophy of Science. D. Reidel, Dordrecht, The Netherlands, pp. 
137-173. 
 79.  Evans, J.J., Heggs, A.J., Antoun, N., Hodges, J.R., 1995. Progressive prosopagnosia 
associated with selective right temporal lobe atrophy - A new syndrome? Brain 118, 
1-13. 
 80.  Evans, M.C., Barnes, J., Nielsen, C., Kim, L.G., Clegg, S.L., Blair, M., Leung, K.K., 
Douiri, A., Boyes, R.G., Ourselin, S., Fox, N.C., 2010. Volume changes in Alzheimer's 
disease and mild cognitive impairment: cognitive associations. European Radiology 
20, 674-682. 
- 192 - 
 81.  Farrer, L.A., Cupples, L.A., Haines, J.L., Hyman, B., Kukull, W.A., Mayeux, R., Myers, 
R.H., Pericakvance, M.A., Risch, N., vanDuijn, C.M., 1997. Effects of age, sex, and 
ethnicity on the association between apolipoprotein E genotype and Alzheimer 
disease - A meta-analysis. Journal of the American Medical Association 278, 1349-
1356. 
 82.  Fennema-Notestine, C., Mcevoy, L.K., Hagler, D.J., Jr., Jacobson, M.W., Dale, A.M., 
The Alzheimer's Disease Neuroimaging Initiative, 2009. Structural neuroimaging in 
the detection and prognosis of pre-clinical and early AD. Behavioural Neurology 21, 
3-12. 
 83.  Ferri, C.P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., 
Hasegawa, K., Hendrie, H., Huang, Y., Jorm, A., Mathers, C., Menezes, P.R., 
Rimmer, E., Scazufca, M., 2005. Global prevalence of dementia: a Delphi consensus 
study. Lancet 366, 2112-2117. 
 84.  Fischl, B., Salat, D.H., Busa, E., Albert, M., Dieterich, M., Haselgrove, C., van der, 
K.A., Killiany, R., Kennedy, D., Klaveness, S., Montillo, A., Makris, N., Rosen, B., 
Dale, A.M., 2002. Whole brain segmentation: automated labeling of neuroanatomical 
structures in the human brain. Neuron 33, 341-355. 
 85.  Fischl, B., Sereno, M.I., Dale, A.M., 1999. Cortical surface-based analysis - II: 
Inflation, flattening, and a surface-based coordinate system. Neuroimage 9, 195-207. 
 86.  Fjell, A.M., Walhovd, K.B., Fennema-Notestine, C., Mcevoy, L.K., Hagler, D.J., 
Holland, D., Brewer, J.B., Dale, A.M., 2009. One-year brain atrophy evident in healthy 
aging. Journal of Neuroscience 29, 15223-15231. 
 87.  Folstein, M.F., Folstein, S.E., Mchugh, P.R., 1975. Mini-mental state - Practical 
method for grading cognitive state of patients for clinician. Journal of Psychiatric 
Research 12, 189-198. 
 88.  Foster, N.L., Heidebrink, J.L., Clark, C.M., Jagust, W.J., Arnold, S.E., Barbas, N.R., 
DeCarli, C.S., Turner, R.S., Koeppe, R.A., Higdon, R., Minoshima, S., 2007. FDG-
PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's 
disease. Brain 130, 2616-2635. 
 89.  Fox, N.C., Black, R.S., Gilman, S., Rossor, M.N., Griffith, S.G., Jenkins, L., Koller, M., 
2005. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume 
in Alzheimer disease. Neurology 64, 1563-1572. 
- 193 - 
 90.  Fox, N.C., Freeborough, P.A., 1997. Brain atrophy progression measured from 
registered serial MRI: validation and application to Alzheimer's disease. Journal of 
Magnetic Resonance Imaging 7, 1069-1075. 
 91.  Fox, N.C., Freeborough, P.A., Rossor, M.N., 1996a. Visualisation and quantification 
of rates of atrophy in Alzheimer's disease. Lancet 348, 94-97. 
 92.  Fox, N.C., Scahill, R.I., Crum, W.R., Rossor, M.N., 1999. Correlation between rates of 
brain atrophy and cognitive decline in AD. Neurology 52, 1687-1689. 
 93.  Fox, N.C., Schott, J.M., 2004. Imaging cerebral atrophy: normal ageing to Alzheimer's 
disease. Lancet 363, 392-394. 
 94.  Fox, N.C., Warrington, E.K., Stevens, J.M., Rossor, M.N., 1996b. Atrophy of the 
hippocampal formation in early familial Alzheimer's disease. A longitudinal MRI study 
of at-risk members of a family with an amyloid precursor protein 717Val-Gly mutation. 
Annals of the New York Academy of Sciences 777, 226-232. 
 95.  Freeborough, P.A., Fox, N.C., 1997. The boundary shift integral: An accurate and 
robust measure of cerebral volume changes from registered repeat MRI. Ieee 
Transactions on Medical Imaging 16, 623-629. 
 96.  Freeborough, P.A., Fox, N.C., 1998. Modeling brain deformations in Alzheimer 
disease by fluid registration of serial 3D MR images. Journal of Computer Assisted 
Tomography 22, 838-843. 
 97.  Freeborough, P.A., Fox, N.C., Kitney, R.I., 1996. Accurate segmentation of 3D brain 
scans: Interactive software and algorithms. In: Raby, R., Vicars, D. (Eds.), 
Proceedings of the Eurographics 14th Annual Conference  (UK Chapter), pp. 261-
270. 
 98.  Freeborough, P.A., Fox, N.C., Kitney, R.I., 1997. Interactive algorithms for the 
segmentation and quantitation of 3-D MRI brain scans. Computer Methods and 
Programs in Biomedicine 53, 15-25. 
 99.  Freedman, L., Selchen, D.H., Black, S.E., Kaplan, R., Garnett, E.S., Nahmias, C., 
1991. Posterior cortical dementia with alexia: neurobehavioural, MRI, and PET 
findings. Journal of Neurology Neurosurgery and Psychiatry 54, 443-448. 
 100.  Frisoni, G.B., Beltramello, A., Geroldi, C., Weiss, C., Bianchetti, A., Trabucchi, M., 
1996. Brain atrophy in frontotemporal dementia. Journal of Neurology Neurosurgery 
and Psychiatry 61, 157-165. 
- 194 - 
 101.  Frisoni, G.B., Pievani, M., Testa, C., Sabattoli, F., Bresciani, L., Bonetti, M., 
Beltramello, A., Hayashi, K.M., Toga, A.W., Thompson, P.M., 2007. The topography 
of grey matter involvement in early and late onset Alzheimer's disease. Brain 130, 
720-730. 
 102.  Frost, C., Kenward, M.G., Fox, N.C., 2004. The analysis of repeated 'direct' measures 
of change illustrated with an application in longitudinal imaging. Statistics in Medicine 
23, 3275-3286. 
 103.  Galton, C.J., Patterson, K., Graham, K., Lambon-Ralph, M.A., Williams, G., Antoun, 
N., Sahakian, B.J., Hodges, J.R., 2001. Differing patterns of temporal atrophy in 
Alzheimer's disease and semantic dementia. Neurology 57, 216-225. 
 104.  Galton, C.J., Patterson, K., Xuereb, J.H., Hodges, J.R., 2000. Atypical and typical 
presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging 
and pathological study of 13 cases. Brain 123, 484-498. 
 105.  Gee, J., Ding, L.J., Xie, Z.Y., Lin, M., DeVita, C., Grossman, M., 2003. Alzheimer's 
disease and frontotemporal dementia exhibit distinct atrophy-behavior correlates: A 
computer-assisted imaging study. Academic Radiology 10, 1392-1401. 
 106.  Genovese, C.R., Lazar, N.A., Nichols, T., 2002. Thresholding of statistical maps in 
functional neuroimaging using the false discovery rate. Neuroimage 15, 870-878. 
 107.  Goethals, M., Santens, P., 2001. Posterior cortical atrophy. Two case reports and a 
review of the literature. Clinical Neurology and Neurosurgery 103, 115-119. 
 108.  Good, C.D., Johnsrude, I.S., Ashburner, J., Henson, R.N.A., Friston, K.J., 
Frackowiak, R.S.J., 2001. A voxel-based morphometric study of ageing in 465 normal 
adult human brains. Neuroimage 14, 21-36. 
 109.  Good, C.D., Scahill, R.I., Fox, N.C., Ashburner, J., Friston, K.J., Chan, D., Crum, 
W.R., Rossor, M.N., Frackowiak, R.S.J., 2002. Automatic differentiation of anatomical 
patterns in the human brain: validation with studies of degenerative dementias. 
Neuroimage 17, 29-46. 
 110.  Goodale, M.A., Milner, A.D., 1992. Separate visual pathways for perception and 
action. Trends in Neurosciences 15, 20-25. 
 111.  Gordon, E., Rohrer, J.D., Kim, L.G., Omar, R., Rossor, M.N., Fox, N.C., Warren, J.D., 
2010. Measuring disease progression in frontotemporal lobar degeneration: a clinical 
and MRI study. Neurology 74, 666-673. 
- 195 - 
 112.  Gorno-Tempini, M.L., Brambati, S.M., Ginex, V., Ogar, J., Dronkers, N.F., Marcone, 
A., Perani, D., Garibotto, V., Cappa, S.F., Miller, B.L., 2008. The 
logopenic/phonological variant of primary progressive aphasia. Neurology 71, 1227-
1234. 
 113.  Gorno-Tempini, M.L., Dronkers, N.F., Rankin, K.P., Ogar, J.M., Phengrasamy, L., 
Rosen, H.J., Johnson, J.K., Weiner, M.W., Miller, B.L., 2004. Cognition and anatomy 
in three variants of primary progressive aphasia. Annals of Neurology 55, 335-346. 
 114.  Grady, C.L., Springer, M.V., Hongwanishkul, D., McIntosh, A.R., Winocur, G., 2006. 
Age-related changes in brain activity across the adult lifespan. Journal of Cognitive 
Neuroscience 18, 227-241. 
 115.  Greicius, M.D., Krasnow, B., Reiss, A.L., Menon, V., 2003. Functional connectivity in 
the resting brain: A network analysis of the default mode hypothesis. Proceedings of 
the National Academy of Sciences of the United States of America 100, 253-258. 
 116.  Greicius, M.D., Srivastava, G., Reiss, A.L., Menon, V., 2004. Default-mode network 
activity distinguishes Alzheimer's disease from healthy aging: evidence from 
functional MRI. Proceedings of the National Academy of Sciences of the United 
States of America 101, 4637-4642. 
 117.  Grossman, M., McMillan, C., Moore, P., Ding, L.J., Glosser, G., Work, M., Gee, J., 
2004. What's in a name: voxel-based morphometric analyses of MRI and naming 
difficulty in Alzheimer's disease, frontotemporal dementia and corticobasal 
degeneration. Brain 127, 628-649. 
 118.  Gutierrez-Galve, L., Lehmann, M., Hobbs, N.Z., Clarkson, M.J., Ridgway, G.R., 
Crutch, S., Ourselin, S., Schott, J.M., Fox, N.C., Barnes, J., 2009. Patterns of cortical 
thickness according to APOE genotype in Alzheimer's disease. Dementia and 
Geriatric Cognitive Disorders 28, 476-485. 
 119.  Hammers, A., Allom, R., Koepp, M.J., Free, S.L., Myers, R., Lemieux, L., Mitchell, 
T.N., Brooks, D.J., Duncan, J.S., 2003. Three-dimensional maximum probability atlas 
of the human brain, with particular reference to the temporal lobe. Human Brain 
Mapping 19, 224-247. 
 120.  Han, X., Jovicich, J., Salat, D., van der Kouwe, A., Quinn, B., Czanner, S., Busa, E., 
Pacheco, J., Albert, M., Killiany, R., Maguire, P., Rosas, D., Makris, N., Dale, A., 
Dickerson, B., Fischl, B., 2006. Reliability of MRI-derived measurements of human 
cerebral cortical thickness: The effects of field strength, scanner upgrade and 
manufacturer. Neuroimage 32, 180-194. 
- 196 - 
 121.  Harvey, R.J., Skelton-Robinson, M., Rossor, M.N., 2003. The prevalence and causes 
of dementia in people under the age of 65 years. Journal of Neurology Neurosurgery 
and Psychiatry 74, 1206-1209. 
 122.  Hashimoto, M., Kazui, H., Matsumoto, K., Nakano, Y., Yasuda, M., Mori, E., 2005. 
Does donepezil treatment slow the progression of hippocampal atrophy in patients 
with Alzheimer's disease? American Journal of Psychiatry 162, 676-682. 
 123.  Hashimoto, M., Yasuda, M., Tanimukai, S., Matsui, M., Hirono, N., Kazui, H., Mori, E., 
2001. Apolipoprotein E epsilon 4 and the pattern of regional brain atrophy in 
Alzheimer's disease. Neurology 57, 1461-1466. 
 124.  Hebert, L.E., Scherr, P.A., Bienias, J.L., Bennett, D.A., Evans, D.A., 2003. Alzheimer 
disease in the US population - Prevalence estimates using the 2000 census. Archives 
of Neurology 60, 1119-1122. 
 125.  Henley, S.M.D., Frost, C., MacManus, D.G., Warner, T.T., Fox, N.C., Tabrizi, S.J., 
2006. Increased rate of whole-brain atrophy over 6 months in early Huntington 
disease. Neurology 67, 694-696. 
 126.  Hodges, J.R., Davies, R.R., Xuereb, J.H., Casey, B., Broe, M., Bak, T.H., Kril, J.J., 
Halliday, G.M., 2004. Clinicopathological correlates in frontotemporal dementia. 
Annals of Neurology 56, 399-406. 
 127.  Hodges, J.R., Patterson, K., 2007. Semantic dementia: a unique clinicopathological 
syndrome. Lancet Neurology 6, 1004-1014. 
 128.  Hof, P.R., Archin, N., Osmand, A.P., Dougherty, J.H., Wells, C., Bouras, C., Morrison, 
J.H., 1993. Posterior cortical atrophy in Alzheimer's disease - Analysis of a new case 
and reevaluation of a historical report. Acta Neuropathologica 86, 215-223. 
 129.  Hof, P.R., Bouras, C., Constantinidis, J., Morrison, J.H., 1989. Balint's syndrome in 
Alzheimer's disease: specific disruption of the occipito-parietal visual pathway. Brain 
Research 493, 368-375. 
 130.  Hof, P.R., Bouras, C., Constantinidis, J., Morrison, J.H., 1990. Selective 
disconnection of specific visual association pathways in cases of Alzheimer's disease 
presenting with Balint's syndrome. Journal of Neuropathology and Experimental 
Neurology 49, 168-184. 
 131.  Hof, P.R., Vogt, B.A., Bouras, C., Morrison, J.H., 1997. Atypical form of Alzheimer's 
disease with prominent posterior cortical atrophy: a review of lesion distribution and 
circuit disconnection in cortical visual pathways. Vision Research 37, 3609-3625. 
- 197 - 
 132.  Holm, I.E., Isaacs, A.M., Mackenzie, I.R.A., 2009. Absence of FUS-immunoreactive 
pathology in frontotemporal dementia linked to chromosome 3 (FTD-3) caused by 
mutation in the CHMP2B gene. Acta Neuropathologica 118, 719-720. 
 133.  Hort, J., O'Brien, J.T., Gainotti, G., Pirttila, T., Popescu, B.O., Rektorova, I., Sorbi, S., 
Scheltens, P., 2010. EFNS guidelines for the diagnosis and management of 
Alzheimer's disease. European Journal of Neurology 17, 1236-1248. 
 134.  Ikonomovic, M.D., Klunk, W.E., Abrahamson, E.E., Mathis, C.A., Price, J.C., 
Tsopelas, N.D., Lopresti, B.J., Ziolko, S., Bi, W.Z., Paljug, W.R., Debnath, M.L., 
Hope, C.E., Isanski, B.A., Hamilton, R.L., Dekosky, S.T., 2008. Post-mortem 
correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's 
disease. Brain 131, 1630-1645. 
 135.  Insausti, R., Juottonen, K., Soininen, H., Insausti, A.M., Partanen, K., Vainio, P., 
Laakso, M.P., Pitkanen, A., 1998. MR volumetric analysis of the human entorhinal, 
perirhinal, and temporopolar cortices. American Journal of Neuroradiology 19, 659-
671. 
 136.  Ishii, K., Kawachi, T., Sasaki, H., Kono, A.K., Fukuda, T., Kojima, Y., Mori, E., 2005a. 
Voxel-based morphometric comparison between early- and late-onset mild 
Alzheimer's disease and assessment of diagnostic performance of Z score images. 
American Journal of Neuroradiology 26, 333-340. 
 137.  Ishii, K., Sasaki, H., Kono, A.K., Miyamoto, N., Fukuda, T., Mori, E., 2005b. 
Comparison of gray matter and metabolic reduction in mild Alzheimer's disease using 
FDG-PET and voxel-based morphometric MR studies. European Journal of Nuclear 
Medicine and Molecular Imaging 32, 959-963. 
 138.  Jack, C.R., Jr., 1994. MRI-based hippocampal volume measurements in epilepsy. 
Epilepsia 35 Suppl 6, S21-S29. 
 139.  Jack, C.R., Jr., Petersen, R.C., O'Brien, P.C., Tangalos, E.G., 1992. MR-based 
hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology 42, 183-
188. 
 140.  Jack, C.R., Jr., Petersen, R.C., Xu, Y., O'Brien, P.C., Smith, G.E., Ivnik, R.J., Boeve, 
B.F., Tangalos, E.G., Kokmen, E., 2000. Rates of hippocampal atrophy correlate with 
change in clinical status in aging and AD. Neurology 55, 484-489. 
 141.  Jack, C.R., Jr., Petersen, R.C., Xu, Y., O'Brien, P.C., Smith, G.E., Ivnik, R.J., 
Tangalos, E.G., Kokmen, E., 1998. Rate of medial temporal lobe atrophy in typical 
aging and Alzheimer's disease. Neurology 51, 993-999. 
- 198 - 
 142.  Jack, C.R., Petersen, R.C., Xu, Y.C., O'Brien, P.C., Smith, G.E., Ivnik, R.J., Boeve, 
B.F., Waring, S.C., Tangalos, E.G., Kokmen, E., 1999. Prediction of AD with MRI-
based hippocampal volume in mild cognitive impairment. Neurology 52, 1397-1403. 
 143.  Jack, C.R., Jr., Petersen, R.C., Xu, Y.C., Waring, S.C., O'Brien, P.C., Tangalos, E.G., 
Smith, G.E., Ivnik, R.J., Kokmen, E., 1997. Medial temporal atrophy on MRI in normal 
aging and very mild Alzheimer's disease. Neurology 49, 786-794. 
 144.  Jack, C.R., Jr., Shiung, M.M., Gunter, J.L., O'Brien, P.C., Weigand, S.D., Knopman, 
D.S., Boeve, B.F., Ivnik, R.J., Smith, G.E., Cha, R.H., Tangalos, E.G., Petersen, R.C., 
2004. Comparison of different MRI brain atrophy rate measures with clinical disease 
progression in AD. Neurology 62, 591-600. 
 145.  Jack, C.R., Jr., Shiung, M.M., Weigand, S.D., O'Brien, P.C., Gunter, J.L., Boeve, B.F., 
Knopman, D.S., Smith, G.E., Ivnik, R.J., Tangalos, E.G., Petersen, R.C., 2005. Brain 
atrophy rates predict subsequent clinical conversion in normal elderly and amnestic 
MCI. Neurology 65, 1227-1231. 
 146.  Jackson, M., Warrington, E.K., 1986. Arithmetic skills in patients with unilateral 
cerebral lesions. Cortex 22, 611-620. 
 147.  James, M., Plant, G.T., Warrington, E.K., 2001. Cortical vision screening test. 
Manual. Thames Valley Test Company Limited, Bury St. Edmunds, England. 
 148.  Janes, H., Longton, G., Pepe, M.S., 2009. Accommodating covariates in receiver 
operating characteristic analysis. Stata Journal 9, 17-39. 
 149.  Jellinger, K.A., 2006. Clinicopathological analysis of dementia disorders in the elderly 
- an update. Journal of Alzheimer's disease 9, 61-70. 
 150.  Jellinger, K.A., Attems, J., 2005. Prevalence and pathogenic role of cerebrovascular 
lesions in Alzheimer disease. Journal of Neurological Sciences 229-230, 37-41. 
 151.  Jellinger, K.A., Attems, J., 2008. Prevalence and impact of vascular and Alzheimer 
pathologies in Lewy body disease. Acta Neuropathologica 115, 427-436. 
 152.  Johnson, J.K., Head, E., Kim, R., Starr, A., Cotman, C.W., 1999. Clinical and 
pathological evidence for a frontal variant of Alzheimer disease. Archives of 
Neurology 56, 1233-1239. 
 153.  Johnson, K.A., Jones, K., Holman, B.L., Becker, J.A., Spiers, P.A., Satlin, A., Albert, 
M.S., 1998. Preclinical prediction of Alzheimer's disease using SPECT. Neurology 50, 
1563-1571. 
- 199 - 
 154.  Jones, B.F., Barnes, J., Uylings, H.B.M., Fox, N.C., Frost, C., Witter, M.P., Scheftens, 
P., 2006. Differential regional atrophy of the cingulate gyrus in Alzheimer disease: A 
volumetric MRI study. Cerebral Cortex 16, 1701-1708. 
 155.  Jorm, A.F., Jolley, D., 1998. The incidence of dementia: a meta-analysis. Neurology 
51, 728-733. 
 156.  Josephs, K.A., Whitwell, J.L., Parisi, J.E., Petersen, R.C., Boeve, B.F., Jack, C.R., 
Dickson, D.W., 2010. Caudate atrophy on MRI is a characteristic feature of FTLD-
FUS. European Journal of Neurology 17, 969-975. 
 157.  Juottonen, K., Laakso, M.P., Insausti, R., Lehtovirta, M., Pitkanen, A., Partanen, K., 
Soininen, H., 1998. Volumes of the entorhinal and perirhinal cortices in Alzheimer's 
disease. Neurobiology of Aging 19, 15-22. 
 158.  Juottonen, K., Laakso, M.P., Partanen, K., Soininen, H., 1999. Comparative MR 
analysis of the entorhinal cortex and hippocampus in diagnosing Alzheimer disease. 
American Journal of Neuroradiology 20, 139-144. 
 159.  Kambe, T., Motoi, Y., Ishii, K., Hattori, N., 2010. Posterior cortical atrophy with [C-11] 
Pittsburgh compound B accumulation in the primary visual cortex. Journal of 
Neurology 257, 469-471. 
 160.  Karas, G., Scheltens, P., Rombouts, S., van Schijndel, R., Klein, M., Jones, B., van 
der Flier, W., Vrenken, H., Barkhof, F., 2007. Precuneus atrophy in early-onset 
Alzheimer's disease: A morphometric structural MRI study. Neuroradiology 49, 967-
976. 
 161.  Karas, G.B., Scheltens, P., Rombouts, S.A.R.B., Visser, P.J., van Schijndel, R.A., 
Fox, N.C., Barkhof, F., 2004. Global and local gray matter loss in mild cognitive 
impairment and Alzheimer's disease. Neuroimage 23, 708-716. 
 162.  Kemppainen, N.M., Aalto, S., Wilson, I.A., Nagren, K., Helin, S., Bruck, A., Oikonen, 
V., Kailajarvi, M., Scheinin, M., Viitanen, M., Parkkola, R., Rinne, J.O., 2007. PET 
amyloid ligand [C-11]PIB uptake is increased in mild cognitive impairment. Neurology 
68, 1603-1606. 
 163.  Kennedy, J., Lehmann, M., Sokolska, M.J., Archer, H., Warrington, E.K., Fox, N.C., 
Crutch, S.J., 2011. Visualising the emergence of posterior cortical atrophy. 
Neurocase in press. 
 164.  Killiany, R.J., Gomez-Isla, T., Moss, M., Kikinis, R., Sandor, T., Jolesz, F., Tanzi, R., 
Jones, K., Hyman, B.T., Albert, M.S., 2000. Use of structural magnetic resonance 
- 200 - 
imaging to predict who will get Alzheimer's disease. Annals of Neurology 47, 430-
439. 
 165.  Killiany, R.J., Moss, M.B., Albert, M.S., Sandor, T., Tieman, J., Jolesz, F., 1993. 
Temporal lobe regions on magnetic resonance imaging identify patients with early 
Alzheimer's disease. Archives of Neurology 50, 949-954. 
 166.  Kitagaki, H., Mori, E., Yamaji, S., Ishii, K., Hirono, N., Kobashi, S., Hata, Y., 1998. 
Frontotemporal dementia and Alzheimer disease: Evaluation of cortical atrophy with 
automated hemispheric surface display generated with MR images. Radiology 208, 
431-439. 
 167.  Klauschen, F., Goldman, A., Barra, V., Meyer-Lindenberg, A., Lundervold, A., 2009. 
Evaluation of automated brain MR image segmentation and volumetry methods. 
Human Brain Mapping 30, 1310-1327. 
 168.  Kloppel, S., Stonnington, C.M., Chu, C., Draganski, B., Scahill, R.I., Rohrer, J.D., 
Fox, N.C., Jack, C.R., Jr., Ashburner, J., Frackowiak, R.S., 2008. Automatic 
classification of MR scans in Alzheimer's disease. Brain 131, 681-689. 
 169.  Klunk, W.E., Engler, H., Nordberg, A., Wang, Y.M., Blomqvist, G., Holt, D.P., 
Bergstrom, M., Savitcheva, I., Huang, G.F., Estrada, S., Ausen, B., Debnath, M.L., 
Barletta, J., Price, J.C., Sandell, J., Lopresti, B.J., Wall, A., Koivisto, P., Antoni, G., 
Mathis, C.A., Langstrom, B., 2004. Imaging brain amyloid in Alzheimer's disease with 
Pittsburgh Compound-B. Annals of Neurology 55, 306-319. 
 170.  Knibb, J.A., Woollams, A.M., Hodges, J.R., Patterson, K., 2009. Making sense of 
progressive non-fluent aphasia: an analysis of conversational speech. Brain 132, 
2734-2746. 
 171.  Knibb, J.A., Xuereb, J.H., Patterson, K., Hodges, J.R., 2006. Clinical and pathological 
characterization of progressive aphasia. Annals of Neurology 59, 156-165. 
 172.  Knight, W.D., Okello, A.A., Ryan, N.S., Turkheimer, F.E., de Llano, S.R.M., Edison, 
P., Douglas, J., Fox, N.C., Brooks, D.J., Rossor, M.N., 2011. Carbon-11-Pittsburgh 
compound B positron emission tomography imaging of amyloid deposition in 
presenilin 1 mutation carriers. Brain 134, 293-300. 
 173.  Knopman, D.S., Dekosky, S.T., Cummings, J.L., Chui, H., Corey-Bloom, J., Relkin, 
N., Small, G.W., Miller, B., Stevens, J.C., 2001. Practice parameter: diagnosis of 
dementia (an evidence-based review). Report of the Quality Standards Subcommittee 
of the American Academy of Neurology. Neurology 56, 1143-1153. 
- 201 - 
 174.  Knopman, D.S., Jack, C.R., Jr., Kramer, J.H., Boeve, B.F., Caselli, R.J., Graff-
Radford, N.R., Mendez, M.F., Miller, B.L., Mercaldo, N.D., 2009. Brain and ventricular 
volumetric changes in frontotemporal lobar degeneration over 1 year. Neurology 72, 
1843-1849. 
 175.  Korf, E.S.C., Wahlund, L.O., Visser, P.J., Scheltens, P., 2004. Medial temporal lobe 
atrophy on MRI predicts dementia in patients with mild cognitive impairment. 
Neurology 63, 94-100. 
 176.  Laakso, M.P., Frisoni, G.B., Kononen, M., Mikkonen, M., Beltramello, A., Geroldi, C., 
Bianchetti, A., Trabucchi, M., Soininen, H., Aronen, H.J., 2000. Hippocampus and 
entorhinal cortex in frontotemporal dementia and Alzheimer's disease: A 
morphometric MRI study. Biological Psychiatry 47, 1056-1063. 
 177.  Lehericy, S., Baulac, M., Chiras, J., Pierot, L., Martin, N., Pillon, B., Deweer, B., 
Dubois, B., Marsault, C., 1994. Amygdalohippocampal MR volume measurements in 
the early stages of Alzheimer disease. American Journal of Neuroradiology 15, 929-
937. 
 178.  Lehmann, M., Douiri, A., Kim, L.G., Modat, M., Chan, D., Ourselin, S., Barnes, J., 
Fox, N.C., 2010. Atrophy patterns in Alzheimer's disease and semantic dementia: a 
comparison of FreeSurfer and manual volumetric measurements. Neuroimage 49, 
2264-2274. 
 179.  Lerch, J.P., Pruessner, J., Zijdenbos, A.P., Collins, D.L., Teipel, S.J., Hampel, H., 
Evans, A.C., 2008. Automated cortical thickness measurements from MRI can 
accurately separate Alzheimer's patients from normal elderly controls. Neurobiology 
of Aging 29, 23-30. 
 180.  Lerch, J.P., Pruessner, J.C., Zijdenbos, A., Hampel, H., Teipel, S.J., Evans, A.C., 
2005. Focal decline of cortical thickness in Alzheimer's disease identified by 
computational neuroanatomy. Cerebral Cortex 15, 995-1001. 
 181.  Leung, K.K., Clarkson, M.J., Bartlett, J.W., Clegg, S., Jack, C.R., Weiner, M.W., Fox, 
N.C., Ourselin, S., 2010. Robust atrophy rate measurement in Alzheimer's disease 
using multi-site serial MRI: Tissue-specific intensity normalization and parameter 
selection. Neuroimage 50, 516-523. 
 182.  Levine, D.N., Lee, J.M., Fisher, C.M., 1993. The visual variant of Alzheimer's disease: 
a clinicopathologic case study. Neurology 43, 305-313. 
 183.  Lewis, E.B., Fox, N.C., 2004. Correction of differential intensity inhomogeneity in 
longitudinal MR images. Neuroimage 23, 75-83. 
- 202 - 
 184.  Likeman, M., Anderson, V.M., Stevens, J.M., Waldman, A.D., Godbolt, A.K., Frost, 
C., Rossor, M.N., Fox, N.C., 2005. Visual assessment of atrophy on magnetic 
resonance imaging in the diagnosis of pathologically confirmed young-onset 
dementias. Archives of Neurology 62, 1410-1415. 
 185.  Lustig, C., Snyder, A.Z., Bhakta, M., O'Brien, K.C., McAvoy, M., Raichle, M.E., Morris, 
J.C., Buckner, R.L., 2003. Functional deactivations: change with age and dementia of 
the Alzheimer type. Proceedings of the National Academy of Sciences of the United 
States of America 100, 14504-14509. 
 186.  MacDonald, D., Kabani, N., Avis, D., Evans, A.C., 2000. Automated 3-D extraction of 
inner and outer surfaces of cerebral cortex from MRI. Neuroimage 12, 340-356. 
 187.  Mackenzie, I.R.A., Baborie, A., Pickering-Brown, S., Du Plessis, D., Jaros, E., Perry, 
R.H., Neary, D., Snowden, J.S., Mann, D.M.A., 2006. Heterogeneity of ubiquitin 
pathology in frontotemporal lobar degeneration: classification and relation to clinical 
phenotype. Acta Neuropathologica 112, 539-549. 
 188.  Mackenzie, I.R.A., Neumann, M., Bigio, E.H., Cairns, N.J., Alafuzoff, I., Kril, J., 
Kovacs, G.G., Ghetti, B., Halliday, G., Holm, I.E., Ince, P.G., Kamphorst, W., Revesz, 
T., Rozemuller, A.J.M., Kumar-Singh, S., Akiyama, H., Baborie, A., Spina, S., 
Dickson, D.W., Trojanowski, J.Q., Mann, D.M.A., 2010. Nomenclature and nosology 
for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta 
Neuropathologica 119, 1-4. 
 189.  Marra, C., Bizzarro, A., Daniele, A., De Luca, L., Ferraccioli, M., Valenza, A., Brahe, 
C., Tiziano, F.D., Gainotti, G., Masullo, C., 2004. Apolipoprotein E epsilon 4 allele 
differently affects the patterns of neuropsychological presentation in early- and late-
onset Alzheimer's disease patients. Dementia and Geriatric Cognitive Disorders 18, 
125-131. 
 190.  Matsuda, H., 2001. Cerebral blood flow and metabolic abnormalities in Alzheimer's 
disease. Annals of Nuclear Medicine 15, 85-92. 
 191.  Mazziotta, J.C., Toga, A.W., Evans, A., Fox, P., Lancaster, J., 1995. A probabilistic 
atlas of the human brain - Theory and rationale for its development. Neuroimage 2, 
89-101. 
 192.  McKeith, I.G., Galasko, D., Kosaka, K., Perry, E.K., Dickson, D.W., Hansen, L.A., 
Salmon, D.P., Lowe, J., Mirra, S.S., Byrne, E.J., Lennox, G., Quinn, N.P., Edwardson, 
J.A., Ince, P.G., Bergeron, C., Burns, A., Miller, B.L., Lovestone, S., Collerton, D., 
Jansen, E.N.H., Ballard, C., Devos, R.A.I., Wilcock, G.K., Jellinger, K.A., Perry, R.H., 
1996. Consensus guidelines for the clinical and pathologic diagnosis of dementia with 
- 203 - 
Lewy bodies (DLB): Report of the consortium on DLB international workshop. 
Neurology 47, 1113-1124. 
 193.  McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., 
1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work 
Group under the auspices of Department of Health and Human Services Task Force 
on Alzheimer's Disease. Neurology 34, 939-944. 
 194.  McMonagle, P., Deering, F., Berliner, Y., Kertesz, A., 2006. The cognitive profile of 
posterior cortical atrophy. Neurology 66, 331-338. 
 195.  Mendez, M.F., Ghajarania, M., Perryman, K.M., 2002. Posterior cortical atrophy: 
Clinical characteristics and differences compared to Alzheimer's disease. Dementia 
and Geriatric Cognitive Disorders 14, 33-40. 
 196.  Mesulam, M.M., 2001. Primary progressive aphasia. Annals of Neurology 49, 425-
432. 
 197.  Meyer, M.R., Tschanz, J.T., Norton, M.C., Welsh-Bohmer, K.A., Steffens, D.C., 
Wyse, B.W., Breitner, J.C., 1998. APOE genotype predicts when--not whether--one is 
predisposed to develop Alzheimer disease. Nature Genetics 19, 321-322. 
 198.  Migliaccio, R., Agosta, F., Rascovsky, K., Karydas, A., Bonasera, S., Rabinovici, 
G.D., Miller, B.L., Gorno-Tempini, M.L., 2009. Clinical syndromes associated with 
posterior atrophy early age at onset AD spectrum. Neurology 73, 1571-1578. 
 199.  Miller, S.L., Celone, K., DePeau, K., Diamond, E., Dickerson, B.C., Rentz, D., 
Pihlajamaki, M., Sperling, R.A., 2008. Age-related memory impairment associated 
with loss of parietal deactivation but preserved hippocampal activation. Proceedings 
of the National Academy of Sciences of the United States of America 105, 2181-
2186. 
 200.  Minoshima, S., Giordani, B., Berent, S., Frey, K.A., Foster, N.L., Kuhl, D.E., 1997. 
Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's 
disease. Annals of Neurology 42, 85-94. 
 201.  Morey, R.A., Petty, C.M., Xu, Y., Hayes, J.P., Wagner, H.R., Lewis, D.V., Labar, K.S., 
Styner, M., McCarthy, G., 2009. A comparison of automated segmentation and 
manual tracing for quantifying hippocampal and amygdala volumes. Neuroimage 45, 
855-866. 
- 204 - 
 202.  Mosconi, L., 2005. Brain glucose metabolism in the early and specific diagnosis of 
Alzheimer's disease. FDG-PET studies in MCI and AD. European Journal of Nuclear 
Medicine and Molecular Imaging 32, 486-510. 
 203.  Mungas, D., Harvey, D., Reed, B.R., Jagust, W.J., DeCarli, C., Beckett, L., Mack, 
W.J., Kramer, J.H., Weiner, M.W., Schuff, N., Chui, H.C., 2005. Longitudinal 
volumetric MRI change and rate of cognitive decline. Neurology 65, 565-571. 
 204.  Neary, D., Snowden, J., 1996. Fronto-temporal dementia: Nosology, 
neuropsychology, and neuropathology. Brain and Cognition 31, 176-187. 
 205.  Neary, D., Snowden, J.S., Gustafson, L., Passant, U., Stuss, D., Black, S., 
Freedman, M., Kertesz, A., Robert, P.H., Albert, M., Boone, K., Miller, B.L., 
Cummings, J., Benson, D.F., 1998. Frontotemporal lobar degeneration - A consensus 
on clinical diagnostic criteria. Neurology 51, 1546-1554. 
 206.  Nestor, P.J., Caine, D., Fryer, T.D., Clarke, J., Hodges, J.R., 2003. The topography of 
metabolic deficits in posterior cortical atrophy (the visual variant of Alzheimer's 
disease) with FDG-PET. Journal of Neurology Neurosurgery and Psychiatry 74, 
1521-1529. 
 207.  Neumann, M., Rademakers, R., Roeber, S., Baker, M., Kretzschmar, H.A., 
Mackenzie, I.R.A., 2009a. A new subtype of frontotemporal lobar degeneration with 
FUS pathology. Brain 132, 2922-2931. 
 208.  Neumann, M., Roeber, S., Kretzschmar, H.A., Rademakers, R., Baker, M., 
Mackenzie, I.R.A., 2009b. Abundant FUS-immunoreactive pathology in neuronal 
intermediate filament inclusion disease. Acta Neuropathologica 118, 605-616. 
 209.  Neumann, M., Sampathu, D.M., Kwong, L.K., Truax, A.C., Micsenyi, M.C., Chou, 
T.T., Bruce, J., Schuck, T., Grossman, M., Clark, C.M., McCluskey, L.F., Miller, B.L., 
Masliah, E., Mackenzie, I.R., Feldman, H., Feiden, W., Kretzschmar, H.A., 
Trojanowski, J.Q., Lee, V.M.Y., 2006. Ubiquitinated TDP-43 in frontotemporal lobar 
degeneration and amyotrophic lateral sclerosis. Science 314, 130-133. 
 210.  Ng, S.Y., Villemagne, V.L., Masters, C.L., Rowe, C.C., 2007. Evaluating atypical 
dementia syndromes using positron emission tomography with carbon 11 labeled 
Pittsburgh Compound B. Archives of Neurology 64, 1140-1144. 
 211.  O'Brien, J.T., Paling, S., Barber, R., Williams, E.D., Ballard, C., McKeith, I.G., 
Gholkar, A., Crum, W.R., Rossor, M.N., Fox, N.C., 2001. Progressive brain atrophy 
on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology 
56, 1386-1388. 
- 205 - 
 212.  Okuizumi, K., Onodera, O., Tanaka, H., Kobayashi, H., Tsuji, S., Takahashi, H., 
Oyanagi, K., Seki, K., Tanaka, M., Naruse, S., 1994. ApoE-epsilon 4 and early-onset 
Alzheimer's. Nature Genetics 7, 10-11. 
 213.  Otten, L.J., Rugg, M.D., 2001. When more means less: neural activity related to 
unsuccessful memory encoding. Current Biology 11, 1528-1530. 
 214.  Palop, J.J., Chin, J., Mucke, L., 2006. A network dysfunction perspective on 
neurodegenerative diseases. Nature 443, 768-773. 
 215.  Pantel, J., O'Leary, D.S., Cretsinger, K., Bockholt, H.J., Keefe, H., Magnotta, V.A., 
Andreasen, N.C., 2000. A new method for the in vivo volumetric measurement of the 
human hippocampus with high neuroanatomical accuracy. Hippocampus 10, 752-
758. 
 216.  Paviour, D.C., Price, S.L., Jahanshahi, M., Lees, A.J., Fox, N.C., 2006. Longitudinal 
MRI in progressive supranuclear palsy and multiple system atrophy: rates and 
regions of atrophy. Brain 129, 1040-1049. 
 217.  Pellerin, L., Magistretti, P.J., 1994. Glutamate uptake into astrocytes stimulates 
aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. 
Proceedings of the National Academy of Sciences of the United States of America 
91, 10625-10629. 
 218.  Pendleton, N., Payton, A., van den Boogerd, E.H., Holland, F., Diggle, P., Rabbitt, 
P.M.A., Horan, M.A., Worthington, J., Ollier, W.E.R., 2002. Apolipoprotein E genotype 
does not predict decline in intelligence in healthy older adults. Neuroscience Letters 
324, 74-76. 
 219.  Pfefferbaum, A., Mathalon, D.H., Sullivan, E.V., Rawles, J.M., Zipursky, R.B., Lim, 
K.O., 1994. A quantitative magnetic resonance imaging study of changes in brain 
morphology from infancy to late adulthood. Archives of Neurology 51, 874-887. 
 220.  Pietrini, P., Furey, M.L., GraffRadford, N., Freo, U., Alexander, G.E., Grady, C.L., 
Dani, A., Mentis, M.J., Schapiro, M.B., 1996. Preferential metabolic involvement of 
visual cortical areas in a subtype of Alzheimer's disease: Clinical implications. 
American Journal of Psychiatry 153, 1261-1268. 
 221.  Pihlajamaki, M., Depeau, K.M., Blacker, D., Sperling, R.A., 2008. Impaired medial 
temporal repetition suppression is related to failure of parietal deactivation in 
Alzheimer disease. American Journal of Geriatric Psychiatry 16, 283-292. 
- 206 - 
 222.  Pruessner, J.C., Li, L.M., Serles, W., Pruessner, M., Collins, D.L., Kabani, N., Lupien, 
S., Evans, A.C., 2000. Volumetry of hippocampus and amygdala with high-resolution 
MRI and three-dimensional analysis software: minimizing the discrepancies between 
laboratories. Cerebral Cortex 10, 433-442. 
 223.  Rabinovici, G.D., Furst, A.J., O'Neil, J.P., Racine, C.A., Mormino, E.C., Baker, S.L., 
Chetty, S., Patel, P., Pagliaro, T.A., Klunk, W.E., Mathis, C.A., Rosen, H.J., Miller, 
B.L., Jagust, W.J., 2007. C-11-PIB PET imaging in Alzheimer disease and 
frontotemporal lobar degeneration. Neurology 68, 1205-1212. 
 224.  Rabinovici, G.D., Jagust, W.J., 2009. Amyloid imaging in aging and dementia: testing 
the amyloid hypothesis in vivo. Behavioural Neurology 21, 117-128. 
 225.  Raichle, M.E., MacLeod, A.M., Snyder, A.Z., Powers, W.J., Gusnard, D.A., Shulman, 
G.L., 2001. A default mode of brain function. Proceedings of the National Academy of 
Sciences of the United States of America 98, 676-682. 
 226.  Ratnavalli, E., Brayne, C., Dawson, K., Hodges, J.R., 2002. The prevalence of 
frontotemporal dementia. Neurology 58, 1615-1621. 
 227.  Raz, N., Gunning-Dixon, F., Head, D., Rodrigue, K.M., Williamson, A., Acker, J.D., 
2004. Aging, sexual dimorphism, and hemispheric asymmetry of the cerebral cortex: 
replicability of regional differences in volume. Neurobiology of Aging 25, 377-396. 
 228.  Renner, J.A., Burns, J.M., Hou, C.E., McKeel, D.W., Jr., Storandt, M., Morris, J.C., 
2004. Progressive posterior cortical dysfunction: a clinicopathologic series. Neurology 
63, 1175-1180. 
 229.  Resnick, S.M., Goldszal, A.F., Davatzikos, C., Golski, S., Kraut, M.A., Metter, E.J., 
Bryan, R.N., Zonderman, A.B., 2000. One-year age changes in MRI brain volumes in 
older adults. Cerebral Cortex 10, 464-472. 
 230.  Resnick, S.M., Pham, D.L., Kraut, M.A., Zonderman, A.B., Davatzikos, C., 2003. 
Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain. 
Journal of Neuroscience 23, 3295-3301. 
 231.  Richards, B.A., Chertkow, H., Singh, V., Robillard, A., Massoud, F., Evan, A.C., 
Kabani, N.J., 2009. Patterns of cortical thinning in Alzheimer's disease and 
frontotemporal dementia. Neurobiology of Aging 30, 1626-1636. 
 232.  Ridgway, G.R., Henley, S.M., Rohrer, J.D., Scahill, R.I., Warren, J.D., Fox, N.C., 
2008. Ten simple rules for reporting voxel-based morphometry studies. Neuroimage 
40, 1429-1435. 
- 207 - 
 233.  Ridgway, G.R., Omar, R., Ourselin, S., Hill, D.L.G., Warren, J.D., Fox, N.C., 2009. 
Issues with threshold masking in voxel-based morphometry of atrophied brains. 
Neuroimage 44, 99-111. 
 234.  Ridha, B.H., Anderson, V.M., Barnes, J., Boyes, R.G., Price, S.L., Rossor, M.N., 
Whitwell, J.L., Jenkins, L., Black, R.S., Grundman, M., Fox, N.C., 2008. Volumetric 
MRI and cognitive measures in Alzheimer disease: comparison of markers of 
progression. Journal of Neurology 255, 567-574. 
 235.  Ridha, B.H., Barnes, J., Bartlett, J.W., Godbolt, A., Pepple, T., Rossor, M.N., Fox, 
N.C., 2006. Tracking atrophy progression in familial Alzheimer's disease: a serial MRI 
study. Lancet Neurology 5, 828-834. 
 236.  Rocher, A.B., Chapon, F., Blaizot, X., Baron, J.C., Chavoix, C., 2003. Resting-state 
brain glucose utilization as measured by PET is directly related to regional 
synaptophysin levels: a study in baboons. Neuroimage 20, 1894-1898. 
 237.  Rogalski, E., Johnson, N., Weintraub, S., Mesulam, M., 2008. Increased frequency of 
learning disability in patients with primary progressive aphasia and their first-degree 
relatives. Archives of Neurology 65, 244-248. 
 238.  Rohrer, J.D., McNaught, E., Foster, J., Clegg, S.L., Barnes, J., Omar, R., Warrington, 
E.K., Rossor, M.N., Warren, J.D., Fox, N.C., 2008. Tracking progression in 
frontotemporal lobar degeneration: serial MRI in semantic dementia. Neurology 71, 
1445-1451. 
 239.  Rohrer, J.D., Warren, J.D., Modat, M., Ridgway, G.R., Douiri, A., Rossor, M.N., 
Ourselin, S., Fox, N.C., 2009. Patterns of cortical thinning in the language variants of 
frontotemporal lobar degeneration. Neurology 72, 1562-1569. 
 240.  Rosen, H.J., Gorno-Tempini, M.L., Goldman, W.P., Perry, R.J., Schuff, N., Weiner, 
M., Feiwell, R., Kramer, J.H., Miller, B.L., 2002. Patterns of brain atrophy in 
frontotemporal dementia and semantic dementia. Neurology 58, 198-208. 
 241.  Rosenbloom, M.H., Alkalay, A., Agarwal, N., Baker, S.L., Oneill, J.P., Janabi, M., 
Yen, I.V., Growdon, M., Jang, J., Madison, C., Miller, B.L., Jagust, W.J., Rabinovici, 
G.D., 2010. Distinct clinical and metabolic deficits in Alzheimer's disease and 
Posterior Cortical Atrophy are not related to amyloid distribution. Neurology 74, A301. 
 242.  Ross, S.J., Graham, N., Stuart Green, L., Prins, M., Xuereb, J., Patterson, K., 
Hodges, J.R., 1996. Progressive biparietal atrophy: an atypical presentation of 
Alzheimer's disease. Journal of Neurology Neurosurgery and Psychiatry 61, 388-395. 
- 208 - 
 243.  Rossor, M., 1993. Alzheimer's disease. British Medical Journal 307, 779-782. 
 244.  Rowe, C.C., Ng, S., Ackermann, U., Gong, S.J., Pike, K., Savage, G., Cowie, T.F., 
Dickinson, K.L., Maruff, P., Darby, D., Smith, C., Woodward, M., Merory, J., Tochon-
Danguy, H., O'Keefe, G., Klunk, W.E., Mathis, C.A., Price, J.C., Masters, C.L., 
Villemagne, V.L., 2007. Imaging beta-amyloid burden in aging and dementia. 
Neurology 68, 1718-1725. 
 245.  Rusinek, H., Endo, Y., De, S.S., Frid, D., Tsui, W.H., Segal, S., Convit, A., de Leon, 
M.J., 2004. Atrophy rate in medial temporal lobe during progression of Alzheimer 
disease. Neurology 63, 2354-2359. 
 246.  Ryan, N.S., Rossor, M.N., 2010. Correlating familial Alzheimer's disease gene 
mutations with clinical phenotype. Biomarkers in Medicine 4, 99-112. 
 247.  Salat, D.H., Buckner, R.L., Snyder, A.Z., Greve, D.N., Desikan, R.S.R., Busa, E., 
Morris, J.C., Dale, A.M., Fischl, B., 2004. Thinning of the cerebral cortex in aging. 
Cerebral Cortex 14, 721-730. 
 248.  Salloway, S., Sperling, R., Gilman, S., Fox, N.C., Blennow, K., Raskind, M., Sabbagh, 
M., Honig, L.S., Doody, R., van Dyck, C.H., Mulnard, R., Barakos, J., Gregg, K.M., 
Liu, E., Lieberburg, I., Schenk, D., Black, R., Grundman, M., 2009. A phase 2 multiple 
ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. 
Neurology 73, 2061-2070. 
 249.  Saunders, A.M., Strittmatter, W.J., Schmechel, D., George-Hyslop, P.H., Pericak-
Vance, M.A., Joo, S.H., Rosi, B.L., Gusella, J.F., Crapper-MacLachlan, D.R., Alberts, 
M.J., 1993. Association of apolipoprotein E allele epsilon 4 with late-onset familial and 
sporadic Alzheimer's disease. Neurology 43, 1467-1472. 
 250.  Savva, G.M., Wharton, S.B., Ince, P.G., Forster, G., Matthews, F.E., Brayne, C., 
2009. Age, neuropathology, and dementia. New England Journal of Medicine 360, 
2302-2309. 
 251.  Scahill, R.I., Frost, C., Jenkins, R., Whitwell, J.L., Rossor, M.N., Fox, N.C., 2003. A 
longitudinal study of brain volume changes in normal aging using serial registered 
magnetic resonance imaging. Archives of Neurology 60, 989-994. 
 252.  Scahill, R.I., Schott, J.M., Rossor, M.N., Fox, N.C., Stevens, J.M., 2002. Mapping the 
evolution of regional atrophy in Alzheimer's disease: Unbiased analysis of fluid-
registered serial magnetic resonance images. Neurobiology of Aging 23, S420-S421. 
- 209 - 
 253.  Scheltens, P., Launer, L.J., Barkhof, F., Weinstein, H.C., Vangool, W.A., 1995. Visual 
assessment of medial temporal lobe atrophy on magnetic resonance imaging - 
Interobserver reliability. Journal of Neurology 242, 557-560. 
 254.  Scheltens, P., Leys, D., Barkhof, F., Huglo, D., Weinstein, H.C., Vermersch, P., 
Kuiper, M., Steinling, M., Wolters, E.C., Valk, J., 1992. Atrophy of medial temporal 
lobes on MRI in probable Alzheimer's disease and normal aging - Diagnostic value 
and neuropsychological correlates. Journal of Neurology Neurosurgery and 
Psychiatry 55, 967-972. 
 255.  Scheltens, P., Pasquier, F., Weerts, J.G., Barkhof, F., Leys, D., 1997. Qualitative 
assessment of cerebral atrophy on MRI: inter- and intra-observer reproducibility in 
dementia and normal aging. European Neurology 37, 95-99. 
 256.  Schott, J.M., Fox, N.C., Frost, C., Scahill, R.I., Janssen, J.C., Chan, D., Jenkins, R., 
Rossor, M.N., 2003. Assessing the onset of structural change in familial Alzheimer's 
disease. Annals of Neurology 53, 181-188. 
 257.  Schott, J.M., Price, S.L., Frost, C., Whitwell, J.L., Rossor, M.N., Fox, N.C., 2005. 
Measuring atrophy in Alzheimer disease - A serial MRI study over 6 and 12 months. 
Neurology 65, 119-124. 
 258.  Schott, J.M., Ridha, B.H., Crutch, S.J., Healy, D.G., Uphill, J.B., Warrington, E.K., 
Rossor, M.N., Fox, N.C., 2006. Apolipoprotein E genotype modifies the phenotype of 
Alzheimer disease. Archives of Neurology 63, 155-156. 
 259.  Seelaar, H., Klijnsma, K.Y., de Koning, I., van der Lugt, A., Chiu, W.Z., Azmani, A., 
Rozemuller, A.J.M., Swieten, J.C., 2010a. Frequency of ubiquitin and FUS-positive, 
TDP-43-negative frontotemporal lobar degeneration. Journal of Neurology 257, 747-
753. 
 260.  Seelaar, H., Rohrer, J.D., Pijnenburg, Y.A., Fox, N.C., van Swieten, J.C., 2010b. 
Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. 
Journal of Neurology Neurosurgery and Psychiatry in press. 
 261.  Seeley, W.W., Bauer, A.M., Miller, B.L., Gorno-Tempini, M.L., Kramer, J.H., Weiner, 
M., Rosen, H.J., 2005. The natural history of temporal variant frontotemporal 
dementia. Neurology 64, 1384-1390. 
 262.  Seeley, W.W., Crawford, R.K., Zhou, J., Miller, B.L., Greicius, M.D., 2009. 
Neurodegenerative diseases target large-scale human brain networks. Neuron 62, 
42-52. 
- 210 - 
 263.  Shallice, T., Evans, M.E., 1978. Involvement of frontal lobes in cognitive estimation. 
Cortex 14, 294-303. 
 264.  Shiino, A., Watanabe, T., Kitagawa, T., Kotani, E., Takahashi, J., Morikawa, S., 
Akiguchi, I., 2008. Different atrophic patterns in early- and late-onset Alzheimer's 
disease and evaluation of clinical utility of a method of regional z-score analysis using 
voxel-based morphometry. Dementia and Geriatric Cognitive Disorders 26, 175-186. 
 265.  Shin, J., Lee, S.Y., Kim, S.J., Kim, S.H., Cho, S.J., Kim, Y.B., 2010. Voxel-based 
analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, 
FDDNP, and FDG. Neuroimage 52, 488-496. 
 266.  Silbert, L.C., Quinn, J.F., Moore, M.M., Corbridge, E., Ball, M.J., Murdoch, G., 
Sexton, G., Kaye, J.A., 2003. Changes in premorbid brain volume predict Alzheimer's 
disease pathology. Neurology 61, 487-492. 
 267.  Siri, A., Benaglio, I., Frigerio, A., Binetti, G., Cappa, S.F., 2001. A brief 
neuropsychological assessment for the differential diagnosis between frontotemporal 
dementia and Alzheimer's disease. European Journal of Neurology 8, 125-132. 
 268.  Small, G.W., Kepe, V., Ercoli, L.M., Siddarth, P., Bookheimer, S.Y., Miller, K.J., 
Lavretsky, H., Burggren, A.C., Cole, G.M., Vinters, H.V., Thompson, P.M., Huang, 
S.C., Satyamurthy, N., Phelps, M.E., Barrio, J.R., 2006. PET of brain amyloid and tau 
in mild cognitive impairment. New England Journal of Medicine 355, 2652-2663. 
 269.  Smith, S.M., De Stefano, N., Jenkinson, M., Matthews, P.M., 2001. Normalized 
accurate measurement of longitudinal brain change. Journal of Computer Assisted 
Tomography 25, 466-475. 
 270.  Smith, S.M., Jenkinson, M., Woolrich, M.W., Beckmann, C.F., Behrens, T.E.J., 
Johansen-Berg, H., Bannister, P.R., De Luca, M., Drobnjak, I., Flitney, D.E., Niazy, 
R.K., Saunders, J., Vickers, J., Zhang, Y.Y., De Stefano, N., Brady, J.M., Matthews, 
P.M., 2004. Advances in functional and structural MR image analysis and 
implementation as FSL. Neuroimage 23, S208-S219. 
 271.  Smith, S.M., Zhang, Y., Jenkinson, M., Chen, J., Matthews, P.M., Federico, A., De, 
S.N., 2002. Accurate, robust, and automated longitudinal and cross-sectional brain 
change analysis. Neuroimage 17, 479-489. 
 272.  Snowden, J., Neary, D., Mann, D., 2007a. Frontotemporal lobar degeneration: clinical 
and pathological relationships. Acta Neuropathologica 114, 31-38. 
- 211 - 
 273.  Snowden, J.S., Stopford, C.L., Julien, C.L., Thompson, J.C., Davidson, Y., Gibbons, 
L., Pritchard, A., Lendon, C.L., Richardson, A.M., Varma, A., Neary, D., Mann, 
D.M.A., 2007b. Cognitive phenotypes in Alzheimer's disease and genetic risk. Cortex 
43, 835-845. 
 274.  Sowell, E.R., Peterson, B.S., Thompson, P.M., Welcome, S.E., Henkenius, A.L., 
Toga, A.W., 2003. Mapping cortical change across the human life span. Nature 
Neuroscience 6, 309-315. 
 275.  Stopford, C.L., Snowden, J.S., Thompson, J.C., Neary, D., 2007. Distinct memory 
profiles in Alzheimer's disease. Cortex 43, 846-857. 
 276.  Tae, W.S., Kim, S.S., Lee, K.U., Nam, E.C., Kim, K.W., 2008. Validation of 
hippocampal volumes measured using a manual method and two automated 
methods (FreeSurfer and IBASPM) in chronic major depressive disorder. 
Neuroradiology 50, 569-581. 
 277.  Takahashi, R., Ishii, K., Miyamoto, N., Yoshikawa, T., Shimada, K., Ohkawa, S., 
Kakigi, T., Yokoyama, K., 2010. Measurement of gray and white matter atrophy in 
dementia with Lewy bodies using diffeomorphic anatomic registration through 
exponentiated lie algebra: A comparison with conventional voxel-based morphometry. 
AJNR Am.J.Neuroradiol. 31, 1873-1878. 
 278.  Talairach, J., Tournoux, P., 1988. Co-planar stereotaxic atlas of the human brain: 3-
dimensional proportional system - an approach to cerebral imaging. Thieme Medical 
Publishers, New York. 
 279.  Tang-Wai, D., Mapstone, M., 2006. What are we seeing? Is posterior cortical atrophy 
just Alzheimer disease? Neurology 66, 300-301. 
 280.  Tang-Wai, D.F., Graff-Radford, N.R., Boeve, B.F., Dickson, D.W., Parisi, J.E., Crook, 
R., Caselli, R.J., Knopman, D.S., Petersen, R.C., 2004. Clinical, genetic, and 
neuropathologic characteristics of posterior cortical atrophy. Neurology 63, 1168-
1174. 
 281.  Tang-Wai, D.F., Josephs, K.A., Boeve, B.F., Dickson, D.W., Parisi, J.E., Petersen, 
R.C., 2003a. Pathologically confirmed corticobasal degeneration presenting with 
visuospatial dysfunction. Neurology 61, 1134-1135. 
 282.  Tang-Wai, D.F., Josephs, K.A., Boeve, B.F., Petersen, R.C., Parisi, J.E., Dickson, 
D.W., 2003b. Coexistent Lewy body disease in a case of "visual variant of 
Alzheimer's disease". Journal of Neurology Neurosurgery and Psychiatry 74, 389. 
- 212 - 
 283.  Taylor, K.I., Probst, A., Miserez, A.R., Monsch, A.U., Tolnay, M., 2008. Clinical 
course of neuropathologically confirmed frontal-variant Alzheimer's disease. Nature 
Clinical Practice Neurology 4, 226-232. 
 284.  Teipel, S.J., Pruessner, J.C., Faltraco, F., Born, C., Rocha-Unold, M., Evans, A., 
Moller, H.J., Hampel, H., 2006. Comprehensive dissection of the medial temporal 
lobe in AD: measurement of hippocampus, amygdala, entorhinal, perirhinal and 
parahippocampal cortices using MRI. Journal of Neurology 253, 794-800. 
 285.  Tenovuo, O., Kemppainen, N., Aalto, S., Nagren, K., Rinne, J.O., 2008. Posterior 
Cortical Atrophy: A rare form of dementia with in vivo evidence of amyloid-beta 
accumulation. Journal of Alzheimers Disease 15, 351-355. 
 286.  Thompson, P.M., Mega, M.S., Woods, R.P., Zoumalan, C.I., Lindshield, C.J., Blanton, 
R.E., Moussai, J., Holmes, C.J., Cummings, J.L., Toga, A.W., 2001. Cortical change 
in Alzheimer's disease detected with a disease-specific population-based brain atlas. 
Cerebral Cortex 11, 1-16. 
 287.  Thompson, S.A., Patterson, K., Hodges, J.R., 2003. Left/right asymmetry of atrophy 
in semantic dementia - Behavioral-cognitive implications. Neurology 61, 1196-1203. 
 288.  Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., 
Delcroix, N., Mazoyer, B., Joliot, M., 2002. Automated anatomical labeling of 
activations in SPM using a macroscopic anatomical parcellation of the MNI MRI 
single-subject brain. Neuroimage 15, 273-289. 
 289.  Ungerleider, L.G., Mishkin, M., 1982. Two cortical visual systems. MIT Press, 
Cambridge MA. 
 290.  Urwin, H., Josephs, K.A., Rohrer, J.D., Mackenzie, I.R., Neumann, M., Authier, A., 
Seelaar, H., van Swieten, J.C., Brown, J.M., Johannsen, P., Nielsen, J.E., Holm, I.E., 
Dickson, D.W., Rademakers, R., Graff-Radford, N.R., Parisi, J.E., Petersen, R.C., 
Hatanpaa, K.J., White, C.L., Weiner, M.F., Geser, F., Van Deerlin, V.M., Trojanowski, 
J.Q., Miller, B.L., Seeley, W.W., van der Zee, J., Kumar-Singh, S., Engelborghs, S., 
De Deyn, P.P., Van Broeckhoven, C., Bigio, E.H., Deng, H.X., Halliday, G.M., Kril, 
J.J., Munoz, D.G., Mann, D.M., Pickering-Brown, S.M., Doodeman, V., Adamson, G., 
Ghazi-Noori, S., Fisher, E.M.C., Holton, J.L., Revesz, T., Rossor, M.N., Collinge, J., 
Mead, S., Isaacs, A.M., 2010. FUS pathology defines the majority of tau- and TDP-
43-negative frontotemporal lobar degeneration. Acta Neuropathologica 120, 33-41. 
 291.  van der Flier, W.M., Pijnenburg, Y.A.L., Fox, N.C., Scheltens, P., 2010. Early-onset 
versus late-onset Alzheimer's disease: the case of the missing APOE epsilon4 allele. 
Lancet Neurology in press. 
- 213 - 
 292.  van Swieten, J., Spillantini, M.G., 2007. Hereditary frontotemporal dementia caused 
by Tau gene mutations. Brain Pathology 17, 63-73. 
 293.  Vance, C., Rogelj, B., Hortobagyi, T., De Vos, K.J., Nishimura, A.L., Sreedharan, J., 
Hu, X., Smith, B., Ruddy, D., Wright, P., Ganesalingam, J., Williams, K.L., Tripathi, 
V., Al-Saraj, S., Al-Chalabi, A., Leigh, P.N., Blair, I.P., Nicholson, G., de Belleroche, 
J., Gallo, J.M., Miller, C.C., Shaw, C.E., 2009. Mutations in FUS, an RNA processing 
protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208-1211. 
 294.  Vapnik, V., 1995. The nature of statistical learning theory. Springer, New York. 
 295.  Vapnik, V., 1998. Statistical learning theory. John Wiley and Sons, New York. 
 296.  Vemuri, P., Whitwell, J., Kantarci, K., Josephs, K., Parisi, J., Knopman, D., Boeve, B., 
Petersen, R., Dickson, D., Jack, C., 2008. Antemortem MRI based structural 
abnormality index (STAND)-scores correlate with postmortem Braak stages. 
Neurology 70, A447. 
 297.  Victoroff, J., Ross, G.W., Benson, D.F., Verity, M.A., Vinters, H.V., 1994. Posterior 
cortical atrophy - Neuropathologic correlations. Archives of Neurology 51, 269-274. 
 298.  Villain, N., Desgranges, B., Viader, F., De La Sayette, V., Mezenge, F., Landeau, B., 
Baron, J.C., Eustache, F., Chetelat, G., 2008. Relationships between hippocampal 
atrophy, white matter disruption, and gray matter hypometabolism in Alzheimer's 
disease. Journal of Neuroscience 28, 6174-6181. 
 299.  Wahlund, L.O., Barkhof, F., Fazekas, F., Bronge, L., Augustin, M., Sjogren, M., 
Wallin, A., Ader, H., Leys, D., Pantoni, L., Pasquier, F., Erkinjuntti, T., Scheltens, P., 
2001. A new rating scale for age-related white matter changes applicable to MRI and 
CT. Stroke 32, 1318-1322. 
 300.  Wahlund, L.O., Julin, P., Johansson, S.E., Scheltens, P., 2000. Visual rating and 
volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a 
comparative study. Journal of Neurology Neurosurgery and Psychiatry 69, 630-635. 
 301.  Wakai, M., Honda, H., Takahashi, A., Kato, T., Ito, K., Hamanaka, T., 1994. Unusual 
findings on PET study of a patient with posterior cortical atrophy. Acta neurologica 
Scandinavica 89, 458-461. 
 302.  Waldemar, G., Dubois, B., Emre, M., Georges, J., McKeith, I.G., Rossor, M., 
Scheltens, P., Tariska, P., Winblad, B., 2007. Recommendations for the diagnosis 
and management of Alzheimer's disease and other disorders associated with 
dementia: EFNS guideline. European Journal of Neurology 14, e1-26. 
- 214 - 
 303.  Wandell, B.A., Dumoulin, S.O., Brewer, A.A., 2007. Visual field maps in human 
cortex. Neuron 56, 366-383. 
 304.  Wang, D., Chalk, J.B., Rose, S.E., de, Z.G., Cowin, G., Galloway, G.J., Barnes, D., 
Spooner, D., Doddrell, D.M., Semple, J., 2002. MR image-based measurement of 
rates of change in volumes of brain structures. Part II: application to a study of 
Alzheimer's disease and normal aging. Magnetic Resonance Imaging 20, 41-48. 
 305.  Warrington, E.K., 1984. Recognition memory test. NFER-Nelson, Windsor, UK. 
 306.  Warrington, E.K., 1996. The Camden Memory Tests. Psychology Press (Erlbaum, 
Taylor & Francis), Hove, UK. 
 307.  Warrington, E.K., 1997. The graded naming test: A restandardisation. 
Neuropsychological Rehabilitation 7, 143-146. 
 308.  Warrington, E.K., James, M., 1988. Visual apperceptive agnosia - A clinico-
anatomical study of 3 cases. Cortex 24, 13-32. 
 309.  Warrington, E.K., James, M., 1991. The Visual Object and Space Battery Perception. 
Thames Valley Company, Bury St Edmunds, UK. 
 310.  Warrington, E.K., McKenna, P., Orpwood, L., 1998. Single word comprehension: A 
concrete and abstract word synonym test. (vol 8, pg 143, 1998). Neuropsychological 
Rehabilitation 8, 472. 
 311.  Watson, C., Andermann, F., Gloor, P., Jones-Gotman, M., Peters, T., Evans, A., 
Olivier, A., Melanson, D., Leroux, G., 1992. Anatomic basis of amygdaloid and 
hippocampal volume measurement by magnetic resonance imaging. Neurology 42, 
1743-1750. 
 312.  Wattjes, M.P., Henneman, W.J.P., van der Flier, W.M., de Vries, O., Traber, F., 
Geurts, J.J.G., Scheltens, P., Vrenken, H., Barkhof, F., 2009. Diagnostic imaging of 
patients in a memory clinic: Comparison of MR imaging and 64-detector row CT. 
Radiology 253, 174-183. 
 313.  Wechsler, D., 1987. Manual for the Wechsler Memory Scale-Revised. The 
Psychological Corporation, San Antonio, TX. 
 314.  Whitwell, J.L., Crum, W.R., Watt, H.C., Fox, N.C., 2001. Normalization of cerebral 
volumes by use of intracranial volume: Implications for longitudinal quantitative MR 
imaging. American Journal of Neuroradiology 22, 1483-1489. 
- 215 - 
 315.  Whitwell, J.L., Jack, C.R., Jr., 2005. Comparisons between Alzheimer disease, 
frontotemporal lobar degeneration, and normal aging with brain mapping. Topics in 
Magnetic Resonance Imaging 16, 409-425. 
 316.  Whitwell, J.L., Jack, C.R., Kantarci, K., Weigand, S.D., Boeve, B.F., Knopman, D.S., 
Drubach, D.A., Tang-Wai, D.F., Petersen, R.C., Josephs, K.A., 2007a. Imaging 
correlates of posterior cortical atrophy. Neurobiology of Aging 28, 1051-1061. 
 317.  Whitwell, J.L., Jack, C.R., Jr., Pankratz, V.S., Parisi, J.E., Knopman, D.S., Boeve, 
B.F., Petersen, R.C., Dickson, D.W., Josephs, K.A., 2008a. Rates of brain atrophy 
over time in autopsy-proven frontotemporal dementia and Alzheimer disease. 
Neuroimage 39, 1034-1040. 
 318.  Whitwell, J.L., Jack, C.R., Jr., Parisi, J.E., Knopman, D.S., Boeve, B.F., Petersen, 
R.C., Ferman, T.J., Dickson, D.W., Josephs, K.A., 2007b. Rates of cerebral atrophy 
differ in different degenerative pathologies. Brain 130, 1148-1158. 
 319.  Whitwell, J.L., Josephs, K.A., Murray, M.E., Kantarci, K., Przybelski, S.A., Weigand, 
S.D., Vemuri, P., Senjem, M.L., Parisi, J.E., Knopman, D.S., Boeve, B.F., Petersen, 
R.C., Dickson, D.W., Jack, C.R., Jr., 2008b. MRI correlates of neurofibrillary tangle 
pathology at autopsy: a voxel-based morphometry study. Neurology 71, 743-749. 
 320.  Whitwell, J.L., Josephs, K.A., Rossor, M.N., Stevens, J.M., Revesz, T., Holton, J.L., 
Al Sarraj, S., Godbolt, A.K., Fox, N.C., Warren, J.D., 2005a. Magnetic resonance 
imaging signatures of tissue pathology in frontotemporal dementia. Archives of 
Neurology 62, 1402-1408. 
 321.  Whitwell, J.L., Sampson, E.L., Watt, H.C., Harvey, R.J., Rossor, M.N., Fox, N.C., 
2005b. A volumetric magnetic resonance imaging study of the amygdala in 
frontotemporal lobar degeneration and Alzheimer's disease. Dementia and Geriatric 
Cognitive Disorders 20, 238-244. 
 322.  Willison, J.R., Warrington, E.K., 1992. Cognitive retardation in a patient with 
preservation of psychomotor speed. Behavioural Neurology 5, 113-116. 
 323.  Wilson, S.M., Ogar, J.M., Laluz, V., Growdon, M., Jang, J., Glenn, S., Miller, B.L., 
Weiner, M.W., Gorno-Tempini, M.L., 2009. Automated MRI-based classification of 
primary progressive aphasia variants. Neuroimage 47, 1558-1567. 
 324.  Woods, R.P., Grafton, S.T., Holmes, C.J., Cherry, S.R., Mazziotta, J.C., 1998. 
Automated image registration: I. General methods and intrasubject, intramodality 
validation. Journal of Computer Assisted Tomography 22, 139-152. 
- 216 - 
 325.  Xu, Y., Jack, C.R., O'Brien, P.C., Kokmen, E., Smith, G.E., Ivnik, R.J., Boeve, B.F., 
Tangalos, R.G., Petersen, R.C., 2000. Usefulness of MRI measures of entorhinal 
cortex versus hippocampus in AD. Neurology 54, 1760-1767. 
 326.  Yoshida, T., Shiga, K., Yoshikawa, K., Yamada, K., Nakagawa, M., 2004. White 
matter loss in the splenium of the corpus callosum in a case of posterior cortical 
atrophy: A diffusion tensor imaging study. European Neurology 52, 77-81. 
 327.  Zhang, H.Y., Wang, S.J., Liu, B., Ma, Z.L., Yang, M., Zhang, Z.J., Teng, G.J., 2010. 
Resting brain connectivity: changes during the progress of Alzheimer disease. 
Radiology 256, 598-606. 
 
 
 
 
 
 
